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SUMMARY 
Leukotrienes (LTs), originated from the enzymatic oxygenation of the C-20:4 polyunsaturated 
arachidonic acid (AA) by 5-lipoxygenase (5-LOX) and its helper protein 5-lipoxygenase-
activating protein (FLAP), are important mediators involved in inflammation (1). While 
cyclooxygenase-(COX)-derived prostaglandins (PGs) are mediating both physiological and 
pathophysiological functions, 5-LOX activation has primarily been associated to inflammatory 
conditions (2). However, to date the agents and receptors inducing 5-LOX activation and LT 
biosynthesis are not completely understood. In particular, how pathogenic bacteria elicit LT 
formation under infectious conditions is poorly characterized. 
The molecular mechanism of bacteria-induced 5-LOX activity was studied in the first part of 
this thesis. Investigations with cell-free bacteria-conditioned medium (BCM) revealed bacterial 
exotoxins, primarily secreted by pathogenic strains, as crucial determinants for in cellulo 5-
LOX activation in HEK293 cells and human neutrophils. Since Staphylococcus (S.) aureus 
infections and the concomitant rise of antibiotic resistant strains are a common threat to human 
(3,4), this study focused on staphylococcal toxins and their impact on lipid mediator (LM) 
biosynthesis. While 5-LOX, stably co-transfected with FLAP in non-immunocompetent 
HEK293 cells, could be activated by both staphylococcal phenol-soluble modulins (PSMs) and 
α-hemolysin, LT formation in neutrophils was exclusively induced by amphipathic α-helical 
PSM peptides. Incubations with BCM of genetically modified S. aureus devoid of PSM 
expression substantiated PSMs as key activators of LT biosynthesis in neutrophils. 
Interestingly, other branches of the AA pathway (e.g. COX, 12- or 15-LOX) appeared to be 
stimulated by other exotoxins apart from PSMs. Supporting this data, we found altered LT 
biosynthesis in vivo after infection of mice paws with S. aureus USA300∆psmαβ compared to 
the corresponding wildtype bacteria, whereas the biosynthesis of COX-derived mediators was 
independent of PSM presence. Moreover, PSM-induced LT formation of neutrophils was 
mediated via the Gi-protein-coupled formyl peptide receptor 2 (FPR2), and selective inhibition 
of FPR2 by the synthetic peptide WRW4 prevented LM biosynthesis. PSMs thereby provoked 
an intracellular Ca2+ increase and activation of the extracellular-signal regulated protein kinase 
ERK1/2, both known to induce 5-LOX activity (5-7). Accordingly, LT formation in neutrophils 
upon PSM challenge was decreased after Ca2+-chelation or inhibition of ERK1/2 activation. 
Taken together, our findings underline the impact of bacterial exotoxins as inducers of LT 
biosynthesis, particularly PSMs acting via the FPR2 during S. aureus-induced infections, which 
should be considered as prospective strategy for the treatment of inflammatory/infectious 
disorders. 
Targeting 5-LOX and/or FLAP displays a common strategy to modulate LT biosynthesis (5,8). 
While the direct 5-LOX inhibitor zileuton is applied in asthmatic diseases (9,10) and numerous 
natural products affect 5-LOX activity (11), only few FLAP inhibitors have been studied in 
clinical trials and none could reach the pharmaceutical market so far (8,10). Moreover, 
although an interaction of 5-LOX and FLAP appeared to be crucial for LT biosynthesis (12), 
the structural requirements for the assembly of a LT-synthetic complex at the nuclear 
membrane remained elusive. Thus, the second part of this thesis focused on the mutagenesis 
of FLAP to deepen the knowledge about 5-LOX/FLAP interaction and subsequent LT 
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formation. Modifications within the second cytosolic loop (C2) of nuclear membrane-bound 
FLAP significantly altered FLAP-mediated 5-LOX activity in a HEK293 cell model, while 
variations of residues located on other FLAP-domains did not notably affect 5-LOX product 
formation. In detail, mutagenesis, or deletion of Ser108 (and minorly Tyr112) entirely prevented 
the in situ interaction of 5-LOX and FLAP and diminished the FLAP-supported formation of 
leukotriene A4 (LTA4) from its precursor 5-hydroperoxyeicosatetraenoic acid (5-HpETE). 
Simultaneously, 5-LOX subcellular translocation and co-localization with FLAP were found to 
be unaffected from FLAP mutagenesis and independent of the location of mutated residues. 
However, it remains to be clarified whether structural modification of loop C2 directly disrupts 
a physical 5-LOX/FLAP interaction by steric hindrance or rather alters the presentation of AA 
and 5-HpETE to the active site of 5-LOX by FLAP. Nevertheless, our data reveal the C2-loop 
of FLAP as potential molecular target for novel FLAP inhibitors to pharmacologically modulate 
LT biosynthesis. Besides, we discussed Ser108 as putative phosphorylation site of FLAP. 
Although striking effects on 5-LOX product formation were found for the FLAP mutant carrying 
a phosphomimetic S108D, we failed to demonstrate FLAP as target for cellular kinases by 
phospho-proteomic approaches with HEK_5-LOX/FLAP cells and human neutrophils. 
However, phosphoregulation of MAPEG-proteins (membrane-associated proteins in 
eicosanoid and glutathione metabolism) as it was recently reported for leukotriene C4 synthase 
(LTC4S) (13) should be explored in future studies for elucidating the molecular regulation of 
LM biosynthesis. In summary, our data provide new insights into the role of distinct FLAP 
residues during the formation and activity of the LT-biosynthetic 5-LOX/FLAP protein complex. 
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ZUSAMMENFASSUNG 
Die enzymatische Oxidation der C-20:4 ungesättigten Fettsäure Arachidonsäure (AA) durch 
5-Lipoxygenase (5-LOX) im Zusammenspiel mit dem zellulären Helfer 5-Lipoxygenase-
aktivierendes Protein (FLAP) resultiert in der Bildung und Freisetzung von Leukotrienen (LTs). 
Diese stellen bedeutsame para- und autokrine Botenstoffe dar und sind in zahlreiche 
inflammatorische Erkrankungen involviert (1). Während durch Cyclooxygenasen (COX) 
gebildete Prostaglandine (PG) sowohl pro- als auch anti-inflammatorische Funktionen 
ausüben, wurde eine Aktivierung von 5-LOX weitestgehend mit entzündlichen Prozessen 
assoziiert (2). Bis heute jedoch sind die Faktoren pathogener Mikroorganismen und die 
Rezeptoren, die zur Bildung von LTs im Verlauf einer Infektion führen, noch immer nicht 
vollständig aufgeklärt. 
Im ersten Teil der vorliegenden Arbeit sollte zunächst der molekulare Mechanismus einer 
bakteriell-induzierten 5-LOX-Aktivierung identifiziert werden. Unsere Untersuchungen mit 
steril-filtrierten Kulturmedien (BCM) pathogener Bakterien zeigten dabei die Notwendigkeit von 
mikrobiell-sekretierten Toxinen für die in cellulo Stimulation von 5-LOX, sowohl in einem nicht-
immunkompetenten HEK293 Zellmodel als auch in humanen Neutrophilen. Im weiteren 
konzentrierten sich unsere Experimente auf das Bakterium Staphylococcus (S.) aureus, das 
wiederholt mit lebensbedrohlichen Infektionen, aber auch mit einer zunehmenden Resistenz 
gegen gängige Antibiotika in Verbindung gebracht wird (3,4). Dabei untersuchten wir zunächst 
den Zusammenhang zwischen der Expression von Staphylococcus-Toxinen und ihrem 
Einfluss auf die Lipidmediator-(LM)-Synthese. Während sowohl α-Hemolysin als auch Phenol-
soluble moduline (PSMs) die mit FLAP co-transfizierte 5-LOX in HEK293 Zellen aktivierten, 
konnten 5-LOX-Translokation und LT-Biosynthese in Neutrophilen ausschließlich durch PSMs 
induziert werden. Zusätzlich unterstrichen Untersuchungen mit genetisch modifizierten S. 
aureus LS1 Stämmen die sekretierten PSMs als Schlüsselfaktoren für die LT-Bildung in 
neutrophilen Leukozyten. Andere LM-bildende Enzyme (z.B. COX, 12- oder 15-LOX) schienen 
dabei jedoch durch andere Exotoxine beeinflusst zu werden. Darüber hinaus zeigte ein in vivo 
Mausmodell verminderte LT-Gewebskonzentrationen nach subkutaner Infektion mit einem S. 
aureus USA300∆psmαβ Knockout-Stamm im Vergleich zur Wildtyp-Kontrolle, obwohl die 
Abwesenheit von PSMs gleichzeitig keinen Einfluss auf die COX-vermittelte Bildung von PGs 
und Thromboxan ausübte. In Übereinstimmung mit aktuellen Veröffentlichungen identifizierten 
wir außerdem den Gi-Protein-gekoppelten Formyl Peptide Rezeptor 2 (FPR2) als molekulares 
Target für PSMs in humanen Neutrophilen. Entsprechend konnte die PSM-induzierte LT-
Bildung nahezu vollständig durch den selektiven Antagonismus an FPR2 durch das 
synthetische Peptid WRW4 verhindert werden. Zudem konnten wir die PSM-vermittelte LM-
Biosynthese auf eine Erhöhung der intrazellulären Ca2+-Konzentration und auf die 
Stimulierung der Extrazellulär-Signal-regulierten Proteinkinase ERK1/2 zurückführen. Beide 
Faktoren sind als Induktoren der 5-LOX-Aktivität bekannt (5-7), und sowohl die Komplexierung 
freier Ca2+-Ionen als auch die Hemmung der zellulären ERK1/2-Aktivität führten zur Reduktion 
der PSM-abhängigen LT-Bildung in unseren Experimenten. Zusammenfassend unterstreichen 
unsere Daten die Sekretion von Exotoxinen und die Aktivierung des FPR2 Rezeptors durch S. 
aureus PSMs als wichtige Induktoren der 5-LOX-Aktivität. Diese Erkenntnisse sollten zukünftig 
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Eingang in die Behandlung infektiös-entzündlicher Erkrankungen erhalten. 
Eine verbreitete Strategie zur pharmakologischen Beeinflussung der LT-Biosynthese ist die 
Modulation von 5-LOX und/oder FLAP (5,8). Während mit dem Hydroxyharnstoff Zileuton ein 
direkter 5-LOX-Inhibitor therapeutischen Einsatz bei asthmatischen Erkrankungen findet 
(9,10) und auch für zahlreiche Naturprodukte eine Hemmung der 5-LOX-Aktivität beschrieben 
werden konnte (11), wurden bisher nur wenige FLAP-Inhibitoren in klinischen Studien 
untersucht und kein einziger Kandidat wurde zur Marktreife entwickelt (8,10). Obwohl gezeigt 
werden konnte, dass die direkte Interaktion von 5-LOX und FLAP entscheidend für die LT-
Biosynthese ist (12), wurden bisher keine genauen Aminosäuren oder strukturelle 
Erfordernisse für die Formation des LT-synthetisierenden Proteinkomplexes diskutiert. Der 
zweite Teil dieser Dissertation beschäftigt sich daher mit der Modifikation ausgewählter 
Strukturelemente im FLAP, um so die bisherigen Erkenntnisse der Interaktion mit 5-LOX und 
der damit verbundenen LT-Synthese zu ergänzen. Dabei konnten wir zeigen, dass Variationen 
in der zweiten zytosolischen Schleife (C2) des integralen Membranproteins deutlich die 5-LOX-
Aktivität in HEK293-Zellen beeinflussten, während Mutationen von Aminosäuren anderer 
FLAP-Domänen kaum Änderungen gegenüber der Wildtyp-Form verursachten. Im Detail 
resultierte der Austausch bzw. die Entfernung von Ser108 (und geringfügig von Tyr112) in der 
vollständigen Prävention der in situ 5-LOX/FLAP Interaktion und verringerte die FLAP-
vermittelte Synthese von Leukotrien A4 (LTA4). Gleichzeitig zeigte keine der getesteten 
Mutationen einen Einfluss auf die zelluläre 5-LOX-Translokation und Co-Lokalisierung mit 
FLAP, unabhängig von der Lokalisation der abgewandelten Aminosäuren im Protein. Zwar 
konnte hier nicht vollständig geklärt werden, ob eine strukturelle Modifikation des C2-Loops 
direkt die physische Wechselwirkung von 5-LOX und FLAP durch eine sterische Hinderung 
oder vielmehr durch einen veränderten Transfer von AA und/oder 5-HpETE zum aktiven 
Zentrum der 5-LOX bedingt. Dennoch identifizieren unsere Daten die zweite zytosolische 
Schleife des FLAP-Proteins als potentielle neuartige Bindestelle für Inhibitoren zur 
pharmakologischen Modulation der LT-Bildung. Darüber hinaus vermuten wir Ser108 als 
mögliche Phosphorylierungsstelle innerhalb FLAPs. Obwohl deutliche Veränderungen der 5-
LOX Produktbildung für die phosphomimetische FLAP-Isoform S108D auftraten, gelang kein 
finaler Beweis einer zellulären Phosphorylierung durch Phosphoproteom-Analysen an HEK_5-
LOX/FLAP-Zellen oder humanen Neutrophilen. Dennoch sollte die Möglichkeit der Regulation 
von MAPEG-Proteinen (Membran-assoziierte Proteine im Eikosanoid- und Glutathion-
metabolismus) durch zelluläre Proteinkinasen für zukünftige Studien der LM-Biosynthese in 
Betracht gezogen werden, da erst kürzlich ein derartiger Mechanismus auch für die FLAP-
verwandte Leukotrien C4 Synthase (LTC4S) veröffentlicht wurde (13). Zusammenfassend 
geben unsere Daten einen neuartigen Einblick in die Rolle verschiedener FLAP-Domänen bei 
der Bildung und Aktivität des LT-synthetisierenden Proteinkomplex mit 5-LOX. 
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1 INTRODUCTION 
1.1 Inflammation 
1.1.1 Infection-induced inflammation 
Inflammation is characterized as adaptive response to homeostatic imbalances within the 
human body, and various factors have been discussed to induce inflammatory processes. 
Microbial infection and tissue injury are thereby the most prominent and best described 
inflammatory inducers. In general, inflammation aims to restore homeostasis by resolving 
infections or repairing tissue damages (14,15). 
The underlying mechanisms of inflammatory responses are well characterized for infection-
induced inflammation and can partially be transferred to other inflammatory states. Infections 
are caused by microbial factors that can be separated into pathogen-associated molecular 
patterns (PAMPs) and virulence factors. The formers are defined molecular structures that can 
be detected by specific receptors of the host and are shared by various microorganisms, 
independent of their pathogenicity. In contrast, virulence factors are restricted to pathogenic 
microbes and execute their activities in a widely receptor-independent way, although 
depending on the presence of specialized sensors in some cases (15). 
Tissue-resident cells such as macrophages, dendritic cells or mast cells are responsible for 
the recognition of microorganisms at the first site of infection. After being challenged with 
invading microbes, these cells induce and release a plethora of mediators including cytokines, 
vasoactive amines and peptides, chemokines, proteolytic enzymes, fragments of complement 
factors, and lipid mediators (LM) to create a local environment of inflammation (15,16). 
Subsequently, resulting from the activities of the indicated mediators, neutrophils circulating in 
the blood are recruited to the inflamed tissue (17). After extravasation, neutrophils are aiming 
to kill microbes by either phagocytosis, degranulation and subsequent release of antimicrobial 
peptides, or formation of neutrophil extracellular traps (NETs) (17). However, besides the local 
response to environmental changes by the innate immune system, intercellular communication 
of leukocytes can further activate systemic reactions and adaptive immune responses (18). 
Finally, inflammatory processes are leading to the cardinal signs of an acute inflammation that 
were already described in ancient medicine: heat (calor), pain (dolor), redness (rubor), swelling 
(tumor) and loss of function (functio laesa), respectively (19). 
While acute inflammation and its resolution are crucial control mechanisms to adequately 
respond to environmental challenges, several diseases are related to pronounced or 
unresolved inflammatory conditions (20). For instance, atherosclerosis, rheumatoid arthritis, 
chronic lung or liver diseases, sepsis, neurodegeneration, gastrointestinal and skin diseases, 
or even cancer and diabetes are characterized by increased levels of inflammatory cytokines, 
predominantly interleukins (ILs) such as IL-1β. Accordingly, widely applied pharmaceuticals in 
the therapy of these disorders are targeting inflammatory processes and thereby underline the 
necessity to explicitly understand the course of inflammation (20). 
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Fig. 1.1 Onset and resolution of inflammation. Adapted from Ortega-Gomez et al. 2013 (21). As soon as 
tissue-resident cells including pro-inflammatory macrophages (MФ) recognize homeostatic alterations, 
chemotactic mediators are released, and neutrophils and monocytes start to invade. While neutrophils rapidly 
migrate to the site of infection and subsequently release an own subset of chemotactic agents, monocyte 
migration was found to be delayed in this respect. The resolution of inflammatory conditions is initiated by 
neutrophil apoptosis and the liberation of eat-me-signals to induce efferocytosis by macrophages, and to 
terminate further leukocyte extravasation. Moreover, macrophages transform into a resolution-phase phenotype 
in order to restore homeostasis within inflamed tissues. 
 
1.1.2 Resolution of inflammation 
Although acute inflammation is essential to initiate the recovery of homeostasis upon damage, 
unlimited and prolonged inflammatory reactions might lead to a permanent tissue disturbance 
and result in chronic diseases. Under normal conditions, the initial step of resolution is related 
to decreasing levels of chemokines and subsequent reduction of infiltrating neutrophils (21-
23). Both, capturing and entrapment of chemotactic agents by decoy receptors and enhanced 
chemokine cleavage have been described in this respect (21,24). Additionally, apoptosis of 
neutrophils is induced after they have executed their anti-microbial activities and apoptotic cells 
are digested by macrophages. Neutrophil efferocytosis thereby drives the maturation of 
macrophages towards the M2-like phenotype with anti-inflammatory properties (Fig. 1.1) 
(21,25). Those macrophages mediate the resolution process by releasing anti-inflammatory 
mediators such as IL-10, transforming growth factor-(TGF)-β, vascular endothelial growth 
factor (VEGF) or specialized pro-resolving mediators (SPMs, discussed under Eicosanoids 
and related lipid mediators) (16,21). However, the termination of inflammation as an active 
process is still not fully understood but displays a potential strategy to manipulate inflammatory 
disorders (21). 
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1.2 Eicosanoids and related lipid mediators (LMs) 
1.2.1 Biosynthetic pathways and roles of LMs 
Among the group of inflammatory mediators, LMs derived from arachidonic acid (AA) and 
related polyunsaturated fatty acids (FAs) execute crucial functions upon physiological and 
pathologic conditions (26,27). Eicosanoids are characterized as oxygenated metabolites of AA 
and other polyunsaturated C-20 FAs by either specific enzymes or non-enzymatic reactions 
(27). More recently, related FAs such as the ω3 C-22:6 docosahexaenoic acid (DHA) were 
shown to be an analogue source for bioactive mediators, termed as docosanoids (27,28).  
In line with their outstanding activities in the course of inflammation, a majority of eicosanoids 
is biosynthesized in innate immune cells including neutrophils, macrophages and dendritic 
cells (2). Once released from the cell, eicosanoids mediate their effects by targeting membrane 
G-protein-coupled receptors (GPCRs) in an auto- or paracrine manner (2).  
Within the AA cascade, three branches of enzymes have been discussed (Fig. 1.2): (I) 
cyclooxygenases (COXs) convert AA into the prostaglandin H2 (PGH2) that is further 
metabolized into various prostanoids, (II) cytochrome P450 (CYP) enzymes generate 
epoxyeicosatrienoic (EETs) or hydroxyeicosatetraenoic acids (HETEs), and (III) lipoxygenases 
(LOXs) dioxygenate AA into hydroperoxyeicosatetraenoic acids (HpETEs). In this context, 5-
lipoxygenase (5-LOX) uniquely catalyzes a second conversion step to form leukotriene A4 
(LTA4) that represents a precursor for the downstream biosynthesis of leukotrienes (LTs) 
including LTB4 and cysteinyl LTs (cysLTs) (1,2,29,30). However, while LTs are predominantly 
produced under inflammatory conditions, PGs execute both inflammatory and homeostatic 
functions and their biosynthesis was found to be almost ubiquitous (2). Accordingly, the 
present thesis focusses on the formation of LTs, although a wide spectrum of eicosanoids and 
docosanoids have been analyzed in several experiments (see Materials and methods and 
Results). Thus, enzymes involved in the biosynthesis of the detected mediators are shortly 
discussed below (Table 1.1, Fig. 1.2, and Fig 1.3). 
 
1.2.2 Enzymes involved in the biosynthesis of LMs 
Polyunsaturated FAs are naturally esterified and stored within phospholipids of cellular 
membranes (27,31). Thus, the release of AA is prerequisite for LM formation and is regulated 
by phospholipases (PLs). Besides Ca2+-independent PLA2 (iPLA2) that is mainly responsible 
for homeostatic FA release and membrane remodeling, cytosolic Ca2+-dependent PLA2 
(cPLA2) and secreted PLA2 (sPLA2) are thought to liberate FAs under specific stimulatory 
conditions (27). It is generally excepted that the formation of PGs and LTs is strongly related 
to cPLA2α activity (1,32). The 85 kDa enzyme is ubiquitously expressed and located within the 
cytosol under resting conditions. Upon cell stimulation, cPLA2α Ca2+-dependently translocates 
to the nuclear membrane or endoplasmic reticulum and subsequently mediates the selective 
hydrolysis of AA from the sn-2 position of phospholipids (1,33,34). Notably, the subcellular 
localization of cPLA2α regulates the eicosanoid profile by generating high local concentrations 
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Fig. 1.2 AA-derived eicosanoid formation. Adapted and modified from Dennis et al. 2015, Lone et al. 2013, 
and Kuhn et al. 2015 (27,35,36). AA released from cellular phospholipids is converted into bioactive lipid 
mediators by distinct enzymatic branches including COXs, LOXs, and CYPs, and further metabolized by a 
subset of downstream enzymes. The biosynthesis of lipoxins and resolvins is presented in Fig. 1.3. COX – 
cyclooxygenase, CYP – cytochrome P450, DiHETrE – dihydroxyeicosatrienoic acid, EET – epoxyeicosatrienoic 
acid, eLOX-3 – epidermal LOX-3, FLAP – 5-LOX-activating protein, GGT – γ-glutamyl transferase, HETE – 
hydroxyeicosatetraenoic acid, LOX – lipoxygenase, LT – leukotriene, LTA4H – LTA4 hydrolase, LTC4S – LTC4 
synthase, MBD – membrane-bound dipeptidase, PG – prostaglandin, PGDS – PGD2 synthase, PGES – PGE2 
synthase, PGFS – PGF2α synthase, PGIS – PGI2 synthase, PL – phospholipase, sEH – soluble epoxide 
hydrolase, TBXAS1 – TXA2 synthase-1. 
 
of FAs in close proximity to enzymes involved in LM biosynthesis (27). As described above, 
PGs are formed via the COX-pathway. Two isoforms of COXs (COX-1 and COX-2) with about 
60% structural identity have been reported and extensively discussed before (37). Human 
COX-1 and COX-2 consist of 576 and 581 amino acid residues, respectively, and are located 
at the lumenal side of endoplasmic reticulum membranes. Both isoenzymes perform a 
dioxygenation of AA resulting in PGG2 and PGH2 that act as substrates for downstream-
synthases creating the bioactive prostaglandins PGE2, PGD2, PGF2α and PGI2 and 
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thromboxane (TX) TXA2 (29,37,38). While COX-1 is constitutively expressed in a wide range 
of tissues, COX-2 expression is predominantly induced under inflammatory conditions (37,39). 
Beside the COX pathway, six human LOXs convert AA into hydroperoxides with distinct 
biologic activities. Corresponding to their stereospecific reaction and FA metabolism,  
15-, 12-, 12R-, and 5-LOX as well as 15-LOX-2 and epidermal LOX-3 have been described 
(40). Although sharing a high overall structural identity, distinctions within their substrate cavity 
are responsible for unique position- and stereoselectivity. Moreover, the expression of LOXs 
is diverse and was related to both physiological and pathophysiological conditions (40). 
However, according to the prominent role during inflammation, LTs produced by 5-LOX have 
primarily been in the focus of research and are therefore discussed in more detail in this thesis 
(see 5-Lipoxygenase and 5-Lipoxygenase-activating protein). 
CYPs represent the third branch of AA metabolizing enzymes and consist of 400-500 amino 
acids and a central heme moiety. Besides their fundamental activities in the biotransformation 
of xenobiotics, CYPs were likewise found to metabolize endogenous compounds including FA 
substrates (30,41). While members of the CYP4A and CYP4F family generate pro-
inflammatory HETEs (predominantly 20-HETE), CYP2C and CYP2J were shown to convert 
AA into EETs with vasodilatory and anti-inflammatory properties (30,42). EETs are degraded 
by the soluble epoxide hydrolase (sEH) by water addition and the subsequent formation of 
dihydroxyeicosatrienoic acids (DiHETrEs) with altered biological activities (43). 
Noteworthy, besides diverse expression levels and subcellular localization, the distribution of 
the emphasized enzymes might be a key determinant for eicosanoid formation, represented 
by the fact that the number of biosynthetic enzymes is usually restricted within a certain cell 
type (27). Thus, the interplay of enzymes located in distinct cells, referred to as transcellular 
eicosanoid biosynthesis, might define the spectrum of LMs under resting and inflammatory 
conditions. For instance, co-incubations of neutrophils with red blood cells, platelets or 
endothelial cells resulted in increased levels of LTs such as LTB4 or LTC4, respectively, 
originating from the expression of the downstream enzymes LTA4 hydrolase (LTA4H) or LTC4 
synthase (LTC4S) that utilize neutrophil-derived LTA4 as substrate (see below) (44). 
Furthermore, a cell-cell transfer of eicosanoids or its unstable intermediates allows the 
biosynthesis of more complex FA metabolites by increasing the number of enzymes 
participating in their formation. In this context, co-incubations of neutrophils and platelets or 
endothelial cells resulted in the biosynthesis of 5S,6R,15S-trihydroxy-eicosa-7,9,13-trans-11-
cis-tetraenoic acid (termed as lipoxin A4) and analogues (22,44). The formation of such multiple 
hydroxylated eicosanoids is related to the resolution of inflammation and will therefore be 
discussed below. 
 
1.2.3 Specialized pro-resolving mediators (SPMs) 
In general, LTs and PGs mediate acute inflammation and chronic inflammatory disorders. LTB4 
acts as one of the most potent chemoattractant, cysLTs regulate vascular permeability and 
bronchoconstriction, and PGs such as PGE2, PGI2 and PGF2α affect the local blood flow 
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Fig. 1.3 The biosynthesis of SPMs derived from AA, EPA, and DHA. Adapted and modified from Bannenberg 
et al. 2010, Stables et al. 2011, and Lopez-Vicario et al. 2016 (22,38,45). A LX formation is related to three main 
pathways, each involving different cell types and enzymes: (I) 15-LOX expressed in eosinophils, monocytes or 
epithelial cells generates 15S-hydroperoxyeicosatetraenoic acid (15S-HpETE) that is transferred to neutrophils 
and converted by 5-LOX yielding LXA4 or LXB4, respectively; (II) LTA4 biosynthesized by 5-LOX in neutrophils 
or monocytes is used as substrate for 12-LOX to generate LXs in platelets; (III) acetylated COX-2, resulting from 
aspirin treatment, was shown to convert AA into 15R-HpETE with subsequent conversion into epimeric “aspirin-
triggered” LXA4 by leukocyte 5-LOX. B E-series Rvs were found to be a transcellular product of neutrophil 5-
LOX and either aspirin-treated COX-2 of endothelial cells, or CYP enzymes, respectively. C The formation of 
D-series Rvs requires a 15-LOX activity by either aspirin-triggered COX-2 or 15-LOX, and subsequent 
conversion by 5-LOX in neutrophils. Moreover (not shown here), PDs derived from DHA are converted uniquely 
by 15-LOX, involving 17S-hydroperoxydocosahexaenoic acid (17S-HpDHA) formation followed by 
epoxygenation and hydrolysis in leukocytes. By contrast, maresins are thought to be exclusively biosynthesized 
from DHA by human 12-LOX including the sequential conversion to 14S-HpDHA and final formation of 7,14S-
dihydroxylated products. AA – arachidonic acid, COX – cyclooxygenase, DHA – docosahexaenoic acid, EPA – 
eicosapentaenoic acid, HDHA – hydroxydocosahexaenoic acid, (H)EPE – (hydroxy)eicosapentaenoic acid, 
(H)ETE – (hydroxy)eicosatetraenoic acid, LOX – lipoxygenase, LT – leukotriene, LX – lipoxin. 
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and induce the cardinal signs of inflammation (see Infection-induced inflammation) (22,27,46). 
However, after intense investigations of these pro-inflammatory mediators, an additional focus 
was set on LMs formed during the resolution phase. Along these lines, SPMs were described, 
including lipoxins (LX) derived from AA, resolvins (Rv) from eicosapentaenoic acid (EPA) (E-
series Rvs) or DHA (D-series Rvs), as well as protectins (PD) and maresins (Mar, macrophage 
mediator in resolving inflammation) from DHA (22). More recently, sulfido-conjugated SPMs 
originated from resolvins, protectins and maresins were discovered and termed as conjugates 
in tissue regeneration (CTRs) according to their tissue repairing properties (47,48). These 
SPMs act as immunoresolvents and promote an active process of resolution (49) by reducing 
neutrophil infiltration and extravasation, improving macrophage phagocytosis and controlling 
tissue regeneration (22,48,50-52). However, in contrast to pro-inflammatory mediators, 
biosynthesis of polyhydroxylated SPMs generally requests the interplay of multiple enzymes 
and transcellular pathways and is therefore dependent on temporal cell recruitment into the 
inflamed tissue (22) (Fig. 1.3). The participation of differentially regulated enzymes such as 
COXs, LOXs, CYPs or downstream synthases and hydrolases might therefore allow a distinct 
regulation of LM by inflammatory stimuli and/or pharmacological agents. 
Table 1.1 AA-derived LM and their bioactivities. Selected mediators that have been analyzed in this 
study are presented below. All information is adopted from Dennis et al. 2015 (27). BLT – LTB4 receptor, 
COX – cyclooxygenase, CYP – cytochrome P450, CysLT – cysteinyl leukotriene receptor, DiHETE – 
dihydroxyeicosatetraenoic acid, DP – PGD2 receptor, EP – PGE2 receptor, EET – epoxyeicosatrienoic 
acid, FP – PGF2α receptor, FPR2 – formyl peptide receptor 2, HETE – hydroxyeicosatetraenoic acid, 
IP – PGI2 receptor, LOX – lipoxygenase, LT – leukotriene, LX – lipoxin, PG – prostaglandin, PPAR – 
peroxisome-proliferator activated receptor, TP – thromboxane receptor, TRPV1 – transient receptor 
potential vanilloid 1, TX – thromboxane. 
Biosynthetic 
pathway 
Lipid mediator Receptor Biochemical effects (selected) 
COX 
PGE2 EP1-4 
Vasodilation, vascular leakage, 
hyperalgesia, fever 
PGD2 DP1-2 
Mast cell maturation, eosinophil 
recruitment 
PGF2α FP 
Smooth muscle contraction 
(airways, blood vessels, uterus) 
PGI2 IP, PPAR∆ 
Decreased platelet aggregation, 
vasodilation 
TXA2 TP Increased platelet aggregation 
5-LOX 
LTB4 BLT1-2, PPARα 
Neutrophil recruitment, vascular 
leakage 
LTC4, LTD4, LTE4 CysLT1-2 
Bronchoconstriction, neutrophil 
extravasation, vascular leakage 
8-/12-/15-
LOX 
HpETEs, HETEs, 
diHETEs 
PPARα, PPARγ, 
TRPV1 
Expression of FA translocase 
(CD36), hyperalgesia 
CYP EETs PPARα and PPARγ
Antihyperalgesia, decreased 
COX2 expression 
LOX-LOX or 
LOX-COX 
LXA4, 15-epi-LXA4, 
LXB4, 15-epi-LXB4 
FPR2 
Increased efferocytosis, 
decreased neutrophil recruitment 
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1.3 5-Lipoxygenase (5-LOX) 
1.3.1 Protein expression and crystal structure of 5-LOX 
Among the family of LOXs, 5-LOX acts as key regulator of inflammatory processes and plays 
a unique role in LT biosynthesis (40). While genes for all other lipoxygenases can be found on 
chromosome 17, ALOX5 encoding for 5-LOX is located on chromosome 10 (53). Mammalian 
5-LOX is exclusively expressed in myeloid cells including granulocytes, monocytes, 
macrophages, mast cells, dendritic cells, and B-lymphocytes, and DNA methylation within the 
promotor region was shown to prevent transcription of ALOX5 in other tissues (1,54). However, 
enzyme expression in bone marrow-derived cells is strongly regulated by several cytokines 
and increased in presence vitamin D3, granulocyte-macrophage colony-stimulating factor (GM-
CSF) or IL-3 (1,55-57). 
Monomeric 5-LOX consists of 673 amino acids with a molecular weight of 78 kDa (58). A high 
resolution 2.4 Å crystal structure for human 5-LOX was first described in 2011, when Gilbert 
et al. were able to stabilize the enzyme by distinct modifications, mainly by replacing Lys-rich 
segments within the C-terminus with an analogue sequence of 8R-LOX from the black sea rod  
 
Fig. 1.4 A Crystal structure of monomeric, human stable-5-LOX (PDB accession number: 3o8y) according 
to Gilbert et al. 2011 (59). The N-terminal C2-like domain is depicted in bright orange and the α-helical C-terminal 
catalytic domain is colored in blue. The non-heme iron (yellow), located at the active site of the enzyme, is 
positioned by His367, His372, His550, and Ile673 (red spheres), and shielded by the characteristic three-turn α-helix 
(green cartoon) that distinguishes 5-LOX from other mammalian lipoxygenases. Phosphorylation sites (Ser271, 
Ser523 and Ser663) are highlighted as magenta spheres. B View into the active site of 5-LOX with iron-stabilizing 
residues shown as red sticks. Phe177 and Tyr181 („FY-cork“) are presented as green sticks and limit the access 
of substrates to the catalytic cavity. 
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Plexaura homomalla, referred to as stable-5-LOX (59). In detail, 5-LOX consists of a N-terminal 
C2-like domain and an α-helical catalytic domain including a non-heme iron within the active 
site of the enzyme (Fig. 1.4A). The iron is stabilized by three histidines (His367, His372, and 
His550) and the C-terminal carboxylate group of isoleucine (Ile673) (Fig. 1.4B) (59). Moreover, 
the crystal structure of 5-LOX unveiled a unique characteristic compared to related LOXs. In 
contrast to 8R- and 15S-LOX from rabbit reticulocytes that were often used to study human 5-
LOX structures in the past, the active site of 5-LOX is shielded by a three-turn α-helix 
containing tyrosine (Tyr181) and phenylalanine (Phe177) that limit the access of substrates to the 
catalytic cavity (Fig. 1.4B) (59). The mechanism of substrate entrance and concurrent 
uncapping of this designated FY-cork is still under investigation, although a recent study 
indicated the participation of the 5-LOX-activating protein (FLAP) in this respect (60). In brief, 
uncapping the cork would favor an entrance of AA with its carboxy-end first, whereas an access 
with the ω-end first might be explainable from the opposite site of the catalytic cavity (59). 
Noteworthy, stable-5-LOX lacks important residues within the N-terminal domain that were 
shown to be responsible for Ca2+ and membrane binding and nuclear translocation upon 
stimulation, respectively (see Subcellular organization of enzymes involved in LT biosynthesis) 
(7,61). Moreover, 5-LOX was recently shown to form dimers, although dimerization apparently 
did not affect catalytic activity and LT formation (62). 
 
1.3.2 Reaction mechanism of 5-LOX-mediated LT formation  
As common for all LOX reactions, 5-LOX catalyzes the insertion of molecular oxygen and 
hence can be classified as dioxygenase enzyme (Fig. 1.5) (1). Enzymatic activity of 5-LOX 
requires an active, ferric form (Fe3+) of the catalytic iron. Thus, hydroperoxides within the 
cellular milieu both activate and control the activity of 5-LOX by regulating the redox tone and 
oxidizing the ferrous ion (Fe2+) into its active state (1,53). C-20:4 polyunsaturated (∆5,8,11,14) AA 
was found to be the main substrate that is converted in a two-step radical reaction (1,63). First, 
homolytic cleavage of the pro-S hydrogen at C-7 results in a delocalized radical and is followed 
by rearrangement of the double bond from ∆5 to ∆6 position and an antarafacial oxygen 
insertion at C-5, generating 5S-hydroperoxy-6-trans-8,11,14-cis-eicosatetraenoic acid (5-
HpETE). In a second step, 5-LOX mediates the formation of LTA4 by pro-R hydrogen 
abstraction at C-10, subsequent ∆7,9-trans-triene formation, and intramolecular 5,6-epoxide 
biosynthesis. Notably, this LTA4 synthase activity has long been thought to be mediated by 
another enzyme, but was found to be an unique property of 5-LOX (1). 
Instable LTA4 can be non-enzymatically converted to dihydroxylated metabolites (LTB4-
isomers), or enzymatically metabolized by specific downstream enzymes into LTs. The 
notation of leukotrienes derives from early experiments with human leukocytes that produced 
polar, dihydroxylated AA metabolites with distinct biological properties. LTA4H converts LTA4 
into LTB4 (5S,12R-dihydroxy-6,14-cis-8,10-trans-eicosatetraenoic acid), which plays crucial 
roles in neutrophil chemotaxis and enzyme release by targeting two GPCRs, BLT1 and BLT2 
(1,64). Human LTA4H consists of 610 amino acid residues with a molecular weight of 69 kDa 
and is ubiquitously expressed, although higher levels were found in neutrophils, monocytes, 
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lymphocytes and erythrocytes (65). By contrast, the 18 kDa membrane-embedded LTC4S 
conjugates GSH to LTA4, yielding LTC4 (5S-hydroxy-6R-S-glutathionyl-7,9-trans-11,14-cis-
eicosatetraenoic acid). LTC4 is subsequently exported to the extracellular milieu, where the 
glutathione (GSH) moiety is cleaved by removing Glu and then Gly to yield LTD4 and LTE4, 
respectively (1,66). Collectively denoted as cysLTs, LTC4, LTD4 and LTE4 mediate vascular 
permeability and smooth muscle contraction and exceed their activities by targeting two 
GPCRs, CysLT1 and CysLT2. Additionally, cysLTs were found to be identical to the “slow-
reacting substance of anaphylaxis” (SRS-A) discovered at the very beginning of the LT history 
(1). 
 
 
Fig. 1.5 Free radical reaction mechanism of 5-
LOX according to Haeggstrom et al. 2011 (1). AA 
is converted into LTA4 within a two-step conversion 
mediated by 5-LOX. Lipoxygenation results in 5-
HpETE formation and is followed by pseudo-
lipoxygenation and subsequent epoxide synthesis of 
the conjugated triene LTA4. 
 
1.3.3 Regulation of 5-LOX activity 
Enzymatic activity of 5-LOX is regulated by the presence of several co-factors. In vitro, 
stimulation of 5-LOX is dependent on Ca2+, adenosine triphosphate (ATP), phospholipid 
binding and the redox status required for iron activation. Additionally, in cellular systems, 
enzyme activity could be related to phosphorylation as well as subcellular translocation and 
co-localization with further enzymes and proteins (see Subcellular organization of enzymes 
involved in LT biosynthesis) (53). 
Ca2+-mediated 5-LOX activation appeared to play a superior role, as induction of LT formation 
was strongly related to increased intracellular Ca2+ levels in cellulo (5,7). 5-LOX binds Ca2+ at 
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a ratio of 1:2 and Asn43, Asp44, and Glu46 within the N-terminal C2-like domain were identified 
to cause binding of the bivalent cation (7,67). Interestingly, a comparison with other mammals 
revealed the presence of these residues only in 5-LOX analogues from rat, mouse, and 
hamster, but not in other lipoxygenases, thus explaining the pronounced Ca2+ sensitivity of 5-
LOX (7). Additionally, Ca2+ mediates binding to phospholipids, mainly phosphatidylcholine (PC) 
species, by increasing the hydrophobicity of the enzyme (53). Interestingly, cell-stress 
induction by osmotic shock, heat shock, or genotoxic agents induces LT formation also in 
absence of Ca2+ (5,68). 
Besides Ca2+ and PC binding, 5-LOX product formation is regulated by kinase activity and 
corresponding phosphorylation. Both phosphorylation at Ser271 by p38 dependent MAPKAP 
kinase (mitogen-activated protein kinase-activated protein kinase) MK-2/3 and at Ser663 
mediated by ERK-1/2 (extracellular-signal regulated kinase) were shown to increase LT 
formation in neutrophils, whereas phosphorylation at Ser523 by protein kinase A (PKA) 
suppressed 5-LOX activity (6,53,69,70). However, whether the subcellular distribution is 
affected by phosphorylation is still under investigation and several, partly oppositional findings 
have been reported to date (53). 
 
1.3.4 Subcellular organization of enzymes involved in LT biosynthesis 
Cellular 5-LOX activity is strongly determined by its subcellular localization and the interaction 
with other proteins (Fig. 1.6). Under resting conditions, 5-LOX is located in soluble cell 
compartments of myeloid cells including nucleus or cytosol (71). However, subcellular 
localization of inactive 5-LOX is strongly cell-dependent and regulated by nuclear localization 
(NLS) and nuclear export signals (NES) (72,73). In human neutrophils, 5-LOX was found to be 
largely cytosolic but rapidly redistributed to the soluble parts of the nucleus after in vitro 
adherence to several surface materials (74). 
Induction of LT formation was related to simultaneous Ca2+-mediated translocation of cPLA2 
and 5-LOX to the nuclear envelope and the assembly of a multi-protein complex involving the 
membrane-embedded helper protein FLAP (see 5-Lipoxygenase-activating protein) (75-77). 
Formation of this complex at either the inner or the outer membrane of the nucleus is supposed 
to determine the formation of LTB4 or LTC4, respectively, since soluble LTA4H was found to be 
expressed within the nucleus and LTC4S is exclusively inserted into the outer nuclear 
membrane (77). Furthermore, binding of 5-LOX to the actin regulating coactosin-like protein 
(CLP) and the RNA helicase dicer was reported and resulted in increased 5-LOX activity in 
vitro (53,78). 
Taken together, subcellular organization of different enzymes might be a key mechanism in 
the regulation of LM biosynthesis and underlines the occurrence of a multifactorial, intricate 
mechanism. Based on these findings, stimulation of cellular 5-LOX product formation in line 
with subcellular translocation is achieved by a plethora of agents including the Ca2+-mobilizing 
compound ionophore A23187, or naturally-occurring soluble factors like N-formylmethionyl-
leucyl-phenylalanine (fMLP), complement component 5a (C5a), platelet-activating factor 
(PAF), IL-8 or zymosan (5,79-84). Noteworthy, endogenous AA release and LT formation is 
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very moderate upon stimulation with these physiological agents, although cell priming using 
GM-CSF, lipopolysaccharides (LPS) or tumor necrosis factor α (TNFα) could strongly increase 
LM biosynthesis (5). 
 
 
 
Fig. 1.6 Subcellular localization of LT-formatting enzymes (given as surface renderings, PDB accession 
numbers: (stable) 5-LOX, blue – 3o8y; FLAP, green - 2q7m; cPLA2α, dark grey – 1cjy; LTA4H, orange – 1hs6; 
LTC4S, red – 2pno), modified from Newcomer et al. 2010 (77). Upon cellular stimulation, 5-LOX and cPLA2α 
translocate to the nuclear envelope with subsequent Ca2+-mediated membrane binding by their N-terminal 
domains (depicted in light colors). AA is released by cPLA2α and converted into LTA4 by the 5-LOX/FLAP 
complex. Depending on cytosolic or nuclear localization of 5-LOX, LTA4 is subsequently metabolized to the 
corresponding LTs by either LTC4S or LTA4H, respectively. 
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1.4 5-Lipoxygenase-activating protein (FLAP) 
1.4.1 Protein expression and crystal structure of FLAP 
As emphasized above, localization of 5-LOX at the nuclear envelope was described as a key 
determinant for endogenous substrate access and LT formation. Soon after the identification 
of 5-LOX and the mediated LT biosynthesis, 5-LOX was transfected to osteosarcoma cells and 
stimulated with A23187, however without apparent product formation (85). In parallel, the 
indole-based inhibitor MK886 (L-663-539) was shown to inhibit LT formation in cellulo without 
directly targeting 5-LOX activity (86). Based on these observations, a novel protein was 
isolated as MK886-binding protein and characterized by Miller et al. in 1990. In detail, 
neutrophil extracts were incubated with the MK886 competing 125I-lablled photoaffinity probe 
L-669,083 to visualize a 18 kDa, membrane-associated protein subsequently termed as 5-
lipoxygenase-activating protein (FLAP) (87). 
Besides microsomal glutathione-S-transferases (MGST1-3), LTC4S, and microsomal 
prostaglandin E synthase-1 (mPGES-1), FLAP belongs to the MAPEG protein family 
(membrane-associated proteins in eicosanoid and glutathione metabolism) (88). Although a 
considerably sequence homology within the family was discussed, FLAP does not possess 
GSH binding sites and lacks any enzymatic activities, which is in clear contrast to the other 
MAPEG members that are involved in the biosynthesis of LMs and metabolism of xenobiotics 
(88). FLAP is encoded by the ALOX5AP gene located on chromosome 13 and is predominately 
expressed in bone marrow-derived cells, although minor protein levels were found in various 
other tissues including epithelia and brain cells (1,72). Similar to 5-LOX, FLAP expression 
could be increased by colony-stimulating factors, vitamin D3 or IL-3 (55,57,72,89). Interestingly, 
ALOX5 and ALOX5AP are not identical in their promoter regions and are located on distinct 
chromosomes, although their translation is restricted to almost identical cell types (72). 
However, 5-LOX knockout mice showed decreased expression of FLAP suggesting a 
correlation that is still elusive (90). 
A 4.0 Å crystal structure of FLAP was obtained in presence of the inhibitor MK-591 by Ferguson 
et al. in 2007 (91). FLAP forms a homotrimer anchored within the phospholipid bilayer (Fig. 
1.7B). Each monomer consists of four α-helices (α1-α4), spanning through the nuclear 
membrane, and a short lumenal helix at the N-terminus (αL). Moreover, a lumenal (L1) and 
two cytosolic (C1 and C2) loops serve as linker of the transmembrane helices, whereas both 
N- and C-terminal ends are facing the inner side of the nuclear double membrane (Fig. 1.7A). 
Interactions between the monomers were found for every subunit except of helix α3 and the 
lumenal loop L1 (91). Three cavities exposed to the lipid surface of FLAP are formed by 
proximate monomers and were shown to be responsible for inhibitor-binding, including van der 
Waals interactions by Val20, Val21, Gly24, Phe25, Ala27, Ala63, Tyr112, Ile113, lle119, Leu120, and 
Phe123 as well as polar interplays by Asn23, Asp62, Thr66, and Lys116 (91). Interestingly, an 
additional cavity within the trimer of FLAP was described. It is directed towards the lumenal 
side of the membrane and reaches from the bottom of the trimer to Pro65 that is located at the 
midpoint of the protein. Noteworthy, Pro65 is positioned at the characteristic bend of helix α2 
(91). Proline- enriched distortions within transmembrane proteins are thereby discussed to be  
INTRODUCTION 
14 
 
Fig. 1.7 Crystal structure of membrane-bound FLAP. A 3D-structure of a FLAP monomer according to 
Ferguson et al. 2007 (91), with helices shown in red and loops in blue (PDB accession number: 2q7r). Each 
monomer consist of a lumenal helix αL (residues 1-9, highlighted in light red), helix α1 (10-37), loop C1 (38-47), 
helix α2 (48-77) with a bend at Pro65 (presented as cyan spheres), loop L1 (78-80), helix α3 (81-101), loop C2 
(102-115), helix α4 (116-138), and the extended C-terminus (139-161). B Membrane-embedded FLAP (PDB 
accession number: 2q7r) shown as homotrimer (cartoon presentation of monomers colored in red, orange, and 
yellow and phospholipids with polar headgroups depicted in light or dark grey lines, respectively) The given 
trimer is 60 Å long and 36 Å wide. The simulation inserting FLAP into a lipid bilayer is adopted from the free 
access MemProtMD database (http://memprotmd.bioch.ox.ac.uk/_ref/PDB/2q7r/ _sim/2q7r_default_dppc/) 
(Newport et al. 2019 (92)) and partially differs from the original opinions of Ferguson et al. 
 
related to transmembrane signaling, that has not been described for FLAP yet (93). Moreover, 
although sharing an overall sequence homology of approximately 31% with LTC4S, FLAP 
displays highly conserved structural differences that might explain its unique role in eicosanoid 
metabolism. In detail, FLAP is devoid of a fifth lumenal helix, whereas loop C2 and the 
intersection to helix α4 is extended, resulting in insufficient GSH binding. In addition, the 
conserved cytosolic loops within the structure of FLAP might be responsible for an interaction 
with 5-LOX that has not been reported for other MAPEG proteins so far (77,88). 
 
1.4.2 Role of FLAP in LM biosynthesis and inflammatory diseases 
Deficient in any enzymatic activity, the role of FLAP during LT biosynthesis has long been 
discussed. Early studies revealed its eminent functions in binding and transferring AA to the 
active site of 5-LOX and inhibitors such as MK886 were shown to directly compete with the 
substrate to bind FLAP (94). However, the presence of these inhibitors could not prevent AA 
release in neutrophils, thus disproving FLAP to have a proper lipase activity (87). Moreover, 
binding to FLAP was reported for several other FAs distinct from AA, although with lower 
affinities (95). 
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Soon after its identification, it was hypothesized that FLAP acts as 5-LOX anchor protein 
mediating 5-LOX translocation and association to the nuclear envelope (85,96), but proceeded 
studies demonstrated that 5-LOX redistribution upon stimulation is FLAP-independent and 
cannot be prevented by MK886 (12,97). A direct interaction of 5-LOX and FLAP was shown 
recently by making advantage of a proximity ligation assay (PLA) that detects in situ protein-
protein interactions at closer proximities than 40 nm (12,60). However, amino acid residues 
involved in this process remain elusive for both proteins. 
As mentioned before, LT formation was moderate when 5-LOX was transfected to intact cells 
alone, while co-expression with FLAP resulted in elevated amounts of 5-LOX products (85). 
The contribution of FLAP is eminent when LT biosynthesis is based on endogenous FA supply. 
In contrast, conversion of exogenous AA sources is supported by, but not exclusively 
depending on FLAP (53). In a recent study, FLAP appeared to play a major role in supporting 
the second step of 5-LOX catalysis by promoting the conversion from 5-HpETE to LTA4 (98). 
Additionally, our group reported that FLAP inhibition specifically decreases LT formation in 
human macrophages treated with intact pathogenic Escherichia (E.) coli bacteria. However, 
pro-resolving mediators appeared to be increased in presence of MK886, pointing out FLAP 
as a promising pharmacological target for the treatment of inflammatory diseases (99). 
Moreover, mice deficient in FLAP showed reduced inflammatory reactions and decreased LT 
formation in isolated peritoneal macrophages. In parallel, ALOX5AP knockout mice developed 
properly and healthy, suggesting FLAP’s unique role in LT biosynthesis without affecting 
physiological processes (100). Expression of FLAP was also related to atherosclerosis and 
cerebral diseases. For instance, mice deficient in ALOX5AP or treated with FLAP inhibitors 
showed attenuated formation of atherosclerosis (101,102). Furthermore, genetic knockout of 
ALOX5AP ameliorated the neuropathology of Alzheimer’s diseases implying a repeatedly 
discussed role of FLAP in the progression of neurological disorders and cerebral inflammation 
(40,103). Besides, a four-SNP haplotype of ALOX5AP was associated with an increased risk 
of stroke and myocardial infarcts in Iceland, apparently due to enhanced LTB4 formation (104). 
 
1.5 Staphylococcus aureus (S. aureus) 
1.5.1 S. aureus in infectious diseases 
As mentioned above, the most prominent inducers of inflammation and related bioactive 
mediator formation are microbial challenges (15). Among bacteria, the Gram-positive 
micrococcus Staphylococcus (S.) aureus is a frequent cause of both community- and hospital-
acquired infections. The bacteria appear in characteristic clusters and are characterized by a 
coagulase activity and gold-pigmentated colonies during cultivation (105). As a commensal, 
30 to 50 percent of the population is colonized with S. aureus without developing an infectious 
disease, but invading bacteria and interaction with the host immune system are often 
associated with life-threatening infections (4,105). 
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Fig. 1.8 Neutrophils challenged with 
S. aureus, microscopic image 
adopted from adopted from Lowy 1998 
(105). 
 
Accordingly, S. aureus can cause a multitude of diseases including pleuropulmonary, skin and 
soft tissue or osteoarticular infections as well as bacteremia or infective endocarditis (4). More 
recently, S. aureus biofilm formation was discussed to be a common risk factor when foreign 
devices are implanted in human (4,106). Noteworthy, staphylococcal infections are strongly 
related to leukocyte infiltration and frequently result in abscess formation (105). In this respect, 
granulocyte-depleted mice could not survive intravenous S. aureus infections, underlining a 
superior role of neutrophils during staphylococcal infection (107) (Fig. 1.8). However, the 
arsenal of factors participating in the pathogenesis of S. aureus is divers and remains far from 
complete understanding (105). It is well excepted that exotoxins secreted from S. aureus are 
involved in disease progression and vaccination with RNAIII activating protein (RAP) that 
regulates toxin formation was protective against cutaneous staphylococcal infections (108). 
Since RAP and RNAIII play crucial roles within a defined quorum-sensing system of S. aureus, 
the underlying regulation of exotoxin expression will be discussed in more detail within the 
following section. 
 
1.5.2 Genomic regulation of staphylococcal exotoxin expression 
Bacterial growth and cell density of S. aureus cultures are regulated by two key mechanism, 
termed as the accessory gene regulator (agr) and the LuxS system (109). The former is 
thought to be crucial for staphylococcal pathogenesis, since agr controls about 70 genes of 
which 23 have been related to the virulence of S. aureus to date (110). 
The agr system consists of four proteins, ArgA, AgrB, AgrC, and AgrD, and their related genes, 
agrA to agrD (Fig. 1.9). AgrD, also referred to as autoinducing peptide (AIP), undergoes 
extracellular export by membrane-bound AgrB and subsequently activates the transmembrane 
kinase AgrC. AgrC in turn phosphorylates intracellular AgrA that finally binds to two distinct 
promoter regions, P2 and P3, and thereby controls the formation of RNAII and RNAIII, 
respectively. While RNAII is regulating the transcription of the agr genes, giving a positive 
feedback loop for the quorum-sensing system, RNAIII is involved in the expression of multiple 
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staphylococcal proteins (109,110). On the one hand, RNAIII directly represents the mRNA for 
δ-hemolysin (δ-toxin) expression and stimulates the translation of α-hemolysin mRNA. On the 
other hand, RNAIII and its related antisense base pairing mechanism inhibits the expression 
of the repressor protein Rot (repressor of toxins), resulting in increased release of virulence 
factors (109). Besides, AgrA was shown to directly mediate the expression of phenol-soluble 
modulins (PSMs, see Staphylococcal exotoxins), independent of RNAII and RNAIII activation 
(111). 
An additional key regulator in exotoxin expression, complementary to the agr system, is the 
staphylococcal accessory regulator A (sarA). SarA mediates the expression of agr genes 
under basal conditions by targeting the promotor region P2 (110,112). Moreover, sarA was 
shown to directly promote the expression of exotoxins such as α-hemolysin, independently of 
Fig. 1.9 Staphylococcal quorum-sensing is mediated by agr. The expression of Agr proteins is regulated by 
the corresponding genes agrA – agrD. AgrB mediates the release of AgrD which in turn can activate AgrC and 
AgrA, or cross-inhibit the growth of non-related staphylococci. Activated AgrA promotes the translation of agr-
genes, thereby giving a feedback-regulation for quorum-sensing, and increases RNAIII transcription. Target 
genes including staphylococcal exotoxins and proteins are directly regulated by AgrA (PSMs, see Fig. 1.10) or 
dependent on RNAIII transcription, as indicated. The figure is adopted and modified from Le et al. 2015 (109). 
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agr, underlining the crucial role of sarA as second important global gene regulator in  
S. aureus (113). Noteworthy, S. aureus strains carrying mutations in either agr or sarA showed 
decreased virulence compared to the corresponding wildtype strains, whereas only the 
agr/sarA double deletion mutant was found to be completely avirulent (110). 
 
1.5.3 Staphylococcal exotoxins 
A multitude of agr-regulated exotoxins are secreted by S. aureus. These polypeptides can be 
separated into distinct classes with highly specific but generally membrane damaging 
properties: (I) α-hemolysin and bi-component leukocidins with pore-forming abilities; (II) β-
hemolysins with sphingomyelinase activity; and (III) small amphipathic PSMs that were shown 
to be cytolytic for leukocytes as well, thus representing a novel group of staphylococcal 
leukocidins (114,115). 
Among staphylococcal toxins, α-hemolysin belongs to the best described virulence factors and 
was associated to several S. aureus diseases (116-118). α-Hemolysin is of 33.4 kDa size and 
its expression is regulated RNAIII-dependently (109,119). The cytolytic activity of α-hemolysin 
relies on the ability to form homoheptameric, β-barrel transmembrane pores with an 14 Å 
diameter that disturb membrane composition and enable the transport of small molecules, 
especially the influx of Ca2+ ions and its subsequent cell death (114,119). Recently, ADAM-10 
(A disintegrin and metalloproteinase domain-containing protein 10) was identified to interact 
with α-hemolysin and organizes pore formation (120). While ADAM-10 is responsible for toxin 
binding, caveolin-1 was identified as a second co-receptor mediating a conformational change 
and insertion of α-hemolysin into the lipid-bilayer (114,121). In this respect, human monocytes 
and lymphocytes showed higher cytolytic sensitivity compared to granulocytes (122). 
Besides α-hemolysin, the subclass of staphylococcal pore-forming toxins (PFTs) is 
complemented by bi-component leukocidins. They consist of four subgroups: (I) γ-hemolysin, 
(II) Panton-Valentine leukocidins (PVLs), (III) leukocidin ED (LukED) and (IV) leukocidin AB 
(LukAB) (114). Each leukocidin is genetically regulated by the agr-Rot system and is built of 
two monomeric, 33 kDa subunits, one S and one F component (slow and fast migration during 
chromatographic analysis). Leukocidins are supposed to form heterooctameric pores within 
the membrane of leukocytes including monocytes, neutrophils, and macrophages. Pore-
formation of leukocidins thereby involves the initial recognition of complement and chemokine 
receptors by the S component and subsequent attachment of a corresponding F component. 
Resulting β-barrel pores allow the influx of cations as described for α-hemolysin lead to cell 
lysis and cell death, respectively (123). 
β-hemolysin exceeds a sphingomyelinase activity by hydrolyzing sphingomyelin into 
phosphorylcholine and ceramide. Thus, it is not considered as a pore-forming staphylococcal 
exotoxin (114). The translation of the corresponding hlb gene is regulated by Rot in a RNAIII-
dependent manner, leading to the expression of β-hemolysin with a molecular weight of 35 
kDa (124,125). The protein shows structural similarities to other bacterial sphingomyelinases 
from Listeria ivanovii and Bacillus cereus and was shown to be active against various human 
immune cells, albeit related studies are partly inconsistent in this respect (125,126). In addition, 
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the mechanism of β-hemolysin-related cytotoxicity remains poorly understood, although the 
influence on membrane fluidity might be a crucial determinant (114). 
PSMs were first described in 1999 when Mehlin et al. performed hot phenol extraction of S. 
epidermidis cultures (127). PSMs consist of PSMα(1-4), PSMβ(1-2) and PSMγ. The latter was 
found to be equivalent to δ-hemolysin (115,127). Two groups of PSMs have been classified 
according to their protein size: PSMα and δ-hemolysin consist of 20-26 amino acids, while 
PSMβ are about 44 residues long (114). The expression of PSMα and PSMβ is directly 
regulated by AgrA, while δ-hemolysin depends on RNAIII formation (109) (Fig. 1.10). Notably, 
high levels of PSMs were found in pathogenic species (128). Due to their amphipathic 
properties, the key feature of PSMs is a cytolytic effect that was shown to be directed towards 
several cell types including endothelial cells, leukocytes, and red blood cells. Along these lines, 
PSMα3 was found to be the most effective cytolytic PSM (115). Interestingly, in contrast to 
other staphylococcal exotoxins, α-type PSMs were shown to mediate neutrophil lysis even 
after phagocytotic ingestion, indicating an important role for bacterial survival during S. aureus 
infections (115). Recent studies revealed a PSM-dependent activation of the formyl peptide 
receptor 2 (FPR2) in human neutrophils resulting in chemotaxis and Ca2+ influx (129). Hence, 
since this thesis focuses on the activities of PSMs on human neutrophils, the general role of 
FPRs will be discussed in the following chapter. 
 
Fig. 1.10 A psm-gene control of staphylococci modified from Le et al. 2015 (109). Expression of α- and β-type 
PSMs is mediated by the promoter AgrA in a RNAIII-independent manner, while γ-type PSMs (equivalent to δ-
hemolysin) are directly encoded by RNAIII (see Fig. 1.9). B-C Crystal structure of amphipathic PSMα3 (PDB 
accession number: 5kgy) in sphere rendering (B, polar residues are highlighted in blue and lipophilic residues 
in red) or as α-helical cartoon with residues presented as sticks (C). N-terminal parts of the peptide are directed 
to the top. D Amino acid sequence of PSMα3 with residues highlighted in the colors as indicated for panel B. E 
Recent opinion about receptor-independent PSM cell lysis: amphipathic PSM molecules attach to cellular 
membranes with subsequent structural disintegration and final pore-formation. Figures B-E are modified from 
Cheung et al. (115). 
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1.6 Formyl peptide receptors (FPRs) 
1.6.1 FPRs in infection and inflammation 
As mentioned before, microbial induction of inflammation relies on both, recognition of PAMPs 
and virulence factors, and the formers require the presence of dedicated pattern recognition 
receptors (PRRs) (15). Nonetheless, a clear discrimination between activation of PRRs and 
receptor-independent effects of virulence factors is often difficult, and several co-receptors are 
involved in toxin activity. 
An important class of PRRs are formyl peptide receptors (FPRs), entitled in terms of their ability 
to recognize bacterial and mitochondrial N-formylated peptides and protein fragments 
(130,131). Three G-protein-coupled human FPRs have been described so far, FPR1, FPR2 
and FPR3, respectively. While FPR1 and FPR2 are predominantly expressed in various 
myeloid cells including monocytes and neutrophils, FPR3 expression is restricted to 
monocytes. In addition, FPR1 could be detected in non-myeloid cells such as hepatocytes, 
astrocytes or microglia cells, and FPR2 transcripts were found in both epithelial and endothelial 
cells, hepatocytes, or neuroblastoma cells (132). Upon activation, FPRs mediate neutrophil 
chemotaxis, degranulation and superoxide formation, but also the expression of inflammatory 
cytokines such as IL-8 or nuclear factor κ-light-chain-enhancer of activated B cells, and finally 
affect neutrophil apoptosis and the subsequent initiation of resolution (131). 
The number and structures of FPR-ligands is rather diverse and will be discussed for FPR1 
and FPR2 in more detail within the next sections. In contrast, the in vivo role of FPR3 is still 
under investigation (130). 
 
1.6.2 Formyl peptide receptor 1 (FPR1) 
FPR1 displays the archetype of G-protein-coupled FPRs and can be activated by a plethora 
of N-formylated bacterial and mitochondrial peptides. The most potent agonist for FPR1 is the 
short peptide fMLP (colloquial, more correctly referred to as fMLF) derived from E. coli, that is 
widely applied to study FPR1 functions (131). In contrast to initial findings, it has been 
demonstrated that FPR1 also binds non-formylated peptides, although in a much lesser extent. 
Agonist binding leads to the subsequent activation of the Gi-type protein and mediates an 
increase in intracellular Ca2+ and stimulation of kinases including phosphoinositide 3-kinase 
(PI3K), p38 mitogen-activated protein kinase (MAPK), and ERK (133). 
Interestingly, bacterial pathogens are able to secrete peptides that antagonize FPR1 ligands 
(130). For instance, a majority of clinical staphylococcal isolates expresses the chemotaxis 
inhibitory protein of Staphylococcus aureus (CHIPS) that selectively inhibits FPR1 activation 
at nanomolecular concentrations and might therefore support S. aureus to evade from host 
recognition (130,134). 
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1.6.3 Formyl peptide receptor 2 (FPR2) 
FPR2, also termed as FPR-like 1 (FPRL1) receptor, shares a 69% sequence homology with 
FPR1 (133). Amongst others, the expression of FPR2 is regulated by TNFα or signaling 
through glucocorticoid receptors and other PRRs (135). In contrast to FPR1, FPR2 shows 
lower affinity towards fMLP and other N-formylated peptide agonists, but recognizes longer 
and more diverse structures (132). In this respect, FPR2 was demonstrated to bind several 
endogenous proteins, peptides and lipids including serum amyloid A (SAA), the antimicrobial 
peptide LL-37, LXA4 (FPR2 is therefore sometimes referred to as FPR2/ALX receptor), or 
annexin A1, respectively. Interestingly, while SAA and LL-37 binding is related to pro-
inflammatory activities, both annexin A1 and LXA4 were shown to inhibit neutrophil migration 
and thus mediate anti-inflammatory responses via FPR2 (133). These contradictory ligand-
dependent effects are still not fully understood but might be explained by distinct homo- and 
heterodimeric states of FPR2 and FPR1 upon stimulation (136). Noteworthy, it was recently 
described that PSMs released from highly pathogenic S. aureus USA300 exceed their 
chemotactic activities by targeting FPR2 at nanomolecular concentrations, thereby underlining 
the eminent roles of both PSMs and FPR2 during staphylococcal-host-interaction (129). 
In contrast, the synthetic peptide Trp-Arg-Trp-Trp-Trp-Trp-CONH2 (WRW4) was shown to be 
a specific antagonist for FPR2 and is therefore widely used as tool in biochemical studies 
targeting FPR2 signaling (137). Moreover, S. aureus secretes a protein termed FPRL1 
inhibitory protein (FLIPr) that shares an overall structural homology of 28% with CHIPS, but 
specifically inhibits FPR2 activation at low concentrations (138). 
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2 AIM OF THE THESIS 
Acute inflammation and its subsequent resolution are key mechanisms of the human immune 
system to respond to homeostatic imbalances. Various innate immune cells including 
neutrophils and tissue-resident cells are involved in inflammatory reactions, and interact and 
regulate their functions via pro- and anti-inflammatory mediators (15,16,21). Among the group 
of these mediators, lipid metabolites derived from polyunsaturated FAs are key regulators 
during inflammatory conditions. Over the past decades, a plethora of LMs have been described 
to be involved in physiologic and pathophysiologic processes (27). Although intensive research 
has focused on eicosanoid formation and pharmacological intervention in related diseases, the 
pathological activation of LM biosynthesis is still not completely understood. 
I - Chemical agents such as the Ca2+ ionophore A23187 are commonly known as agents 
to induce the biosynthesis of bioactive LMs, while naturally occurring agents such as fMLP, 
PAF or C5a were virtually incapable in sufficient FA release and subsequent formation of LMs 
(5,53,79,139). It was recently described that human macrophages challenged with intact 
bacteria display distinct LM biosynthesis that was clearly related to their phenotypical subtype 
and the pathogenicity of the applied microbes (140). 
This thesis aims to describe the underlying molecular mechanisms for bacterial 
stimulation of bioactive lipids in neutrophils and focuses on the activation of 5-
LOX that acts as a key enzyme in LT formation (1). 
For that reason, intact pathogenic and non-pathogenic bacteria as well as sterile-filtered 
bacteria-conditioned medium containing secreted microbial exotoxins were investigated to 
activate 5-LOX in different human cell types. In order to relate the resulting LT formation with 
particular bacterial secondary metabolites, genetically modified S. aureus strains, deficient in 
distinct toxin expression and isolated bacterial exotoxins were evaluated for their ability to 
activate LM formation in human neutrophils. Moreover, the rise of drug-resistant infections 
strengthens the necessity of alternative therapeutic strategies besides established 
antimicrobials (3,141). Thus, the involvement of the PRR FPR2 and pharmacological 
intervention using the receptor antagonist WRW4 were studied to give insights into potential 
therapy strategies against S. aureus infections. 
II - Considering the eminent role of LTs in acute phases of inflammation, various 
compounds have been described to modulate LM formation (10,142). Besides nonsteroidal 
anti-inflammatory drugs (NSAIDs) that inhibit COX-mediated prostanoid formation, only the 
direct 5-LOX inhibitor zileuton and the cysLT receptor antagonist montelukast could reach 
therapeutic application (37,142,143). Targeting 5-LOX-mediated LT formation seems to be 
reasonable since both LTB4 and cysLTs were shown to drive inflammatory processes (1,64). 
On the other hand, 5-LOX may contribute to beneficial LX and Rv formation via transcellular 
pathways involving several leukocytes, tissue associated cells and corresponding biosynthetic 
pathways (22). Considering the obvious overall structural similarities of mammalian LOXs, 
selective inhibition of a certain isoform seems to be challenging (40). In this respect, direct 
inhibition of 5-LOX might be an inappropriate strategy to manipulate inflammatory processes. 
Accordingly, recent studies claimed an increase in anti-inflammatory SPM biosynthesis and 
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beneficial 12-/15-LOX activity in human macrophages and whole blood preparations pre-
treated with the FLAP inhibitors MK886 or MK-0591 (99,144). In addition, previous publications 
described the importance of a 5-LOX/FLAP in situ interaction for sufficient LT formation, and 
that the assembly of this protein complex can be prevented by inhibition of FLAP (12,60). 
Unfortunately, FLAP inhibitors could not reach the pharmaceutical market to date, mainly due 
to inappropriate pharmacokinetic properties of highly lipophilic compounds and the in vivo loss 
of potency (8,10). 
The present thesis aims to elucidate possible interaction sites of FLAP with 5-
LOX in order to understand the in situ assembly of a LT-biosynthetic protein 
complex and thereby might optimize the development of novel FLAP inhibitors. 
For this reason, site-directed mutagenesis of amino acid residues (Ala27, Ser41, Thr66, Ser108, 
Tyr112, Ile119) located in distinct parts of the homotrimeric FLAP protein (91) was performed and 
5-LOX/FLAP interaction as well as LT formation of these mutants were investigated using a 
HEK293 (human embryonic kidney) cell model stably transfected with human 5-LOX and FLAP 
isoforms as reported previously (98). Furthermore, putative phosphorylation sites within the 
FLAP structure (Ser41, Ser108) were examined, as a recent study revealed the presence of such 
residues within the structurally related LTC4S (13). 
Taken together, this thesis aims to enhance the knowledge of LT biosynthesis in infection-
induced inflammation and the concurrent participation of 5-LOX and its helper protein FLAP. 
Additionally, mutagenesis and activity studies addressing FLAP might support prospective 
drug development approaches. 
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3 MATERIALS AND METHODS 
3.1 Materials 
Unless depicted specifically, reagents were obtained from the following providers: 
Acetic acid VWR (Darmstadt, Germany) 
Acetonitrile GE Healthcare Life Science (Freiburg, Germany) 
Acrylamide VWR (Darmstadt, Germany) 
Alexa Fluor 488 goat anti-rabbit Invitrogen (Darmstadt, Germany) 
Alexa Fluor 555 goat anti-mouse Invitrogen (Darmstadt, Germany) 
AA Cayman Chemical (Biomol, Hamburg, Germany) 
Bovine serum albumin (BSA) AppliChem (Darmstadt, Germany) 
Brain heart infusion broth (BHI) Sigma-Aldrich (Taufkirchen, Germany) 
Bromophenol blue Merck (Darmstadt, Germany) 
Ca2+ ionophore A23187 Cayman Chemical (Biomol, Hamburg, Germany) 
CaCl2 AppliChem (Darmstadt, Germany) 
CellTiter-Glo® Promega GmbH (Mannheim, Germany) 
ChemoTxSystem ChemoTx Nr 101-5 Neuro Probe, Inc. (Gaithersburg, MD, USA) 
CHIPS HycultBiotech (Uden, Netherlands) 
d4-LTB4 Cayman Chemical (Biomol, Hamburg, Germany) 
d4-PGE2 Cayman Chemical (Biomol, Hamburg, Germany) 
d5-LXA4 Cayman Chemical (Biomol, Hamburg, Germany) 
d5-RvD2 Cayman Chemical (Biomol, Hamburg, Germany) 
d8-5S-HETE Cayman Chemical (Biomol, Hamburg, Germany) 
d8-AA Cayman Chemical (Biomol, Hamburg, Germany) 
Dextrane Sigma-Aldrich (Taufkirchen, Germany) 
DMEM with glutamine GE Healthcare Life Science (Freiburg, Germany) 
DMSO Merck (Darmstadt, Germany) 
Dulbecco’s Buffer Substance (PBS) SERVA Electrophoresis (Heidelberg, Germany) 
Duolink® detection reagents FarRed Sigma-Aldrich (Taufkirchen, Germany) 
Duolink® PLA probe anti-mouse MINUS Sigma-Aldrich (Taufkirchen, Germany) 
Duolink® PLA probe anti-rabbit PLUS Sigma-Aldrich (Taufkirchen, Germany) 
EDTA AppliChem (Darmstadt, Germany) 
Ethanol Fisher Scientific (Schwerte, Germany) 
FA free BSA Sigma-Aldrich (Taufkirchen, Germany) 
Fetal calf serum (FCS) Sigma-Aldrich (Taufkirchen, Germany) 
fMLP Sigma-Aldrich (Taufkirchen, Germany) 
Fura-2AM Fisher Scientific (Schwerte, Germany) 
Geneticin G418 GE Healthcare Life Science (Freiburg, Germany) 
Glucose AppliChem (Darmstadt, Germany) 
Glutathione AppliChem (Darmstadt, Germany) 
Glycerol Caesar & Loretz GmbH (Hilden, Germany) 
HEPES Merck (Darmstadt, Germany) 
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HPLC/UPLC solvents VWR (Darmstadt, Germany) 
HCl VWR (Darmstadt, Germany) 
Hygromycin B Invitrogen (Darmstadt, Germany) 
Leupeptin Sigma-Aldrich (Taufkirchen, Germany) 
L-Glutamine BioChem GmbH (Karlsruhe, Germany) 
LipofectamineTM LTX Plus Reagent Invitrogen (Darmstadt, Germany) 
LY293111 Cayman Chemical (Biomol, Hamburg, Germany) 
LY294002 Cayman Chemical (Biomol, Hamburg, Germany) 
MgCl2 VWR (Darmstadt, Germany) 
MgSO4 AppliChem (Darmstadt, Germany) 
Methanol Fisher Scientific (Schwerte, Germany) 
Methyl formate VWR (Darmstadt, Germany) 
MK886 Cayman Chemical (Biomol, Hamburg, Germany) 
n-Hexane VWR (Darmstadt, Germany) 
Non-essential amino acids Sigma-Aldrich (Taufkirchen, Germany) 
Non-immune goat serum Invitrogen (Darmstadt, Germany) 
Nutrient broth no 1 medium (NB) Sigma-Aldrich (Taufkirchen, Germany) 
Penicillin/Streptomycin-solution GE Healthcare Life Science (Freiburg, Germany) 
PGB1 Cayman Chemical (Biomol, Hamburg, Germany) 
Phenylmethylsulfonyl fluoride Sigma-Aldrich (Taufkirchen, Germany) 
Pierce™ 16% Formaldehyde Fisher Scientific (Schwerte, Germany) 
KCl VWR (Darmstadt, Germany) 
KH2PO4 AppliChem (Darmstadt, Germany) 
PSMα1 and PSMα3 synthesized at Genosphere Biotechnology  
 (Stuttgart, Germany) 
RO-31-8220 Tocris Bioscience (Ellisville, MI, USA) 
RPMI 1640 Medium Sigma-Aldrich (Taufkirchen, Germany) 
RSC-3388 VWR (Darmstadt, Germany) 
Saccharose AppliChem (Darmstadt, Germany) 
SB203580 Cayman Chemical (Biomol, Hamburg, Germany) 
SDS  Roth GmbH (Karlsruhe, Germany) 
Skepinone-L Cayman Chemical (Biomol, Hamburg, Germany) 
NaCl Roth GmbH (Karlsruhe, Germany) 
Soybean trypsin inhibitor Sigma-Aldrich (Taufkirchen, Germany) 
Trifluoroacetic acid (TFA) Merck (Darmstadt, Germany) 
Tris-HCl Roth GmbH (Karlsruhe, Germany) 
Tritium-labeled 3H-AA Biotrend Chemicals GmbH (Köln, Germany) 
Triton X-100 Roth GmbH (Karlsruhe, Germany) 
Trypan blue Sigma-Aldrich (Taufkirchen, Germany) 
Trypsin-EDTA GE Healthcare Life Science (Freiburg, Germany) 
Tween® 20 Roth GmbH (Karlsruhe, Germany) 
UO126 Sigma-Aldrich (Taufkirchen, Germany) 
WKYMVm Tocris Bioscience (Ellisville, MI, USA) 
WRW4 VWR (Darmstadt, Germany) 
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Zileuton Sequoia Research Products (Oxford, UK) 
α-Hemolysin Sigma-Aldrich (Taufkirchen, Germany) 
β-Mercaptoethanol Roth GmbH (Karlsruhe, Germany) 
 
 
3.2 Buffers and media 
Acidified water 8 mL PBS-HCl 
 912 mL MilliQ water 
BHI medium 37 g BHI 
 1 L MilliQ water 
KREPS-HEPES 20 mM HEPES 
 135 mM NaCl 
 5 mM KCl 
 1 mM MgSO4 
 0.4 mM KH2PO4 
 5.5 mM glucose 
 in MilliQ water, pH 7.4 
Laemmli buffer 50 mM Tris-HCl pH 6.8 
 2% SDS 
 10% glycerol 
 2% β-mercaptoethanol 
 12.5 mM EDTA 
 0.02% bromophenol blue 
 in MilliQ water 
NB medium 25 g NB 
 1 L MilliQ water 
PBS 9.55 g Dulbecco’s Buffer Substance 
 1 L MilliQ water 
PBS+/+ 1 mM CaCl2 
 0.5 mM MgCl2 
 in PBS 
PBS-HCl 60 mL HCl 1 M 
 1 L PBS 
PGC 0.1% glucose 
 1 mM CaCl2 
 in PBS 
Stripping buffer 15 g glycine 
 1 g SDS 
 10 mL Tween® 20 
 in 1 L MilliQ, adjust pH 2.2 
TBS 151.5 g Tris-HCl 
 146 g NaCl 
 in 2.5 L MilliQ water, pH 7.4 
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TBS-tween 0.1% Tween® 20 
 in TBS buffer 
Triton lysis buffer 20 mM Tris-HCl pH 7.4 
 150 mM NaCl 
 2 mM EDTA 
 1% Triton-X-100 
 Add freshly: 
 1 mM phenylmethylsulfonyl fluoride 
 10 µg/mL soybean trypsin inhibitor 
 10 µg/mL leupeptin 
 
 
3.3 Methods 
3.3.1 Leukocyte isolation from human blood preparations 
Peripheral human blood was collected from healthy fasted donors at the university hospital 
Jena, Germany. Leukocytes were freshly isolated from concentrated heparinized blood 
preparations as published previously (145). In brief, dextran-sedimentation of erythrocytes was 
followed by density gradient centrifugation on lymphocyte separation medium (Histopaque® -
1077, Sigma-Aldrich, Taufkirchen, Germany). Pelleted polymorphonuclear leukocytes (PMNL, 
neutrophils) were resuspended in ice-cold PBS prior to hypoosmotic lysis of remaining 
erythrocytes. Subsequently, neutrophils were washed twice with ice-cold PBS and diluted to a 
final cell density in buffer solution as indicated for each assay. 
All experiments with human blood preparations were performed in accordance with relevant 
guidelines and were approved by the ethical review committee of the university hospital Jena, 
Germany (license number: 4968-11/16). The donors further excluded any inflammatory 
diseases and the taking of drugs prior to blood donation. 
 
3.3.2 HEK293 cell cultivation 
HEK293 cells were cultivated as adherent monolayers using DMEM (Dulbecco's Modified 
Eagle's Medium with glutamine) containing 10% heat-inactivated FCS, 100 U/mL penicillin and 
100 µg/mL streptomycin. In order to study the subcellular translocation of 5-LOX and the in 
situ assembly of a LT-biosynthetic complex with FLAP at the nuclear envelope, HEK293 were 
stably transfected with pcDNA3.1 plasmids encoding for 5-LOX and FLAP, respectively, using 
a LipofectamineTM LTX Plus Reagent according to the manufacturer’s instructions. 400 µg/mL 
geneticin G418 (for 5-LOX) and 200 µg/mL hygromycin B (for FLAP) were supplemented to 
the cultivation medium to allow polyclonal selection. Western blot analysis (see Preparation of 
Western blot samples) and IF microscopy (Immunofluorescence Microscopy (IF)) were 
performed in to evaluate proper expression of transfected proteins. 
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To investigate the effect of mutated amino acid residues within the structure of FLAP, a Q5TM 
Site-Directed Mutagenesis Kit (New England Biolabs GmbH, Frankfurt a. M., Germany) was 
used according to the vendor’s protocol to construct pcDNA3.1 plasmids for the transfection 
of HEK293 cells. pcDNA3.1_FLAP(hygromycin) was utilized as template for mutation (98). 
Primers were designed with NEBaseChanger software (New England Biolabs GmbH, 
Frankfurt a. M., Germany) as follows: 
Table 3.1 Primer-sequences for mutation using Q5TM Site-Directed Mutagenesis Kit, Ta - annealing 
temperature. 
Mutation Primer – forward (5‘-3‘) Primer – reverse (5‘-3‘) 
Ta 
(°C) 
I119A GAAACGCATCGCACTCTTCCTGTTC CCAAATATGTAGCCAGGG 60 
Y112A CACCCCTGGCGCCATATTTGGGAAAC CTCTGCGTTCTCTCTCCTAG 63 
T66A TGCGTACCCCGCTTTCCTCGC TCTACACAGTTCTGGTTGGCAG 68 
A27L TGGATTCTTTCTCCATAAAGTGGAGC TTCTGGACCACGCTGATG 63 
S41A GAATGGGAGGGCCTTCCAGAGGACC TGGGTCCTGCTTTCGTGC 68 
S41D GAATGGGAGGGACTTCCAGAGGACC TGGGTCCTGCTTTCGTGC 68 
S108A GAGAACGCAGGCCACCCCTGGC TCTCCTAGGTAACCGACAAAG 65 
S108D GAGAACGCAGGACACCCCTGGC TCTCCTAGGTAACCGACAAAG 68 
S108∆ ACCCCTGGCTACATATTTG CTGCGTTCTCTCTCCTAG 62 
 
pcDNA3.1_5-LOX-S271A(G418) and pcDNA3.1_5-LOX-S663A(G418) were prepared as 
described (6,69). Plasmids were amplified overnight in NB medium at 37 °C after 
transformation in One Shot™ TOP10 Chemically Competent E. coli (Invitrogen, Darmstadt, 
Germany), and DNA was extracted using a GeneJET™ Plasmid Midiprep Kit (Fisher Scientific, 
Schwerte, Germany) according to the provider’s protocol. Efficient mutagenesis was verified 
by external plasmid sequencing by Eurofins Umwelt Ost GmbH (Jena, Germany). 
 
3.3.3 Determination of cell density 
Automatic cell counting of leukocytes and HEK293 cells was performed with Vi-CELLTM XR 
Beckmann Coulter (Beckmann Coulter GmbH, Krefeld, Germany) including trypan blue 
staining and viability determination. 
 
3.3.4 Cultivation of bacteria 
In order to investigate the effect of bacterial virulence factors on 5-LOX activity and LM 
formation, the following bacterial strains were utilized: 
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Table 3.2 Bacterial strains applied in this study. Transductants of S. aureus strains were all obtained 
from L. Tuchscherr from the Institute of Medical Microbiology (University Hospital Jena, Germany). 
Strain Description/Reference 
LS1 S. aureus, isolated from swollen joint of arthritic mice (107,146)
LS1∆agr/sarA 
S. aureus, LS1 derivative carrying agr::tet and 
sarA::Tn917LTV1 mutations (147) 
LS1∆hla S. aureus, LS1 hla knockout derivative (148) 
LS1∆psmαβ 
S. aureus, generated by transduction using lysates of RN4220-
307 (∆psmα1-4:tetM) and RN4220-308 (∆psmβ1-2:tetM) (149)
USA300 S. aureus, CA-MRSA (150) 
USA300∆pvl S. aureus, lukF/S-PV knockout derivative of USA300 (150) 
USA300∆psmαβ S. aureus, psmαβ knockout derivative of USA300 (151) 
USA300∆agr S. aureus, agr::tet derivative of USA300 (152) 
TM300 S. carnosus (153) 
O6:K2:H1 E. coli, ATCC19138 from Castellani and Chalmers ATCC® 
BL21 
E. coli, (DE3) competent E. coli, obtained from New England 
Biolabs GmbH (Frankfurt a. M., Germany) 
 
E. coli were grown in NB medium overnight under continuous shaking at 37 °C. On the next 
day, 50 mL of fresh NB medium were inoculated with 10 µL of overnight cultures and cultivated 
at 37 °C till an OD600 of 1 was reached. S. aureus and S. carnosus were grown in BHI medium 
overnight and diluted to an OD600 of 0.05 with fresh BHI medium on the next day. Subsequently, 
staphylococci were cultivated at 37 °C under shaking for another 4 – 5 h. Bacteria cultures 
were finally centrifuged (3,000 g, 5 min, RT) and resuspended in stimulation buffer as depicted 
for each experiment. OD600 was determined prior to infection of the indicated human cells. An 
OD600 of 1 was thereby assumed to represent 1 x 109 bacteria/mL for each strain. In order to 
gain cell-free bacteria-conditioned medium (BCM) for stimulation, centrifugation-supernatants 
from overnight cultures of staphylococci or E. coli were sterile-filtered using 0.22 µm PVDF 
syringe filters (Roth GmbH, Karlsruhe, Germany). Bacterial absence within the BCMs was 
verified by overnight cultivation at 37 °C and subsequent visual control. 
 
3.3.5 Immunofluorescence Microscopy (IF) 
In order to investigate the subcellular localization of 5-LOX and FLAP, immunofluorescence 
(IF) microscopy was performed. Freshly isolated human neutrophils were diluted in PBS 
containing 1 mM CaCl2 and 0.5 mM MgCl2 (PBS+/+) to a cell density of 2 x 106 cells/sample, 
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seeded onto glass coverslips and incubated for 15 min at 37 °C and 5% CO2. Cells were 
subsequently stimulated in PBS+/+ at 37 °C and 5% CO2 as indicated. Trypsinized HEK293 
cells stably co-expressing 5-LOX and FLAP, wildtype or mutant, respectively, were seeded 
onto poly-D-lysine coated coverslips (Kleinfeld Labortechnik GmbH, Gehrden, Germany) at a 
cell density of 0.35 x 106 cells/sample in appropriate medium 2 days prior the experiment. 
Subsequently, HEK293 cells were stimulated in either DMEM without additives or PBS+/+ at  
37 °C and 5% CO2 as indicated. 
Incubations were terminated by adding 4% formaldehyde solution (diluted from Pierce™ 16% 
Formaldehyde) in PBS for 15 min at RT. Samples were washed with PBS prior to cell 
permeabilization with 100% ice-cold acetone for 5 min and 0.25% Triton X-100 in PBS for 10 
min at RT. PBS-washed samples were incubated overnight at 4 °C with primary antibodies 
using a mouse-anti-5-LOX monoclonal antibody (6A12, dilution 1:100, kindly provided from 
Prof. D. Steinhilber, Goethe University Frankfurt, Germany) or mouse-anti-5-LOX (1:1,000, BD 
Biosciences, Heidelberg, Germany), and rabbit-anti-FLAP polyclonal antibody (Abcam, 
Cambridge, UK), each diluted in 10% non-immune goat-serum. Samples were then incubated 
with Alexa Fluor 488 goat-anti-rabbit (1:1,000) and Alexa Fluor 555 goat-anti-mouse (1:1,000) 
secondary antibodies at RT for 1 h and finally fixated on microscope slides using ProLong 
Diamond Antifade Mountant (Invitrogen, Darmstadt, Germany) containing DAPI to stain cell 
nuclei. IF images were collected with a Zeiss Axiovert 200M microscope, and a Plan-
APOCHROMAT 40x/1.3 Oil DIC (UV)VIS-IR 0.17/∞ objective using AxioCam MR camera (Carl 
Zeiss, Jena, Germany) for image acquisition. Pictures, given with a size of 15 µm (neutrophils) 
or 20 µm (HEK293), are representative for at least three independent experiments. 
 
3.3.6 Proximity Ligation Assay (PLA) 
In order to visualize in situ protein-protein interactions, PLA was performed according to the 
provider’s instructions (Duolink® PLA Technology, Sigma-Aldrich, Taufkirchen, Germany). 
HEK293 cells stably expressing 5-LOX and FLAP, wildtype or mutant, respectively, were 
seeded, incubated and permeabilized as described for IF microscopy. An additional blocking 
procedure for 1 h at 37 °C using Duolink® blocking solution was performed prior to overnight 
incubation at 4 °C with primary antibodies as mentioned. Subsequently, samples were 
incubated with Duolink® In Situ PLA Probes for 1 h at 37 °C. PLA probes (anti-mouse MINUS 
and anti-rabbit PLUS) thereby represent specific secondary antibodies carrying 
oligonucleotides that can be linked in case the investigated proteins are in closer proximity 
than 40 nm (12). Samples were thereto incubated with a ligase and appropriate nucleotides at  
37 °C for 30 min. Newly generated, circled DNA fragments were subsequently amplified by 
rolling circle amplification (RCA) by incubation with polymerase for 100 min at 37 °C. Protein-
protein interactions are visualized by fluorescently labeled oligonucleotides that were used for 
RCA. PLA images were acquired as described for IF microscopy after fixation of samples with 
DAPI-containing ProLong Diamond Antifade Mountant (Invitrogen, Darmstadt, Germany) on 
glass slides. Pictures are given as overview of 100 µm or single-cell image of 20 µm size and 
are representative for at least 3 independent experiments. 
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3.3.7 Analysis of intracellular Ca2+ 
Intracellular Ca2+ influx upon stimulation with various virulence factors was assayed by 
continuous fluorescence reading. In brief, 5 x 107 neutrophils were stained with 2 µM Fura-
2AM after resuspension in KREPS-HEPES buffer for 45 min at 37 °C and 5% CO2 in the dark. 
Cells were centrifuged (300 g, 5 min) and subsequently resuspended to a density of 5 x 106 
neutrophils/mL in KREBS-HEPES buffer containing 0.1% BSA and 1 mM CaCl2. 100 µL of this 
suspension were pipetted onto black 96-well microplates PS F-bottom (Greiner bio-one, 
Frickenhausen, Germany) prior to the depicted stimulation. Fluorescence emission λem at 510 
nm was continuously measured following excitation λex at 340 nm and 380 nm, respectively. 
In order to normalize ratios of emissions at both excitation wavelengths (340 nm / 380 nm), 
cells were treated with 1% Triton X-100 representing maximal Ca2+ influx that was set to 1.  
Adherent HEK293 cells stably expressing 5-LOX and FLAP were stained in KREBS-HEPES 
buffer supplemented with 2 µM Fura-2AM for 30 min at 37 °C and 5% CO2 (dark). Detached 
HEK293 cells were pelleted (300 g, 5 min) and resuspended in KREBS-HEPES buffer 
containing 0.1% BSA and 1 mM CaCl2. 0.1 x 106 cells/well were seeded and assayed for Ca2+ 
influx as described for neutrophils. 
 
3.3.8 Cytotoxicity assays 
In order to evaluate the cytotoxic effect of various stimulatory agents, lactate dehydrogenase 
(LDH) release was assayed in freshly isolated human neutrophils. In brief, 5 x 106 cells/mL 
PGC buffer were treated with the indicated stimuli or 1% Triton X-100 (as total cell lysis control) 
for 10 min at 37 °C and subsequently pelleted at 350 g (4 °C, 5 min). Supernatants were diluted 
1:20 with PBS containing 0.1% glucose and LDH release was detected by CytoTox-ONE™ 
Homogenous Membrane Integrity assay kit (Promega GmbH, Mannheim, Germany) according 
to the provided protocol, followed by fluorometric detection (λex 560 nm, λem 590 nm). 
Cell viability was additionally measured with Vi-CELLTM XR Beckmann Coulter GmbH (Krefeld, 
Germany). Briefly, 5 x 106 neutrophils in PGC buffer were treated as indicated and 
subsequently stained with trypan blue prior to automatic cell counting (see Determination of 
cell density). Viability is given as percentage of viable compared to the total number of cells. 
 
3.3.9 Determination of 5-LOX product formation in HEK293 cells 
5-LOX product formation of HEK293 cells stably expressing 5-LOX and FLAP, wildtype or 
mutant, respectively, was assayed after trypsinization of adherent cells, centrifugation (300 g, 
10 min, RT) and resuspension to a final cell density of 1 x 106 cells/mL in PGC buffer. Cells 
were preincubated with 0.1% DMSO (vehicle control) or 300 nM MK866 for 10 min at 37 °C 
prior to stimulation with 2.5 µM Ca2+ ionophore A23187 and 2 µM AA for another 10 min at  
37 °C. Incubations were terminated by adding one volume of ice-cold methanol. Solid-phase  
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extraction (SPE I) was performed as described (see Solid-phase extraction) after addition of 
200 ng PGB1 (internal standard) and sample acidification using PBS-HCl. 5-LOX products 
include 5-HpETE, the corresponding alcohol 5-HETE, and all-trans-isomers of LTB4 and were 
analyzed by RP-HPLC (see RP-HPLC-UV analysis). 
 
3.3.10 Determination of LM formation in human neutrophils 
Freshly isolated human neutrophils were diluted in PGC buffer to a final density of 5 x 106 
cells/mL. As indicated, cells were preincubated for 15 min with vehicle or compounds, 
respectively, prior to stimulation with the indicated agents for 10 min at 37 °C. Incubations were 
stopped with two volumes of ice-cold methanol and 0.99 ng d8-5S-HETE, 46.8 ng d8-AA, 1.07 
ng d4-PGE2, 1.08 ng d5-LXA4, 1.14 ng d5-RvD2 and 1.02 ng d4-LTB4 (Cayman Chemical, 
Biomol, Hamburg, Germany) were added as diagnostic ions for internal standardization. 
Samples were kept on ice for at least 3 h in order to precipitate remaining proteins and were 
finally subjected to solid-phase extraction (SPE II) as stated below (see Solid-phase 
extraction), followed by UPLC-MS/MS analysis of LMs (see UPLC-MS/MS analysis). 
 
3.3.11 Determination of LMs from in vivo experiments 
In order to investigate the effect of bacterial exotoxins on LM formation in vivo, a murine 
footpad infection model was performed by A. Siegmund and L. Tuchscherr at the Institute of 
Medical Microbiology (University Hospital Jena). In brief, C57BL/6 mice were kept under 
pathogen-free conditions prior to subcutaneous footpad infection (right hind) with 2 × 107 CFU 
(colony-forming units) of S. aureus, wildtype or mutant strain, in 50 μL PBS, respectively. The 
left hind footpad was simultaneously inoculated with 50 µL of vehicle control. USA300 infected 
mice were sacrificed 2, 6, 9, 24, and 48 h after infection, whereas USA300∆psmαβ infected 
animals were sacrificed 48 h post-infection. Samples from 4 randomly selected mice were 
utilized per group/experiment. Homogenized foot pad tissues were stored at -80 °C and finally 
subjected to solid-phase extraction (SPE II) in order to isolate LMs prior to analysis by UPLC-
MS/MS. Total LM formation was normalized to 1 µg total protein within the homogenates. 
All animal experiments were performed in accordance with the guidelines of the German 
Society for Laboratory Animal Science 22-2684-04-02-003/15 (Thüringen, Jena) as published 
previously (154). 
 
3.3.12 Chromatographic analysis of LMs 
Solid-phase extraction 
Depending on the further chromatographic analysis, LMs were isolated and concentrated using 
the following SPE methods: 
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SPE I: In order to prepare samples for RP-HPLC-UV analysis, incubations were centrifuged at 
800 g for 10 min at 4 °C and subsequently subjected to MilliQ water conditioned Clean up C18 
RP-columns (100 mg, UCT, Bristol, PA, USA). Flushing with 1 mL MilliQ water and 1 mL 0.25% 
methanol was followed by elution with 300 µL 100% methanol. 
SPE II: Samples for UPLC-MS/MS analysis were centrifuged at 1,200 g, 10 min,  
4 °C and supernatants were diluted with 8 mL acidified water prior to application to MilliQ water 
conditioned Waters Sep-Pak® Vac 6cc extraction columns (Waters, Milford, MA, USA). 
Samples were washed with 6 mL MilliQ water and n-hexane, respectively, and eluted with 6 
mL methyl formate. Subsequently, samples were dried under nitrogen stream with TurboVap 
LV (Biotage, Uppsala, Sweden) and resuspended in 100 – 200 µL ice-cold 50% methanol. 
Analysis of LMs was performed as described below, and as published recently (99). 
 
RP-HPLC-UV analysis 
5-LOX products were analyzed by RP-HPLC using a Nova-Pak C18 Radial-Pak Cartridge, 60 
Å, 4 µm, 5 mm X 100 mm, 1/pkg (Waters, Eschborn, Germany). 50 - 100 µL sample preparation 
from SPE I were injected and separated with an isocratic mixture of methanol/ 
water/trifluoroacetic acid (73:27:0.007) and constant flow of 1.2 mL/min followed by UV-
detection at 280 nm (for trans-LTB4-isomers) or 235 nm (for 5-H(p)ETE), respectively. 
Quantification was performed using PGB1 as internal standard. 
 
UPLC-MS/MS analysis 
In order to detect LMs formed in neutrophils or in vivo, sample preparations from SPE II were 
analyzed by UPLC-MS/MS (Acquity™ UPLC system, Waters, Milford, MA, USA; QTRAP 5500 
Mass Spectrometer, ABSciex, Darmstadt, Germany; Turbo V™ Source and electrospray 
ionization) as reported recently (99). In brief, LMs were separated on an ACQUITY UPLC® 
BEH C18 column (1.7 µm, 2.1 × 100 mm; Waters, Eschborn, Germany) with a flow rate of 0.3 
mL/min at 50 °C. MilliQ water (A) and methanol (B) both acidified with 0.01% acetic acid were 
used as mobile phase starting with 42% methanol (v/v), increasing up to 86% (v/v) over 12.5 
min and ending isocraticly with 98% till 15.5 min. Negative ion mode (ion spray voltage 4000 
V, heater temperature 500 °C) was used to detect the following lipids with their corresponding 
transitions: 
Table 3.3 UPLC-MS/MS analysis of LMs determined in this study. DP - Declustering Potential, EP - 
Entrance Potential, CE - Collision Energy, CXP - Collision Cell Exit Potential, RT - Retention Time, Q1 - 
first quadrupole; Q3 - third quadrupole. 
Lipid mediator 
Q1 
(m/z) 
Q3 
(m/z) 
RT 
(min) 
DP 
(V) 
EP 
(V) 
CE 
(eV) 
CXP 
(V) 
d5-RvD2 380.3 141.2 6.4 -80 -10 -23 -14 
RvD1 375.2 215.1 6.8 -80 -10 -26 -13 
RvD2 375.2 175.1 6.4 -80 -10 -30 -13 
RvD3 375.2 147.1 6.4 -80 -10 -25 -13 
RvD4  375.2 101.1 7.8 -80 -10 -22 -10 
MATERIALS AND METHODS 
34 
Lipid mediator 
Q1 
(m/z) 
Q3 
(m/z) 
RT 
(min) 
DP 
(V) 
EP 
(V) 
CE 
(eV) 
CXP 
(V) 
d5-LXA4 356.3 115.2 6.8 -80 -10 -19 -14 
LXA4 351.2 115.1 6.9 -80 -10 -20 -13 
LXA5 349.2 115.1 5.8 -80 -10 -20 -13 
LXB4 351.2 221.1 6.3 -80 -10 -20 -13 
d4-PGE2 355.3 193.2 6.1 -80 -10 -25 -16 
PGE2 351.2 271.0 6.1 -120 -10 -20 -13 
PGD2 351.3 233.1 6.3 -80 -10 -16 -15 
PGF2α 353.3 193.1 6.5 -80 -10 -34 -11 
TXB2 369.3 169.1 5.8 -80 -10 -22 -15 
d4-LTB4 339.3 197.2 9.2 -80 -10 -22 -13 
20-OH-LTB4 351.3 195.1 4.8 -80 -10 -24 -15 
PD1/PDX 359.2 153.1 8.8 -80 -10 -21 -9 
RvD5 359.2 199.1 8.9 -80 -10 -21 -13 
Mar1 359.2 250.1 9.1 -80 -10 -20 -16 
t-LTB4 335.2 195.1 8.7 -80 -10 -22 -13 
LTB4 335.2 195.1 9.2 -80 -10 -22 -13 
5S,6R-diHETE 335.2 115.1 10.6 -80 -10 -20 -13 
5,15-diHETE 335.2 201.0 8.8 -50 -10 -30 -13 
d8-5S-HETE 327.3 116.1 12 -80 -10 -17 -10 
17-HDHA 343.2 245.1 11.5 -80 -10 -17 -14 
14-HDHA 343.2 205.1 11.7 -80 -10 -17 -14 
13-HDHA 343.2 193.1 11.6 -80 -10 -17 -14 
7-HDHA 343.2 141.1 11.9 -80 -10 -18 -15 
4-HDHA 343.2 101.1 12.4 -80 -10 -17 -15 
18-HEPE 317.2 259.1 10.5 -80 -10 -16 -23 
15-HEPE 317.2 219.1 10.7 -80 -10 -18 -12 
12-HEPE 317.2 179.1 10.8 -80 -10 -19 -12 
11-HEPE 317.2 167.1 10.7 -80 -10 -19 -12 
5-HEPE 317.2 115.1 11.2 -80 -10 -18 -12 
15-HETE 319.2 219.1 11.4 -80 -10 -19 -12 
12-HETE 319.2 179.1 11.7 -80 -10 -21 -12 
11-HETE 319.2 167.1 11.6 -80 -10 -21 -12 
8-HETE 319.2 155.0 11.7 -50 -10 -18 -13 
5-HETE 319.2 115.1 12.1 -80 -10 -21 -12 
d8-AA 311.3 267.1 13.8 -100 -10 -16 -18 
AA 303.3 259.1 13.8 -100 -10 -16 -18 
EPA 301.3 257.1 13.6 -100 -10 -16 -18 
DHA 327.3 283.1 13.8 -100 -10 -16 -18 
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Quantification was performed using standard calibration curves for each LM and subsequent 
correction of variations within the set of samples with the help of the corresponding deuterated 
diagnostic ion (indicated in bold letters). All LM standards were obtained from Cayman 
Chemical (Biomol, Hamburg, Germany). 
 
3.3.13 Western blot analysis 
Preparation of Western blot samples 
Neutrophils were diluted in PBS containing 0.1% glucose and 1 mM CaCl2 to a final cell density 
of 2 x 107 cells/mL. 500 µL of the cell suspension were treated as indicated for each experiment 
and reactions were terminated by centrifugation (500 g, 30 s, 4 °C) followed by lysis of pelleted 
cells with 100 µL triton lysis buffer for 20 min on ice. If necessary, remaining cell fragments 
were degraded by sonication (output control 1, const. duty cycle, 3 x 10 s) with Branson 
Ultrasonics™ Sonifier S-250A (Fisher Scientific, Schwerte, Germany). 
Trypsinized HEK293 cells were centrifuged (300 g, 5 min) and resuspended in fresh DMEM 
medium. 1 x 107 cells were subsequently pelleted and lysed using 100 µL of triton lysis buffer 
for 15 min on ice and repeated vortexing. 
Finally, cell lysates were centrifuged for 10 min (20,000 g, 4 °C) prior to collection of resulting 
supernatants. In order to determine protein concentrations of Western blot samples, a DCTM 
protein assay (Bio-Rad Laboratories, Munich, Germany) was performed. In brief, 5 µL of cell 
lysates were incubated with 25 µL of reagent A’ (freshly prepared mixture of Biorad Reagent 
A and Biorad reagent S, 50:1) and 200 µL of Biorad Reagent B for 15 min at RT prior to 
absorbance detection at 750 nm. Protein concentrations were calculated using a BSA standard 
curve ranging from 0 to 2,000 µg/mL. 60 µL of cell lysates were finally diluted with 20 µL of 4-
fold Laemmli buffer and boiled at 96 °C for 5 min. 
 
SDS-PAGE and Western blot 
SDS-Polyacrylamide gel electrophoresis (SDS-PAGE) was performed in order to separate 
proteins prior to wet-tank blotting on nitrocellulose membranes. 10% polyacrylamide gels were 
utilized for investigations of 5-LOX, ERK1/2, p38 MAPK and β-actin, 12% polyacrylamide gels 
for human FPR2 and 16% polyacrylamide gels for 5-LOX, β-actin, and FLAP, respectively. 
Blocking with 5% BSA in TBS for 1 h was performed in order to exclude unspecific antibody-
binding, followed by overnight incubation at 4 °C with primary antibodies at an antibody-specific 
dilution in 5% BSA in TBS-tween solution (Table 3.4). On the next day, fluorescence-labeled 
antibodies diluted in 5% BSA in TBS were used for visualization of blotted proteins after 
incubation for 1 h at RT (Table 3.5). 
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Table 3.4 Antibodies and corresponding dilutions for Western blot analysis. (m) - monoclonal, 
(p) – polyclonal. 
Antibody Dilution Provider 
rabbit-anti-ERK1/2 (m) 1:1,000 
Cell Signaling Technology Inc. 
(Danvers, MA, USA) 
mouse-anti-Thr202/Tyr204phospho-ERK1/2 (m) 1:2,000 
Cell Signaling Technology Inc. 
(Danvers, MA, USA) 
rabbit-anti-p38 MAPK(m) 1:1,000 
Cell Signaling Technology Inc. 
(Danvers, MA, USA) 
rabbit-anti-Thr180/Tyr182phospho-p38 MAPK (p) 1:1,000 
Cell Signaling Technology Inc. 
(Danvers, MA, USA) 
mouse-anti-β-actin (m) 1:1,000 
Cell Signaling Technology Inc.  
(Danvers, MA, USA) 
rabbit-anti-β-actin (m) 1:1,000 
Cell Signaling Technology Inc.  
(Danvers, MA, USA) 
mouse-anti-5-LOX (m) 1:1,000 
BD Biosciences, (Heidelberg,  
Germany) 
rabbit-anti-FLAP (p) 1:1,000 Abcam (Cambridge, UK) 
rabbit-anti-FPR2 (p) 1:1,000 Novus Biologicals (Abingdon, UK) 
 
Secondary antibodies were selected as follows: Proteins of interest were stained in green 
(IRDye® 800 CW) and housekeeping proteins were stained in red (IRDye® 680 LT). Images 
were obtained using an Odyssey infrared imager (Li-Cor Biosciences, Lincoln, NE, USA) with 
subsequent densitometric analysis with the corresponding Odyssey scan software. 
Immunoblotting of phosphorylated proteins was followed by overnight incubations of 
nitrocellulose membranes in stripping buffer at RT and detection of the corresponding native 
protein in order to normalize phosphorylation events to equal protein amounts. 
Table 3.5 Fluorescence-labeled secondary antibodies and corresponding dilutions for Western 
blot analysis. 
Secondary antibody Dilution Provider 
IRDye® 680 LT goat-anti-mouse 1:40,000 
Li-Cor Biosciences GmbH (Bad  
Homburg, Germany) 
IRDye® 680 LT goat-anti-rabbit 1:80,000 
Li-Cor Biosciences GmbH (Bad  
Homburg, Germany) 
IRDye® 800 CW goat-anti-mouse 1:10,000 
Li-Cor Biosciences GmbH (Bad 
Homburg, Germany) 
IRDye® 800 CW goat-anti-rabbit 1:15,000 
Li-Cor Biosciences GmbH (Bad  
Homburg, Germany) 
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3.3.14 Neutrophil chemotaxis assay 
Neutrophil migration through a 5 µm ChemoTx® 101-5 membrane was assayed using a 
Promega CellTiter-Glo® Luminescent Cell Viability Assay. In brief, freshly isolated human 
neutrophils were diluted in RPMI containing 10% heat-inactivated FCS, 100 U/mL penicillin, 
and 100 µg/mL streptomycin to a final density of 3.2 x 106 cells/mL and preincubated with 
inhibitors for 10 min on ice, as indicated. Subsequently, chemotactic stimuli including 30 nM 
LTB4 and 10 µg/mL PSMα3 were added to a 96-well-plate prior to covering the plate with a 
ChemoTx® 101-5 membrane. 80,000 neutrophils were pipetted on top of the membrane and 
infiltration into the lower chamber containing chemotactic agents or vehicle control, 
respectively, was determined after 1 h at 37 °C (5% CO2). Infiltrated cells were thereby stained 
with CellTiter-Glo® on a 384-well-plate according to the manufacturer’s protocol followed by 
luminescence measurement. Calculation of migrated cells was performed with the help of a 
neutrophil standard curve directly added to the migration chamber without chemotactic agent. 
 
3.3.15 3H-Arachidonic acid release 
Release of [5,6,8,9,11,12,14,15-3H(N)]-AA (3H-AA) was assayed in freshly isolated human 
neutrophils. In brief, neutrophils, resuspended in RPMI medium to a density of 1 x 107 cells/mL, 
were incubated with 0.5 µCi/mL of 3H-AA for 2 h at 37 °C and 5% CO2. Cells were subsequently 
washed with PBS containing 2 mg/mL of FA-free BSA in order to remove unbound 3H-AA and 
finally resuspended in PGC buffer prior to preincubation with test compounds or 0.1% DMSO 
vehicle, respectively (on ice). Stimulation with the indicated agents was performed for 10 min 
at 37 °C and reactions were stopped on ice, followed by centrifugation at 300 g (4 °C). 500 µL 
of supernatants were collected, diluted with 2 mL of liquid scintillation counting solution 
Rotiszint® eco plus (Roth GmbH, Karlsruhe, Germany) and radioactivity was measured by 
scintillation counting (Micro Beta Trilux, Perkin Elmer, Waltham, MA). 
 
3.3.16 Statistics and graphical presentation 
Graphs were generated using a GraphPad Prism software (GraphPad Software Inc., San 
Diego, CA). Data are given as mean ± standard error of the mean (SEM) of N independent 
experiments or N different donors. Statistical analysis was performed using GraphPad InStat 
3 (GraphPad Software Inc., San Diego, CA) or SigmaPlot 13.0 software (Systat Software Inc., 
San Jose, CA) by applying an appropriate statistical test as indicated in each figure. In case 
data lacked a gaussian normal distribution, tested by Shapiro-Wilk test, raw data was 
logarithmized to 10 (log10) for analysis. p-values < 0.05 were considered as significant and 
labeled with * or #, respectively, while concrete values are denoted for 0.05 ≤ p ≤ 0.20. Principle 
component analysis (PCA) was performed using OriginPro 2015G software (OriginLab 
Corporation, Northampton, MA).  
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Microsoft PowerPoint was used to reassemble microscopic images. PyMOL Tcl-Tk GUI 
(Schrödinger, Mannheim, Germany) was utilized for graphical visualization of crystal structures 
with PDB accession numbers given for every presented protein/enzyme, and ChemSketch 
Software (ACD/Labs, Toronto, Canada) was used to create structural formula. 
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4 RESULTS 
Please note that the following figures are partly adopted from our recent publication Exotoxins 
from Staphylococcus aureus activate 5-lipoxygenase and induce leukotriene biosynthesis 
(Romp et al.), that is currently in press at Cellular and Molecular Life Sciences, see Appendix) 
(155). 
 
4.1 Bacterial exotoxins stimulate 5-LOX activity in cellulo 
4.1.1 Pathogenic bacteria and their secreted exotoxins induce 5-LOX translocation in HEK_5-
LOX/FLAP cells 
It was recently reported by our group that macrophages challenged with intact bacteria release 
a distinct pattern of LMs depending on the macrophage phenotype (140). Since LT formation 
was strikingly induced upon bacterial stimulation, we aimed at investigating the underlying 
molecular mechanism that activate the 5-LOX pathway. Hence, a HEK293 cell-system stably 
co-expressing 5-LOX with its helper protein FLAP (HEK_5-LOX/FLAP) was used as 
experimental model and stimulated with intact bacteria in order to assess a possible bacterial 
induction of LM formation besides immunospecific effects such as receptor activation and 
phagocytosis, respectively (98). 
 
Fig. 4.1 Pathogenic bacteria and their corresponding bacteria-conditioned medium activate 5-LOX-
translocation in HEK_5-LOX/FLAP cells. Subcellular distribution of 5-LOX was investigated in non-
immunocompetent HEK293 cells stably expressing 5-LOX and FLAP. A HEK_5-LOX/FLAP cells were stimulated 
by intact pathogenic E. coli (O6:K2:H1) or S. aureus (LS1) and non-pathogenic E. coli (BL21) or 
S. carnosus (TM300) at 37 °C for the indicated timepoints using a MOI ratio of 1:50 (HEK293 cells versus bacteria) 
in PBS+/+. B HEK_5-LOX/FLAP cells were incubated in PBS+/+ in presence of 10% bacteria-conditioned medium 
(BCM) collected by sterile-filtration of cultures from E. coli (O6:K2:H1), S. aureus (LS1), E. coli (BL21) or S. carnosus 
(TM300). Incubations were performed at 37 °C for the indicated periods of BCM-exposure. Images of 20 µm size 
are shown as overlay of 5-LOX (Alexa Fluor 555, red) and FLAP (Alexa Fluor 488, green) staining and represent 
three independent experiments. Unstimulated samples were kept in PBS+/+ for either the longest or shortest 
incubation time in order to exclude unspecific side effects on 5-LOX activation. 
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In resting HEK_5-LOX/FLAP cells, 5-LOX is located within soluble parts of the nucleus, while 
it co-localizes with FLAP at the nucleus upon activation (98). Both pathogenic bacteria, the 
Gram-negative E. coli strain O6:K2:H1 (156) and the Gram-positive S. aureus LS1 (146), 
stimulated 5-LOX translocation, starting at approximately 30 min (E. coli) or 90 min (S. aureus) 
after bacterial exposure. By contrast, HEK_5-LOX/FLAP challenged with non-pathogenic E. 
coli BL21 (157) or S. carnosus TM300 (158,159) did not show 5-LOX redistribution even after 
90 min of stimulation (Fig. 4.1A). Since secretion of exotoxins is discussed to be a key 
determinant for bacterial pathogenicity (160), we performed the stimulation with sterile-filtered 
medium of bacterial cultures (BCM) that lacks intact bacteria or cell debris. In fact, BCMs 
derived from pathogenic bacteria induced 5-LOX/FLAP co-localization at the nucleus. 
Noteworthy, for BCM of S. aureus LS1 activation of 5-LOX appeared to be faster compared to 
the stimulation with corresponding intact bacteria and was observable already 10 min after 
BCM addition. Again, BCMs of non-pathogenic bacteria failed to induce 5-LOX translocation 
(Fig. 4.1B). 
The exotoxin α-hemolysin from S. aureus is described to be a crucial virulence factor in 
staphylococcal-related diseases (116-118,161). We therefore investigated time- and dose-
dependent effects of this PFT on HEK_5-LOX/FLAP cells. 5-LOX translocation occurred after 
30 min of exposure to toxin-concentrations of 1 and 10 µg/mL, while 0.1 µg/mL  
α-hemolysin were insufficient to induce 5-LOX/FLAP co-localization, even after 90 min of 
stimulation. By contrast, Ca2+ ionophore A23187, which is commonly applied to study 5-LOX 
activity, induced subcellular translocation of 5-LOX already within 10 min after addition (98) 
(Fig. 4.2A). 
 
 
Fig. 4.2 Staphylococcal exotoxins mediate 5-LOX translocation in HEK293 cells. Subcellular localization 
of 5-LOX was evaluated by IF microscopy. A HEK_5-LOX/FLAP cells were stimulated by recombinant 
α-hemolysin at the indicated concentrations (0.1 to 10 µg/mL) or 0.5 µM A23187 at 37 °C for the indicated 
exposure times. B HEK_5-LOX/FLAP cells were exposed to 10% BCM of S. aureus LS1 (wildtype, LS1∆hla, 
LS1∆agr/sarA) in PBS+/+ at 37 °C and for the indicated time periods. Unconditioned medium was applied for the 
longest and shortest incubation time in order to exclude an influence of the vehicle (not shown). Images of 
20 µm size are shown as overlay of 5-LOX (Alexa Fluor 555, red) and FLAP (Alexa Fluor 488, green) staining 
and are representative for three independent experiments. 
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Next, HEK_5-LOX/FLAP cells were stimulated with BCMs from S. aureus LS1 wildtype and 
from two genetically modified strains lacking either α-hemolysin (∆hla) or complete agr- and 
sarA-mediated exotoxin expression (∆agr/sarA) (147,148). While both, BCMs from wildtype 
and LS1∆hla induced 5-LOX translocation already 10 min after BCM exposure, only a 
complete knockout of exotoxins in LS1∆agr/sarA could prevent the activation of 5-LOX in this 
respect (Fig. 4.2B). Taken together, these data suggest a key participation but not an exclusive 
role of α-hemolysin in bacterial stimulation, at least in the HEK293 cell-model. 
 
4.1.2 Bacterial activation of 5-LOX in HEK293 cells is mediated by increased intracellular Ca2+ 
levels but independent of phosphorylation 
α-Hemolysin is described to activate cellular kinases (162), and enzymatic activity of 5-LOX is 
strongly upregulated by phosphorylation by p38 MAPK-dependent MK-2/3 (163). Therefore, 
we aimed at investigating the role of p38 MAPK during bacterial stimulation in HEK_5-
LOX/FLAP cells. Interestingly, pretreatment with the selective p38 MAPK inhibitors skepinone-
L or SB203580 (164) did not prevent 5-LOX translocation upon stimulation with BCM from S. 
aureus LS1 (Fig. 4.3A). Additionally, the 5-LOX mutant S271A, that cannot be phosphorylated 
by p38 MAPK-dependent MK-2/3 (69), co-localized with FLAP upon BCM exposure (Fig. 
4.3B). Equal co-expression of 5-LOX wildtype or 5-LOX(S271A) together with FLAP was 
confirmed by Western blot analysis (Fig. 4.3C). Accordingly, these results indicate an 
alternative mechanism of 5-LOX activation by bacterial toxins in HEK_5-LOX/FLAP cells, 
independent of kinase-mediated events. 
Besides phosphorylation, intracellular Ca2+ levels and Ca2+ binding to the N-terminal domain 
of 5-LOX are key determinants for enzyme activity (7). Thus, stimulation of HEK_5-LOX/FLAP 
cells by either recombinant α-hemolysin or S. aureus LS1 wildtype BCM were performed in 
presence of 10 mM EDTA. In fact, 5-LOX translocation was prevented by Ca2+ complexation 
for both stimuli, substantiating an eminent role of Ca2+ influx for bacterial 5-LOX activation (Fig. 
4.3D). Moreover, examination of intracellular Ca2+ levels in HEK293 cells by fluorescence-
based analysis revealed a significant, time-dependent increase of Ca2+ concentrations upon 
stimulation with either isolated α-hemolysin or BCM of LS1 wildtype compared to vehicle 
incubations (Fig. 4.3E/F). Interestingly, BCM from LS1 wildtype caused a minor but obviously 
faster reply then α-hemolysin and showed comparable kinetics as found for ionomycin-induced 
Ca2+ influx. Additionally, while the complete depletion of exotoxins in BCM from LS1∆agr/sarA 
could be related to insufficient Ca2+ mobilization, BCM from LS1 solely lacking α-hemolysin 
(LS1∆hla) still induced comparable Ca2+ influx as the wildtype control (Fig. 4.3F). Together, 
the bacterial activation of 5-LOX translocation in HEK_5-LOX/FLAP cells strongly correlates 
with the increase of intracellular Ca2+. However, efficient stimulation apparently requires further 
staphylococcal exotoxins distinct from α-hemolysin, although this archetype of PFTs appears 
to be involved in this process. 
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Fig. 4.3 Bacteria-induced 5-LOX translocation in HEK293 cells is affected from intracellular Ca2+ influx 
but independent of p38 MAPK activation. Subcellular distribution of 5-LOX was examined by IF microscopy. 
A HEK_5-LOX/FLAP cells were preincubated with 0.1% DMSO (vehicle control), 0.3 µM skepinone-L, or 1 µM 
SB203580 prior to stimulation by 10% BCM of S. aureus LS1 in PBS+/+ at 37 °C for the indicated timepoints. 
B HEK293 cells stably expressing FLAP and the mutant 5-LOX(S271A) were incubated in presence of 10% 
BCM of S. aureus LS1 for the indicated exposure times at 37 °C in PBS+/+. Microscopic images of 20 µm size 
are given as overlay of 5-LOX or 5-LOX(S271A) (Alexa Fluor 555, red) and FLAP (Alexa Fluor 488, green) 
staining and are representative for three independent experiments. C Stable expression of 5-LOX, wildtype or 
mutant, and FLAP in HEK293 cells was verified by immunoblotting. Western blot images are representative for 
three independently collected HEK293 cell lysates. D Subcellular 5-LOX localization of HEK_5-LOX/FLAP cells 
was examined by microscopic analysis upon stimulation by 10% LS1 BCM or 10 µg/mL α-hemolysin in presence 
of 10 mM EDTA or vehicle control. Images of 20 µm size are given as overlay of 5-LOX (Alexa Fluor 555, red) 
and FLAP (Alexa Fluor 488, green) staining and represent three independent experiments. E-F Intracellular 
Ca2+ levels were continuously detected in Fura-2AM-labeled HEK293 cells upon stimulation with 10 µg/mL 
α-hemolysin (E) or 10% BCM of S. aureus LS1 (wildtype, ∆hla or ∆agr/sarA) (F), 2 µM ionomycin or vehicle 
control (water or unconditioned medium) at 37 °C. Data are normalized to subsequent Triton X-100 cell lysis 
and are presented as mean ± SEM of three experiments. #p < 0.05, ##p < 0.01 and ###p < 0.001 LS1, α-hemolysin 
or ionomycin vs. vehicle control, *p < 0.05, **p < 0.01 and ***p < 0.001 S. aureus LS1 mutant strain vs. the 
corresponding LS1 wildtype applying one-way ANOVA with Tukey multiple comparison post-hoc test. 
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4.1.3 Staphylococcal exotoxins mediate LM formation in human neutrophils 
Since staphylococcal exotoxins mediate 5-LOX redistribution in HEK_5-LOX/FLAP cells, we 
asked whether stimulation by bacterial toxins cause LT formation also in neutrophils. 
Noteworthy, the HEK293 cell model was shown to lack LT biosynthesis from endogenous AA 
even after treatment with A23187 and is therefore inappropriate to study LM biosynthesis in 
general (98). For that reason, we utilized freshly isolated human neutrophils that are prominent 
leukocytes participating in LT formation (64). LM formation of neutrophils induced by S. aureus 
BCMs or isolated exotoxins was assayed by UPLC-MS/MS and biosynthesis of 5-HETE, LTB4, 
t-LTB4 and the LTB4-degradation product 20-OH-LTB4 were chosen as representative 5-LOX 
products. Notably, neutrophils appeared to be much more sensitive for bacterial toxins than 
HEK_5-LOX/FLAP cells since concentrations of 1% BCM were sufficient to examine 5-LOX 
activity in this respect. Exposure time was evaluated in advance and revealed 10 min as 
optimum for LT formation (data not shown).  
As indicated in Fig. 4.4A, neutrophil stimulation with BCMs from S. aureus LS1 wildtype 
significantly induced the formation of bioactive lipids. By contrast, exposure to BCM from 
LS1∆agr/sarA did not cause 5-LOX product formation. Interestingly, strains deficient in α-
hemolysin expression induced equal amounts of 5-LOX products compared to wildtype. In line 
with these findings, only minor activation of 5-LOX was observed after treatment with isolated 
α-hemolysin, even at a high concentration of 100 µg/mL (Fig. 4.4A). Analysis of additional LMs 
revealed a slight decrease in 12- and 15-LOX activity (represented by 14-HDHA, 12-HEPE 
and 12-HETE biosynthesis) and PG formation upon stimulation with LS1∆hla BCMs, while the 
global knockout of exotoxins in LS1∆agr/sarA prevented the formation of LMs independently 
from their biosynthetic origin (Fig. 4.4B). In addition, both BCMs from LS1 wildtype and 
LS1∆hla significantly increased intracellular Ca2+ concentrations up to 10 min of exposure and 
in a comparable manner as the ionomycin control. By contrast, BCM from LS1∆agr/sarA was 
not capable to induce Ca2+ influx. As expected from the results on LT formation, isolated α-
hemolysin that was able to induce Ca2+ mobilization in the HEK293 cell-model failed to 
stimulate neutrophils even at higher concentrations (Fig. 4.4C), explaining the absent release 
of LMs from neutrophils discussed above. 
Subcellular localization of 5-LOX and FLAP was analyzed upon stimulation with staphylococcal 
BCMs, and both BCMs from LS1 wildtype and LS1∆hla induced 5-LOX/FLAP co-localization 
in neutrophils, while 5-LOX remained in soluble parts of the nucleus upon exposure to BCM 
that completely lacks agr- and sarA-mediated exotoxin expression (LS1∆agr/sarA) (Fig. 4.4D). 
Intriguingly, isolated α-hemolysin appeared to be incapable to induce 5-LOX translocation 
indicating an involvement of other toxins in the activation of LM formation in human neutrophils. 
Thus, these data also underline cell-specific effects that have to be considered for terminating 
conclusions. 
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Fig. 4.4 5-LOX activation and concurrent LM formation in neutrophils by staphylococcal exotoxins is 
mediated by an elevation of intracellular Ca2+ levels. A-B 5 x 106 neutrophils/mL were stimulated by 1% 
BCM of S. aureus (LS1 wildtype, LS1∆hla or LS1∆agr/sarA), 100 µg/mL recombinant α-hemolysin or vehicle 
control (unconditioned medium or water) for 10 min at 37 °C. Data are presented as mean ± SEM (A) or as heat 
map in % of LS1 wildtype (B) of N=3 different blood donors. #p < 0.05, ##p < 0.01 and ###p < 0.001 LS1 or α-
hemolysin vs. vehicle control or *p < 0.05, **p < 0.01 and ***p < 0.001 vs. the corresponding LS1 wildtype strain 
using one-way ANOVA with Tukey multiple comparison post-hoc test. C Fura-2AM-labeled neutrophils were 
stimulated by 2 µM ionomycin, 100 µg/mL α-hemolysin, 1% unconditioned medium or 1% BCM of S. aureus 
(LS1, LS1∆hla or LS1∆agr/sarA) under continuous fluorescence reading at 37 °C followed by Triton X-100 cell 
lysis. Intracellular Ca2+ concentrations normalized to Triton X-100 lysis are given as mean ± SEM of N=4 different 
donors. #p < 0.05, ##p < 0.01 and ###p < 0.001 LS1 or ionomycin vs. vehicle control or *p < 0.05, **p < 0.01 and 
***p < 0.001 LS1 deletion mutant vs. the corresponding LS1 wildtype strain using one-way ANOVA with Tukey 
multiple comparison post-hoc test. D 5-LOX translocation in neutrophils challenged with 1% BCM of S. aureus 
LS1 (wildtype, LS1∆hla, LS1∆agr/sarA), 1% unconditioned medium or 100 µg/mL α-hemolysin was evaluated 
by IF microscopy. Microscopic images of 20 µm size are given as overlay of 5-LOX (Alexa Fluor 555, red) and 
FLAP (Alexa Fluor 488, green) staining and are representative for three independent experiments. 
 
4.1.4 Effects of staphylococcal PSMs on LM biosynthesis in human neutrophils 
In contrast to α-hemolysin-stimulated HEK_5-LOX/FLAP cells, neutrophils appeared to be 
resistant against the archetype of staphylococcal exotoxins, implying the contribution of other 
released bacterial inducers for 5-LOX activation. In order to reveal the staphylococcal 
exotoxins that are involved in LM formation of neutrophils, cells were stimulated with BCM of 
LS1∆psmαβ that lacks the expression of α- and β-type PSMs. LT formation was significantly 
decreased upon exposure to LS1∆psmαβ BCM compared to the wildtype control (Fig. 4.5A). 
Interestingly, while knockout of PSMs resulted in impaired LT levels, LMs derived from other 
enzymes (i.e. 12- and 15-LOX, COX) remained less affected (Fig. 4.5B). Additionally, 
neutrophils were stimulated with BCMs from the methicillin-resistant S. aureus strain USA300 
and its corresponding strain USA300∆pvl, insufficient in PVL expression, to investigate the 
effects of these cytolytic exotoxins on LM biosynthesis. Intriguingly, knockout of PVLs did not 
alter LT formation compared with USA300 wildtype BCM (Fig. 4.5A, grey bars), indicating a 
superior role of PSMs on 5-LOX activation compared to other staphylococcal exotoxins. In line 
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with this, isolated PSMα1 and PSMα3, both considered to be the most potent PSMs, dose-
dependently induced LT formation at concentrations of 1 and 10 µg/mL, that generally 
correspond to PSM amounts detected in S. aureus strains before (165) (Fig. 4.5C). 
In order to summarize the findings from neutrophil stimulations with either BCMs of LS1 
wildtype or genetically modified derivatives (∆hla, ∆psmαβ, ∆agr/sarA) as well as 
corresponding recombinant exotoxins, a principle component analysis (PCA) was performed 
as shown in Fig. 4.5D. While 5-LOX product formation clearly correlated with the presence of 
PSMs within BCMs of LS1 wildtype and LS1∆hla or stimulation by isolated PSMα3, a tendency 
towards 12-LOX- and COX-mediated LMs was found for stimuli lacking PSM expression (i.e. 
vehicle (unconditioned medium), LS1∆psmαβ, LS1∆agr/sarA or recombinant α-hemolysin 
(alpha-toxin)). 
Knockout of PSMα and PSMβ significantly decreased BCM-mediated Ca2+ influx in neutrophils 
compared to wildtype and ionomycin treatment, whereas isolated PSMα3 induced a fast but 
less intense intracellular Ca2+ mobilization that declined up to 10 min of exposure time (Fig. 
4.5E). Accordingly, LM mediator formation was completely abolished in presence of 10 mM 
EDTA (Fig. 4.5F). Moreover, 5-LOX subcellular localization was affected by both LS1 wildtype 
BCM and isolated PSMs, respectively, leading to co-localization with FLAP at the nuclear 
membrane. By contrast, stimulation with BCM of LS1∆psmαβ failed to induce 5-LOX 
translocation (Fig. 4.5G), underlining the importance of PSMs for S. aureus-induced LT 
formation in human neutrophils. However, both BCM of LS1∆psmαβ and recombinant PSMs 
induced 5-LOX redistribution in HEK_5-LOX/FLAP cells which might further indicate cell-
specific effects of staphylococcal exotoxins (Fig. 4.5G). Moreover, these findings are in line 
with our results for HEK_5-LOX/FLAP stimulations. 
Staphylococcal toxins mainly cause pore-formation and subsequent cell death (114). We 
therefore asked whether LM formation of neutrophils might be related to cell lysis instead of 
specific molecular mechanisms. 5-LOX activity in cellulo was shown to be dependent on  
5-LOX/FLAP co-localization and interaction, and FLAP inhibitors such as MK886 are 
ineffective in incubations with isolated 5-LOX or under cell-free conditions (86,98). 
Pretreatment of neutrophils with the FLAP inhibitor MK886 and stimulation with LS1 wildtype 
BCM significantly reduced LT formation, indicating a functional cellular environment during LM 
formation. Presence of the direct 5-LOX inhibitor zileuton was less effective but likewise 
decreased 5-LOX related products to approximately 50% of the vehicle control (Fig. 4.6A). In 
line with recent findings by our group that investigated the pharmacological profile of inhibitors 
targeting distinct branches of LM biosynthesis in human macrophages (99), FLAP inhibition 
selectively decreased the formation of 5-LOX-mediated products in neutrophils compared to 
other enzymatic pathways (i.e. COX, 12- or 15-LOX) (Fig. 4.6B). Moreover, inhibition of the 5-
LOX pathway increased the formation of mediators derived from other biosynthetic branches, 
presumably due to a substrate shunt, and this effect was less pronounced for the direct 
inhibition of 5-LOX by zileuton compared to MK886. 
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Fig. 4.5 PSMs of S. aureus mediate 5-LOX activation in neutrophils. A-B 5 x 106 neutrophils/mL were stimulated 
by 1% BCM of S. aureus LS1 wildtype, LS1∆psmαβ, USA300 wildtype or USA300∆pvl for 10 min at 37 °C and LM 
formation was determined by UPLC-MS/MS. Data are given as pg (A) or % of the corresponding wildtype S. aureus
strain (B) and as mean ± SEM for N=3 independent donors. #p < 0.05, ##p < 0.01 and ###p < 0.001 wildtype strains 
vs. vehicle control (unconditioned medium) or *p < 0.05, **p < 0.01 and ***p < 0.001 knockout vs. the corresponding
S. aureus wildtype strain using one-way ANOVA with Tukey multiple comparison post-hoc test. C LM formation of 
neutrophils upon stimulation with 1 or 10 µg/mL PSMα1 and PSMα3 for 10 min at 37 °C was assessed by UPLC-
MS/MS. Data are expressed in pg of 5 x 106 neutrophils as mean ± SEM of N=3 donors. *p < 0.05, **p < 0.01, 
***p < 0.001 vs. vehicle using one-way ANOVA with Tukey multiple comparison post-hoc test. D Principal 
component analysis (PCA) of LMs (red) detected by UPLC-MS/MS upon treatment of neutrophils with isolated 
bacterial toxins (α-toxin = α-hemolysin, PSMα3), LS1 BCM (del = ∆) or unconditioned medium (vehicle) (blue). Free 
FA were excluded for analysis to focus on biosynthesized mediators. E Intracellular Ca2+ levels of Fura-2AM-labeled 
neutrophils were assessed upon stimulation with 2 µM ionomycin, 10 µg/mL PSMα3, 1% unconditioned medium or
1% BCM of S. aureus (LS1, LS1∆psmαβ or LS1∆agr/sarA) under continuous fluorescence reading for 10 min at 
37 °C. Data are presented as mean ± SEM of Triton X-100 normalized values, N=7 donors. #p < 0.05, ##p < 0.01 
and ###p < 0.001 LS1 or ionomycin vs. vehicle control or *p < 0.05, **p < 0.01 and ***p < 0.001 mutant vs. the 
corresponding LS1 wildtype strain using one-way ANOVA with Tukey multiple comparison post-hoc test. F LM 
formation of 5 x 106 neutrophils stimulated by 10 µg/mL PSMα3 for 10 min at 37 °C in presence of 10 mM EDTA 
was evaluated by UPLC-MS/MS. Data are given as % of the vehicle control and as mean of N=3 independent
donors. G Subcellular localization of 5-LOX (Alexa Fluor 555, red) and FLAP (Alexa Fluor 488, green) in HEK_5-
LOX/FLAP cells or human neutrophils was examined by IF microscopy upon treatment with 10% (HEK) or 1%
(neutrophils) BCM of LS1 wildtype, LS1∆psmαβ, or 10 µg/mL PSMα1 or PSMα3 for 10 min at 37 °C. Images are
representative for three different experiments (HEK) or donors (neutrophils), respectively. 
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In addition, estimation of cell viability by either trypan blue staining or analysis of LDH release 
revealed only minor cytotoxic effects upon BCM treatment. BCM of LS1∆agr/sarA did not affect 
cell viability and thus confirm the less-virulent state of the strain (Fig. 4.6C/D). Finally, in order 
to exclude cell lysis as crucial factor for LM biosynthesis, neutrophils were treated with lytic 
concentrations of Triton X-100. Interestingly, triton-induced cell lysis could not be related to LT 
formation compared to PSMα3 stimulation, underlining a distinct mechanism of LOX activation 
far from ordinary cell disruption (Fig. 4.6E). 
 
 
Fig. 4.6 Exotoxin-induced LT formation requires an intact cellular context and is independent of cell 
lysis. A-B 5 x 106 neutrophils/mL were preincubated with 300 nM MK886 or 3 µM zileuton for 10 min at 37 °C 
and subsequently stimulated by 1% LS1 BCM for another 10 min at 37 °C. LM formation was determined by 
UPLC-MS/MS. Data are expressed in % of the vehicle control (0.1% DMSO) as bars for 5-LOX products (A) or 
heat map including additional LMs (B) and as mean ± SEM of N=3 different donors. *p < 0.05, **p < 0.01 and 
***p < 0.001 vs. vehicle control using two-tailed Student’s t-test. C Neutrophils were challenged with 1% BCM 
of LS1 wildtype, LS1∆hla, LS1∆psmαβ, and LS1∆agr/sarA followed by assessment of cell viability by trypan 
blue staining and automatic cell counting. Data are given as % of viable cells vs. total cell number. D LDH 
release of neutrophils was assayed upon treatment with 1% BCM of S. aureus LS1 wildtype, LS1∆hla, 
LS1∆psmαβ, and LS1∆agr/sarA for 10 min at 37 °C. Values are presented as % of Triton X-100 total cell lysis 
and as mean ± SEM of N=3 independent donors. #p < 0.05, ##p < 0.01 and ###p < 0.001 LS1 vs. vehicle control 
or *p < 0.05, **p < 0.01 and ***p < 0.001 knockout vs. the corresponding LS1 wildtype strain using one-way 
ANOVA with Tukey multiple comparison post-hoc test. E LM formation of 5 x 106 neutrophils stimulated by 
10 µg/mL PSMα3, 0.1% Triton X-100 or vehicle control (unstim) for 10 min at 37 °C. Data are presented in pg 
and as mean ± SEM of N=3 independent donors. 
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4.1.5 Analysis of staphylococcal-induced LM formation in vivo 
In vivo LM formation was examined by UPLC-MS/MS in tissue homogenates of mice hind paws 
that were subcutaneously infected with S. aureus USA300. Formation of 5-LOX products 
including 5-HETE, LTB4, and t-LTB4 were found to be induced compared to vehicle control and 
showed increased levels up to 48 h with a temporal decline at 24 h post-infection. By contrast, 
the COX-mediated metabolites PGE2 and TXB2 lacked an analogue time course and were 
constantly increased in infected tissues up to 48 h after infection. Interestingly, while 5-LOX 
products and TXB2 remained at basal levels within uninfected tissues, PGE2 was increased in 
a comparable manner within corresponding vehicle controls, indicating a formation 
independent of bacterial presence and apparently resulting from tissue damage by the buffer 
injection (Fig. 4.7A). 
Additionally, mice paws infected with USA300∆psmαβ showed a significant decrease in LTB4 
formation compared to wildtype preparations at 48 h post-infection. While 5-HETE and t-LTB4 
showed an equal tendency to be decreased by PSM knockout, PGE2 and TXB2 derived from 
COX-enzymes appeared to be unaltered in this respect (Fig. 4.7B). These findings indicate 
the involvement of PSMs in LM formation following bacterial infection in vivo and underline the 
dependency of staphylococcal infections from exotoxin secretion. 
 
 
Fig. 4.7 LM formation upon staphylococcal infection in vivo is affected from PSM expression. C57BL/6 
mice were subcutaneously infected by injection of 2 x 107 CFU of S. aureus USA300, wildtype or PSM deletion 
mutant, into the right hind paw of each mouse. A LM formation of mice infected with USA300 wildtype for the 
indicated timepoints. B LMs detected in murine paws 48 h post-infection with either USA300 wildtype or 
USA300∆psmαβ, respectively. LM formation within paw homogenates was evaluated by UPLC-MS/MS and 
normalized to 1 µg total protein. Data are given as mean ± SEM of 4 mice per group and are compared to the 
vehicle control, represented by simultaneous injection of 50 µL PBS buffer into the opposite (left) hind paw. 
*p < 0.05, **p < 0.01 and ***p < 0.001 vs. the corresponding USA300 wildtype strain using one-way ANOVA 
with Tukey multiple comparison post-hoc test. 
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4.2 The FPR2 receptor mediates PSM-induced 5-LOX activation in human 
neutrophils 
4.2.1 The FPR2 receptor antagonist WRW4 antagonizes PSM-induced LM formation 
As it was reported before that PSMs mediate their chemotactic abilities by targeting the FPR2 
(also referred to as FPR2/ALX or FPRL1) receptor (129,131,166), we aimed at investigating 
the role of this receptor for PSM-induced LM biosynthesis. Western blot analysis revealed the 
highest FPR2 expression in neutrophils compared to lysates from monocytes and monocyte-
derived macrophages (M1 and M2 phenotype, respectively) (Fig. 4.8A). 
As mentioned earlier, FPRs are characterized by recognition of bacterial and mitochondrial N-
formylated peptides (130,131), and the synthetic peptide fMLP induced LT formation in 
neutrophils after LPS priming (80,167). In line, fMLP was characterized as a highly specific 
FPR1 receptor agonist with low FPR2 affinity (131). In order to prove FPR2 over FPR1 as 
cellular target for PSMs and to evaluate a simultaneous activation of FPR1 by formylated 
staphylococcal peptides within the applied BCMs, we examined the LM profile of human 
neutrophils challenged with either BCM from S. aureus LS1 or fMLP (Fig. 4.8B). 
Fig. 4.8 PSM-induced LT formation is prevented by FPR2 receptor antagonism. A FPR2 expression of human 
leukocytes was verified by immunoblotting and subsequent densitometric evaluation and normalization to β-actin. 
Western blot images are representative for lysates from three independent cell donors. B-D 5 x 106 neutrophils/mL 
were pretreated for 10 min at 37 °C with 10 µM WRW4 or vehicle control (0.1% DMSO) prior to stimulation with 1% 
LS1 BCM or 1 µM fMLP (B), 10 µg/mL PSMα3 (C), or 2.5 µM A23187 (D) for another 10 min at 37 °C. LM formation 
was determined by UPLC-MS/MS. Data are presented in pg as mean ± SEM of N=3 independent blood donors. 
Statistical analysis was performed using paired, two-tailed Student‘s t-test. ***p < 0.001, **p < 0.01, *p < 0.05 
WRW4 vs. the corresponding vehicle control. 
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fMLP appeared to be much inferior to activate LT biosynthesis compared to LS1 BCM (more 
than 20-fold). Moreover, when cells were pretreated with the selective FPR2 peptide 
antagonist WRW4 (137), LM formation was significantly reduced in neutrophils stimulated with 
LS1 BCM, while fMLP activation remained unaffected in this respect (Fig. 4.8B). However, 
when neutrophils were challenged with recombinant staphylococcal PSMα3, LT formation 
could be inhibited significantly and almost completely by WRW4 (Fig. 4.8C). Noteworthy, 
antagonism of FPR2 by WRW4 did not affect Ca2+ ionophore A23187-induced 5-LOX product 
formation (Fig. 4.8D), indicating that WRW4 selectively decreases bacteria-induced LM 
biosynthesis independent of a direct 5-LOX inhibition. 
 
4.2.2 Modulation of FPR2 but not FPR1 affects PSM-induced 5-LOX activation 
In order to substantiate the PSM-mediated activation of FPR2, we investigated LM formation 
of neutrophils in presence of the chemotaxis inhibitory protein of S. aureus (CHIPS), which 
was shown to selectively antagonize the FPR1 ligand fMLP at nanomolecular concentrations 
(134). Stimulation by either fMLP or PSMα3 both induced LM formation in neutrophils, although 
PSM-mediated activation appeared to be superior compared to fMLP. In addition, while fMLP-
induced LT biosynthesis could be inhibited by CHIPS to approximately 50%, PSM-activation 
remained unaffected in presence of the inhibitory protein (Fig. 4.9A). 
 
Fig. 4.9 Activation of FPR2 but not FPR1 is crucial for PSM-mediated LT formation. A 5 x 106 
neutrophils/mL were pretreated with 1 µg/mL CHIPS (chemotaxis inhibitory protein of Staphylococcus aureus) 
or vehicle control (0.1% DMSO) prior to stimulation with 10 µg/mL PSMα3 or 1 µM fMLP for 10 min at 37 °C. 
Statistical analysis was performed using paired, two-tailed Student‘s t-test. ***p < 0.001, **p < 0.01, *p < 0.05 
CHIPS vs. the corresponding vehicle control. B Neutrophils were challenged by PSMα3 or WKYMVm at the 
indicated concentrations for 10 min at 37 °C. 5-LOX product formation was detected by UPLC-MS/MS and is 
presented in pg as mean ± SEM of N=2-3 independent donors. 
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Moreover, LT formation of neutrophils was examined upon treatment with the synthetic 
hexapeptide WKYMVm (methionine-D-conformer) that was shown to activate the FPR2 
receptor. Interestingly, conformational variations within the N-terminal amino acid residue of 
WKYMVm was related to a 25-fold increased FPR2 activation compared to WKYMVM 
(168,169). Accordingly, WKYMVm dose-dependently induced 5-LOX product formation of 
neutrophils to a comparable extent as PSMα3 at concentrations of 10 and 100 nM (Fig. 4.9B). 
Taken together, our data indicate a similar activation and LM biosynthesis for PSMs compared 
to agents predominantly modulating FPR2 instead of FPR1. 
 
4.2.3 Activation of ERK1/2 by S. aureus BCM and isolated PSMα3 modulates LM biosynthesis 
Binding to FPR2 and subsequent Gi-protein-coupled activation of cellular kinases such as ERK 
and the p38 MAPK was discussed for a plethora of natural and synthetic peptides and lipids 
(170). Moreover, 5-LOX product formation was found to be increased by p38 MAPK-dependent 
phosphorylation at Ser271 and ERK-mediated phosphorylation at Ser663 (6,69,171). In order to 
investigate the effects of staphylococcal peptides on 5-LOX-affecting kinases in neutrophils, 
cells were stimulated with BCM from S. aureus, isolated PSMα3, or A23187 for the indicated 
time points followed by subsequent determination of p38 MAPK and ERK1/2-phosphorylation 
by Western blot analysis. All stimuli induced phosphorylation of p38 MAPK at Thr180/Tyr182 
(172) to a similar extent and with a maximum between 3 and 5 min of exposure (Fig. 4.10A). 
Comparable activation patterns could be observed for ERK1/2 phosphorylation at Thr202/Tyr204 
(for ERK1, and Thr185/Tyr187 for ERK2) (173), reaching highest levels between 3 to 5 min and 
decreasing up to 10 min of stimulation. Noteworthy, PSMα3 appeared to be the most effective 
activator of ERK1/2 in this respect (Fig. 4.10A). 
Additionally, neutrophils were pretreated with the FPR2 receptor antagonist WRW4 and kinase 
activation was evaluated after 5 min of exposure to the indicated stimuli. Interestingly, while 
p38 MAPK phosphorylation appeared to be widely unaffected from WRW4, both BCM- and 
PSM-induced ERK1/2 activation could be decreased by FPR2 antagonism, although not 
statistically significant (p=0.06 and 0.13) (Fig. 4.10B). Again, PSMα3 was found to be superior 
over BCM or A23187 in activating ERK1/2 signaling. Noteworthy, preincubation at 37 °C 
apparently reduced overall kinase activation compared neutrophils that were directly 
stimulated without any pretreatment (compare Fig. 4.10A and 4.10B). 
Besides p38 MAPK and ERK1/2 activation, FPR2 signaling was also related to the activation 
of protein kinase C (PKC) and PI3K (170). Therefore, neutrophils were pretreated with WRW4, 
skepinone-L (a selective inhibitor for p38 MAPK), UO126 (ERK1/2 activation inhibitor), 
LY294002 (PI3K inhibitor) or RO-31-8220 (PKC inhibitor) (164,174-176), respectively, and 
stimulated with A23187, LS1 BCM or isolated PSMα3 for 10 min at 37 °C. As shown before, 
WRW4 markedly reduced BCM- and PSM-induced LM formation, while A23187 activation 
remained widely unaffected from FPR2 antagonism. 
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Fig. 4.10 PSM-induced LM formation is mediated by ERK1/2 activation. A 1 x 107 neutrophils/mL were 
stimulated by 1% LS1 BCM, 10 µg/mL PSMα3, or 2.5 µM A23187 for the indicated timepoints at 37 °C. 
B Neutrophils were preincubated with 10 µM WRW4 or vehicle control (0.1% DMSO) for 5 min at 37 °C prior to 
stimulation with 1% LS1 BCM, 10 µg/mL PSMα3, or 2.5 µM A23187 for 5 min at 37 °C. Cells were lysed and 
phosphorylation of p38 MAPK and ERK1/2 was verified by immunoblotting. Data are given as phosphorylated 
normalized to native protein and as mean ± SEM. Images are representative for N=4 lysates of independent cell 
donors. ***p < 0.001, **p < 0.01, *p < 0.05 WRW4 vs. vehicle control performing paired, two-tailed Student‘s 
t-test. C LM formation of 5 x 106 neutrophils/mL after pretreatment with 10 µM WRW4, 1 µM skepinone-L, 1 µM 
UO126, 10 µM LY294002, 1 µM RO-31-8220 or vehicle control on ice for 15 min prior to stimulation with 
10 µg/mL PSMα3, 1% LS1 BCM or 2.5 µM A23187 for 10 min at 37 °C. Data shown in heat maps are given as 
% of vehicle control and as mean of N=4 independent donors. D HEK293 cells expressing 5-LOX(S663A) were 
treated with 10% LS1 BCM or 10 µg/mL PSMα3 for the indicated timepoints. Images are representative for three 
independent experiments and show an overlay of 5-LOX(S663A) (Alexa Fluor 555, red) and DAPI-stained 
nuclei. W/o samples were kept in buffer for the shortest or longest incubation time to exclude unspecific effects. 
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Noteworthy, WRW4 inhibition appeared to be insufficient upon BCM stimulation for mediators 
that were formed independently from the 5-LOX pathway (i.e. COX, 12- and 15-LOX products), 
while PSM-induced LM formation was almost completely inhibited by WRW4. By contrast, 
inhibition of either PI3K, PKC or p38 MAPK did not affect LM biosynthesis, regardless of the 
applied stimulus. Intriguingly, the ERK1/2-inhibitor UO126 showed a comparable reduction of 
LMs as WRW4 when neutrophils were stimulated with either BCM or PSMα, but appeared to 
be less active upon A23187 treatment, especially in respect of reducing 5-LOX products (Fig. 
4.10C). 
Since PSM-mediated ERK-activation might play an eminent role in LM formation, we aimed to 
investigate the effect of phosphorylation at 5-LOX-Ser663 upon stimulation with S. aureus-
derived stimuli. In HEK293 cells stably transfected with the 5-LOX(S663A), both BCM of LS1 
and recombinant PSMα3 induced 5-LOX translocation to the nuclear envelope after 10 min of 
stimulation (Fig. 4.10D), indicating that FPR2-mediated and ERK1/2 dependent 
phosphorylation of 5-LOX might be subordinated for sufficient translocation in HEK293 cells. 
 
4.2.4 PSMs mediate LM biosynthesis by affecting cPLA2α activity and FA release 
Besides activation of biosynthetic enzymes, LM formation strongly depends on sufficient FA 
release. Among different PLs, cPLA2α is eminent for AA liberation and depends on Ca2+ and 
on phosphorylation by ERK (27,32,177). Therefore, the role of PSMs and staphylococcal 
exotoxins on FA release was investigated in neutrophils challenged by recombinant PSMα3, 
LS1 BCM or A23187 in presence of the selective cPLA2α inhibitor RSC-3388 (178,179), and 
UPLC-MS/MS analysis was performed to evaluate LM biosynthesis. While all A23187-induced 
LMs were found to be reduced by RSC-3388, the inhibitory effect was less pronounced in 
neutrophils stimulated by PSMα3 or LS1 BCM, respectively. Interestingly, although the overall 
inhibitory potency was less, RSC-3388 showed a comparable pattern as the FPR2 antagonist 
WRW4 upon PSM and BCM treatment (Fig. 4.11A and compare Fig. 4.10C). This observation 
supports the involvement of cPLA2α-dependent FA release in PSM-induced FPR2 activation 
and LM formation. 
Furthermore, release of 3H-AA in neutrophils stimulated with BCM of S. aureus LS1 wildtype 
or mutants and recombinant exotoxins was evaluated. While BCM of LS1 wildtype and 
LS1∆hla as well as isolated PSMα3 markedly induced 3H-AA release, both LS1∆agr/sarA and 
α-hemolysin were apparently insufficient to mediate AA liberation (Fig. 4.11B). LS1∆psmαβ-
induced effects could be related to a clear but not complete reduction of 3H-AA release, 
indicating the participation of additional staphylococcal toxins in releasing FA from membrane 
phospholipids. 
Interestingly, when neutrophils were pretreated with WRW4, RSC-3388 or UO126, the 3H-AA 
release upon stimulation with PSMα3, LS1 BCM and A23187 was found to be decreased 
depending on the applied stimulus. On the one hand, WRW4 was most effective in inhibiting 
AA release upon treatment with PSMα3, whereas RSC-3388 and UO126, that both reduced 
LM biosynthesis upon PSM-challenge (Fig. 4.10C), barely affected the liberation of 3H-AA in 
this respect. However, no differences were found in the inhibitory potency of the applied 
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compounds when BCM of LS1 was utilized for stimulation. On the other hand, RSC-3388 was 
most effective for A23187-treated neutrophils, underlining the eminent role of cPLA2α for AA 
release under challenge with this Ca2+ mobilizing agent (180). In line with the results from 
above, both WRW4 and UO126 did not significantly affect the release of 3H-AA upon A23187 
stimulation (Fig. 4.11C). Moreover, the overall AA release was found to be superior for A23187 
treatment, which correlates with the overall LM biosynthesis in this respect. Intriguingly, 
PSMα3 showed increased FA liberation compared to LS1 BCM challenge, which is in a sharp 
contrast to the total amount of detected LMs that were markedly higher for BCM stimulations 
(compare Fig. 4.8B). Together, our findings suppose a complex interplay of FA release and 
phospholipase A2 activation that seems to be strikingly stimulus dependent. 
 
Fig. 4.11 PSMs regulate LM biosynthesis 
by induction of FA release in neutrophils. 
A 5 x 106 neutrophils were preincubated on 
ice for 15 min with 10 µM RSC-3388 prior to 
stimulation with 10 µg/mL PSMα3, 1% LS1 
BCM or 2.5 µM A23187 for 10 min at 37 °C. 
LM formation was determined by UPLC-
MS/MS. Data shown in heat maps are given 
as % of the vehicle control and as mean of 
N=4 independent donors. B 3H-AA-labeled 
neutrophils were stimulated with 1% BCM of 
LS1 (wildtype, LS1∆hla, LS1∆psmαβ, 
LS1∆agr/sarA), 10 µg/mL PSMα3 or 
10 µg/mL α-hemolysin for 10 min at 37 °C. 
Radioactivity in the supernatant was 
subsequently detected by scintillation 
counting. Data are given as fold-increase of 
unstimulated samples and as mean ± SEM 
of N=4 (N=3 for α-hemolysin) independent 
donors. #p < 0.05, ##p < 0.01 and ###p < 0.001 
LS1, PSMα3 or α-hemolysin vs. unstimulated 
or *p < 0.05, **p < 0.01 and ***p < 0.001 LS1 
mutant vs. the corresponding wildtype strain 
using one-way ANOVA with Tukey multiple 
comparison post-hoc test. C 3H-AA-labeled 
neutrophils were pretreated with 10 µM 
WRW4, 10 µM RSC-3388, 1 µM UO126 or 
0.1% DMSO (vehicle) for 5 min on ice prior 
to stimulation by 1% BCM of LS1 wildtype, 
10 µg/mL PSMα3 or 2.5 µM A23187, 
followed by scintillation counting. Data are 
given as fold-increase of 3H-related radio-
activity of unstimulated samples and as 
mean ± SEM of N=3 independent donors. 
#p < 0.05, ##p < 0.01 and ###p < 0.001 PSMα3, 
LS1 BCM or A23187 vs. unstimulated control 
using paired, two-tailed Student’s t-test or 
*p < 0.05, **p < 0.01 and ***p < 0.001 
inhibitors vs. the vehicle using one-way 
ANOVA with Tukey multiple comparison 
post-hoc test. 
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4.2.5 Role of PSM-induced LT formation during inflammation 
Besides their cytolytic activity, PSMs and the related activation of FPR2 have been recently 
shown to play pivotal roles in inducing neutrophil infiltration upon staphylococcal infections 
(129,166). Thus, we asked whether PSM-induced LT formation could be involved in neutrophil 
recruitment by mediating the release of chemotactic LTB4 and the subsequent activation of the 
high-affinity LTB4 receptor BLT1 (181). A chemotaxis assay was performed and neutrophil 
infiltration through a 5 µm ChemoTx® 101-5 membrane was assayed upon treatment with LTB4 
or PSMα3, respectively. As expected, LTB4 induced neutrophil recruitment that in turn was 
blocked by the BLT1-receptor antagonist LY293111 (182). By contrast, PSMα3 apparently 
mediated a direct neutrophil infiltration by targeting the FPR2 receptor, since WRW4 was found 
to reduce leukocyte recruitment. Notably, preliminary determination of sufficient PSM-
concentrations to induce chemotaxis was in contrast to recent findings that described a bell-
shaped effect with highest magnitude at 1 µg/mL PSMα3 (129). However, 10 µg/mL PSMα3 
appeared to be superior for chemotaxis in our experimental setting (data not shown), although 
differences within cell number determination and incubation conditions might be an explanation 
for this discrepancy. Interestingly, inhibition of LT formation by the FLAP inhibitor MK886 (86) 
or LTB4 binding to BLT1 by LY293111 failed to prevent neutrophil infiltration upon PSM-
stimulation (Fig. 4.12A). Although considerable amounts of LTs are released by neutrophils 
challenged with PSMα3, these data indicate that neutrophil recruitment primarily depends on 
the direct binding of PSMs to FPR2 without involving the chemotactic abilities of LTB4, at least 
in our experimental setup. 
 
 
Fig. 4.12 A PSM-mediated chemotaxis is independent of LT formation. Migration of neutrophils through a 
5 µm ChemoTx® 101-5 membrane was assayed after pretreatment with 30 µM LY293111, 10 µM WRW4, 
300 nM MK866 or vehicle control for 10 min on ice prior to applying 30 nM LTB4 or 10 µg/mL isolated PSMα3 
as chemotactic agents. Infiltrated cells were detected by CellTiter-Glo® according to the manufacturer’s protocol. 
Data are given as migrated cells relative to the corresponding unstimulated samples and as 
mean ± SEM of N=4 independent donors. Statistical analysis was performed using paired, two-tailed Student‘s 
t-test. *p < 0.05, **p < 0.01 and ***p < 0.001 inhibitor vs. vehicle control. B LXA4 does not affect PSM-induced 
LM formation. 5-LOX product formation of 5 x 106 neutrophils/mL was determined by UPLC-MS/MS. Cells were 
simultaneously stimulated by 10 µg/mL PSMα3 and the indicated concentrations of LXA4 (0.1 to 100 nM), 
respectively, for 10 min at 37 °C. Data are given as % of the vehicle control and as mean ± SEM of N=3 
independent donors. 
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Finally, FPR2 is discussed to mediate the anti-inflammatory, pro-resolving effects of LXA4 
(183,184). Thus, PSMα3-induced 5-LOX product formation was determined in presence of this 
well-established SPM. As presented in Fig. 4.12B, LM formation remained unaffected from 
simultaneous stimulation by increasing concentrations of LXA4 (0.1 to 100 nM). This data 
supports previous findings showing that distinct ligand-specific conformations of FPR2 and 
subsequent signaling cascades might be different for LXA4 and PSMs, respectively (136). 
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4.3 Mutagenesis of FLAP affects the interaction with 5-LOX and the inhibition by 
MK886 
4.3.1 Sequence analysis of mutated pcDNA3.1_FLAP(hygromycin) 
When Ferguson and co-workers first revealed an inhibitor-bound crystal structure of FLAP in 
2007, they described distinct characteristic subunits including four transmembrane helices, two 
cytosolic and one lumenal loop as well as the N- and C-terminal segments facing the inner 
side of phospholipid membranes (91). Moreover, the authors reported on inhibitor binding 
deduced from directed mutagenesis studies (91). Here we performed a site-directed 
mutagenesis study in order to identify a possible binding site for 5-LOX at FLAP (Fig. 4.13A). 
 
 
 
Fig. 4.13 Site-directed mutagenesis of putative residues involved in 5-LOX/FLAP interaction. A Three-
dimensional structure of FLAP (PDB accession number 2q7m) as trimer (minor). Locations of mutated amino 
acid residues (light blue) are shown for one selected monomer (red) in presence of the FLAP inhibitor MK-591 
(blue). B Phosphoprediction by NetPhos3.1 using the FLAP amino acid sequence including the corresponding 
probability scores. C Sufficient mutations within the plasmid pcDNA3.1_FLAP(hygromycin) encoding for each 
FLAP isoform were verified by Eurofins Umwelt Ost GmbH (Jena, Germany). 
  
RESULTS 
58 
Ile119 located at the intersection of C2 to helix α4, Tyr112 positioned at the second cytosolic loop 
C2, and polar Thr66 of transmembrane helix α2 in FLAP were replaced by alanine residues 
(I119A, Y112A, T66A), thereby changing the bulky amino acid side chains into small lipophilic 
moieties. Additionally, lipophilic Ala27 from helix α1 was mutated into leucine in order to achieve 
a steric hindrance at this position (A27L). Recently, it was published that serine 
phosphorylation affects LTC4S activity mediated by p70S6 kinase in vitro (13). Since FLAP is 
sharing an overall sequence homology of 31% with LTC4S and likewise belongs to the MAPEG 
protein family (88), we asked whether FLAP might be a target for phosphorylation-dependent 
regulation. Amongst others, the phosphoprediction software NETPhos3.1 revealed two 
putative phosphorylation sites at Ser41 and Ser108 with corresponding phosphorylation 
probability scores of 0.877 and 0.736, respectively (Fig. 4.13B). Thus, Ser41 and Ser108 were 
additionally investigated as possible phosphorylation sites of FLAP in this part of the thesis. 
Both residues were mutated to either phosphomimetic aspartate or to alanine (S41A, S108A, 
S41D, and S108D) (185). Moreover, a deletion mutant of FLAP that lacks Ser108 was created 
(S108∆). Mutation was performed using a Q5TM Site-Directed Mutagenesis Kit. Mutagenesis 
was verified by DNA sequencing and is presented in Fig. 4.13C. 
 
4.3.2 Expression of 5-LOX and FLAP wildtype or mutants in HEK293 cells 
HEK293 cells were stably transfected with 5-LOX and FLAP wildtype or mutants, respectively, 
using a LipofectamineTM LTX with Plus Reagent kit as described, and subsequent polyclonal 
selection by geneticin (5-LOX) or hygromycin (FLAP) was performed. Sufficient transfection 
after antibiotic selection was verified by IF analysis. Representative overview images of each 
cell line are shown in Fig. 4.14A, with 5-LOX stained in red and FLAP in green color and 
indicate an equal expression of both 5-LOX and FLAP wildtype or mutated isoforms. Moreover, 
Western blot analysis and densitometric evaluation confirmed protein expression (Fig. 4.14B). 
 
Fig. 4.14 HEK293 cells stably co-express 5-LOX and FLAP. A IF microscopy was performed to evaluate 
equal co-expression of 5-LOX (Alexa Fluor 555, red) and FLAP- (Alexa Fluor 488, green) wildtype or mutant, 
respectively. B Western blot analysis with subsequent densitometric analysis relative to β-actin was applied to 
evaluate expression of 5-LOX and FLAP. 
RESULTS 
59 
5-LOX appeared to be equal for each cell line, except of HEK_5-LOX/FLAP(S41A) and 
HEK_5-LOX/FLAP(S41D) cells that showed minor but still adequate expression of the enzyme. 
On the other hand, FLAP expression was found to be more diverse, but satisfactory for each 
cell line, although HEK_5-LOX/FLAP(I119A) and HEK_5-LOX/FLAP(Y112A) showed a lower 
expression of FLAP compared to HEK_5-LOX/FLAP(wildtype) cells (Fig. 4.14B). Noteworthy, 
variations within the antibody recognition that may have resulted from the structural 
modifications of FLAP have not been considered in our experimental setting but might further 
impact the binding intensities. The results for HEK_5-LOX/FLAP(S108∆) are presented in  
Fig. 4.18. 
 
4.3.3 Influence of FLAP mutagenesis on 5-LOX product formation 
In the respective HEK293 cell lines, 5-LOX product formation was examined in presence of 
the FLAP inhibitor MK886 upon stimulation with 2.5 µM Ca2+ ionophore A23187 and 2 µM 
exogenous AA. Total cellular LT formation including 5-H(p)ETE (alcohol and peroxide) and 
trans-isomers of LTB4 appeared to be comparable and independent of FLAP mutations, 
although barely lower amounts were detected within HEK_5-LOX/FLAP(S41A) and HEK_5-
LOX/FLAP(S41D), apparently resulting from lower expression of 5-LOX within these cells (Fig. 
4.15A/B). Pretreatment with MK886 significantly decreased product formation in cells 
expressing wildtype FLAP to approximately 60% of vehicle control. In case of mutated FLAP 
isoforms, only A27L and S41A could be inhibited to the same extent, while a minor but still 
significant inhibition to 70 – 80% was observed for I119A, T66A, S41D and S108A, respectively 
(Fig. 4.15A/B/C). Surprisingly, the inhibitory effect of MK886 was completely abolished in both 
HEK_5-LOX/FLAP(Y112A) and HEK_5-LOX/FLAP(S108D), indicating either FLAP-
independent 5-LOX product formation or insufficient MK886 binding to the FLAP mutant in 
these cells (Fig. 4.15A/B/C). 
5-LOX is catalyzing a two-step conversion of AA into 5-HpETE and subsequently into the 
instable intermediate LTA4 (1). In cellulo, FLAP may enhance the second reaction step to form 
LTs (53,98), while exogenous addition of AA somehow limits its participation in this respect 
(98). Since FLAP seemingly lacks any enzymatic activity (88), we examined the ratio of 5-
H(p)ETE versus LTB4-isomers in order to evaluate the influence of FLAP and respective 
mutations on 5-LOX product formation in the HEK293 cell model; i.e. insufficient FLAP action 
is indicated by higher values of the metabolic ratio of 5-H(p)ETE/LTB4-isomers. HEK_5-
LOX/FLAP(wildtype) cells stimulated by A23187 plus AA displayed a ratio of roughly 1.2 of 5-
H(p)ETE compared to LTB4-isomers and almost equal values were found when 5-LOX was 
co-expressed with the FLAP mutants I119A (1.4), Y112A (1.5), A27L (1.2), S41A (1.7), and 
S108A (1.0). However, cells expressing S41D (2.3) and S108D (2.0) showed increased ratios 
implying a subordinate role of FLAP compared to the wildtype protein. On the other hand, 
FLAP appeared to enhance the second reaction step of 5-LOX in HEK_5-LOX/FLAP(T66A) 
(0.7) cells (Fig. 4.15D). 
Although decreasing the overall 5-LOX product formation, MK886 was reported to increase 
the ratio of 5-H(p)ETE versus LTB4-isomers by augmented inhibition of the pseudo-
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lipoxygenation of 5-LOX compared to the peroxide formation within the first reaction step (98). 
Notably, pretreatment with MK886 significantly increased this ratio in HEK_5-
LOX/FLAP(wildtype) cells as well as in the FLAP mutant strains T66A, A27L, S41A, S41D and 
S108A. However, cells expressing the FLAP mutants I119A, Y112A and S108D showed 
unaltered ratios of 5-H(p)ETE versus LTB4-isomers in presence of MK886. These results are 
in line with the inhibitory potency of MK886 for these mutants and show a direct correlation 
between the ability of MK886 to reduce 5-LOX product formation and the simultaneous 
increase of the metabolic ratio (Fig. 4.15D). (Note that LTA4H expression within HEK293 cells 
appears to be insufficient to form detectable amounts of LTB4 from LTA4. Thus, non-
enzymatically produced trans-LTB4-isomers were evaluated and included in the overall 5-LOX 
product formation.) 
 
 
 
Fig. 4.15 Mutagenesis of FLAP affects 5-LOX product formation and inhibition by MK886. HEK_5-
LOX/FLAP cells stably co-expressing 5-LOX with the indicated mutant of FLAP were stimulated with 2.5 µM 
A23187 and 2 µM AA in presence of 300 nM MK886 or vehicle control (0.1% DMSO) for 10 min at 37 °C. 
5-LOX product formation including 5-H(p)ETE and trans-isomers of LTB4 was determined using RP-HPLC. 
A-B Product formation of 1 x 106 HEK293 cells in ng. C Inhibition by MK886 presented as 5-LOX product 
formation in % of the corresponding vehicle control. D Ratio of 5-H(p)ETE to trans-isomers of LTB4 in presence 
of 300 nM MK886 or vehicle control. All data are given as mean ± SEM, N=5. Statistical analysis was performed 
using paired, two-tailed Student‘s t-test. N.s. - not significant. ***p < 0.001, **p < 0.01, *p < 0.05 MK886 vs. the 
corresponding vehicle control. 
 
 
A B
C D
HEK_5-LOX/FLAP 
(ng/10
6
 cells)
wildtype 88.9 ± 4.5 54.6 ± 3.6
I119A 79.0 ± 7.0 64.3 ± 5.6
Y112A 80.2 ± 12.2 73.2 ± 8.5
T66A 92.5 ± 5.8 67.7 ± 5.9
A27L 77.4 ± 4.0 48.3 ± 3.8
S41A 64.0 ± 6.6 34.4 ± 4.0
S41D 31.6 ± 4.4 23.2 ± 3.2
S108A 87.3 ± 5.4 69.0 ± 4.4
S108D 75.3 ± 10.2 78.2 ± 11.4
MK886 vehicle
HEK_5-LOX/FLAP
HEK_5-LOX/FLAP HEK_5-LOX/FLAP
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4.3.4 Subcellular distribution of 5-LOX is independent of FLAP mutagenesis 
Subcellular distribution of 5-LOX under stimulatory conditions has been connected to 5-LOX 
activity in the cellular context (53,71). In addition, mutations of 5-LOX affecting the ability to 
associate with FLAP at the nuclear envelope have been related to altered 5-LOX product 
formation before (60). We therefore asked whether structural modifications of FLAP influence 
the co-localization with 5-LOX at the nuclear envelope, estimated by IF microscopy upon 
stimulation with A23187 for either 10 or 30 min. 5-LOX, located within the nucleus under resting 
conditions, translocated to the nuclear membrane in all cell lines, independent of mutations 
within FLAP. Moreover, the co-localization of 5-LOX and FLAP was apparent at the nuclear 
envelope already after 10 min of stimulation and did not vary at 30 min A23187 exposure  
(Fig. 4.16). 
 
 
Fig. 4.16 Subcellular localization of 
5-LOX is independent of mutagenesis of 
FLAP. Subcellular localization of 5-LOX was 
determined by IF microscopy in HEK293 cells 
stably expressing 5-LOX (Alexa Fluor 555, 
red) and FLAP wildtype or mutant (Alexa 
Fluor 488, green), upon stimulation with 
2.5 µM A23187 at 37 °C for the indicated time 
points. Images of 20 µm size are represent-
ative for three independent experiments. 
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4.3.5 In situ interaction of mutated FLAP isoforms with 5-LOX 
Besides co-localization at the nuclear membrane, an in situ interaction of 5-LOX and FLAP 
resulting in a LT-synthetic protein complex was shown more recently to affect 5-LOX product 
formation (12,60). Hence, a proximity-ligation approach (PLA) was applied in order to study 5-
LOX/FLAP interactions at closer proximity than 40 nm. 
As expected, direct interactions of 5-LOX and FLAP remained absent under unstimulated 
conditions in all investigated cell lines, whereas stimulation by A23187 resulted in a time- and 
FLAP-dependent assembly of protein complexes at the nuclear envelope (Fig. 4.17). 5-
LOX/FLAP interactions appeared to be unaffected from the mutagenesis of FLAP at Thr66, 
Ala27, Ser41, and Ser108 (only S108A), as fluorescent proximity signals could be observed 
similarly to the wildtype control after both 10 and 30 min of A23187 activation. By contrast, 
despite evident co-localization, HEK293 cells co-expressing 5-LOX and either I119A or Y112A 
showed noticeably reduced interactions at 10 min of ionophore exposure, although the signal 
appeared to be enhanced after prolonged A23187 challenge of 30 min. Intriguingly, a 5-
LOX/FLAP interaction remained absent within HEK_5-LOX/FLAP(S108D) cells, even at long 
time stimulations with A23187 (Fig. 4.17). These findings suggest that structural variations of 
FLAP due to selected mutations affect the ability to interact with 5-LOX to form a synthetic 
complex, which was found to be a key feature for sufficient AA transfer and LT formation (12). 
In particular, mutation of Ser108 towards a phosphomimetic aspartate moiety abolishes the 
interaction of FLAP with 5-LOX upon stimulation with A23187. 
 
4.3.6 Deletion of Ser108 results in insufficient 5-LOX/FLAP interaction 
Besides tyrosine and threonine, serine residues serve as crucial phosphorylation sites for 
eukaryotic cellular kinases, and replacement of these amino acids by phosphomimetic 
aspartate or non-phosphorylatable alanine are common strategies to study phosphorylation 
events in cellulo (185,186). However, although our previous data might indicate Ser108 as 
potential kinase target within FLAP to regulate 5-LOX product formation, all efforts to prove an 
existing phosphorylation by phospho-proteomics in either HEK_5-LOX/FLAP cells or human 
neutrophils failed due to insufficient detection of FLAP (data not shown). We therefore asked 
whether Ser108, located on the second cytosol-facing loop (C2) of FLAP, might act as essential 
residue for 5-LOX/FLAP interaction and activity, independent of the possibility of being affected 
by phosphorylation. Thus, stable co-expression of 5-LOX with a mutant of FLAP that lacks 
Ser108 (S108∆) was performed and equal protein amounts could be verified by both, 
immunofluorescent staining and Western blot analysis followed by densitometric evaluation, 
respectively (Fig. 4.18A/B). Upon stimulation with A23187 and AA for 10 min, a total 5-LOX 
product formation of approximately 65 ng per 1 x 106 cells could be detected, which is 
comparable to the FLAP wildtype (88.9 ng, Fig. 4.18C and Fig. 4.15B). 
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Fig. 4.17 Mutagenesis of FLAP 
affects the interaction of 
5-LOX and FLAP at the 
nuclear envelope. In situ 5-
LOX/FLAP-interaction in HEK293 
cells stably ex-pressing 5-LOX 
and FLAP-wildtype or mutant, 
respectively, was determined by 
PLA upon stimulation with 2.5 µM 
A23187 at 37 °C for the indicated 
time points. Overview images 
(100 µm) and selected cells 
(20 µM) are representative for at 
least three independent experi-
ments. Protein-protein inter-
actions are represented as 
magenta spots within an overlay 
image with DAPI-stained nuclei 
(blue). 
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Noteworthy, 5-LOX product formation remained unaffected from pretreatment with 300 nM 
MK886, indicating an inferior role of the structurally modified FLAP mutant in LM biosynthesis. 
Accordingly, the metabolic ratio of 5-H(p)ETE versus all-trans LTB4-isomers was found to be 
3-fold higher than in wildtype cells and appeared unaltered in presence of MK886 (Fig. 4.18D). 
Although 5-LOX translocated to the nucleus upon A23187 stimulation (Fig. 4.18E and Fig. 
4.16), an in situ assembly of the LT-synthetic complex could not be observed in HEK_5-
LOX/FLAP(S108∆) cells (Fig. 4.18F and Fig. 4.17). Taken together, our data indicate a crucial 
role of Ser108 and the corresponding steric arrangement of loop C2 of the FLAP trimer in 
supporting 5-LOX activity and LT formation. 
 
 
Fig. 4.18 Deletion of Ser108 prevents 5-LOX/FLAP interaction and inhibition by MK886. A Western blot 
analysis was performed in order to determine stable expression of 5-LOX and FLAP wildtype or S108∆, 
respectively, in HEK293 cells followed by densitometric evaluation relative to β-actin. B Stable co-expression of 
5-LOX and FLAP(S108∆) in HEK293 cells was determined by IF microscopy (5-LOX - Alexa Fluor 555, red; 
FLAP - Alexa Fluor 488, green). C/D 1 x 106 HEK_5-LOX/FLAP(S108∆) cells/mL were preincubated with 300 
nM MK886 or vehicle (0.1% DMSO) for 10 min at 37 °C prior to stimulation with 2.5 A23187 and 2 µM AA for 
another 10 min at 37 °C. 5-LOX products including 5-H(p)ETE and all-trans-isomers of LTB4 were detected by 
RP-HPLC. Data are given as mean ± SEM in ng (C) or as ratio of 5-H(p)ETE vs. trans LTB4-isomers (D), N=5. 
Statistical analysis was performed using paired, two-tailed Student‘s t-test. N.s. - not significant. E Subcellular 
localization of 5-LOX was determined by IF microscopy in HEK293 cells stably expressing 5-LOX (Alexa Fluor 
555, red) and FLAP(S108∆) (Alexa Fluor 488, green) upon stimulation with 2.5 µM A23187 at 37 °C for the 
indicated time points. F PLA was performed to detect an in situ interaction of 5-LOX and FLAP(S108∆) in 
HEK293 cells upon stimulation with 2.5 µM A23187 at 37 °C. Protein-protein interactions are represented as 
magenta spots within an overlay image with DAPI-stained nuclei (blue). 
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5 DISCUSSION 
5-LOX activation and the subsequent formation of LTs are associated with inflammatory 
processes and disorders (1). Although intensive research efforts have focused on LM 
formation during the last century, only few and widely artificial chemical compounds have been 
applied to study 5-LOX regulation in vitro (5). By contrast, it has been reported recently by our 
group that human macrophages release a subset of pro- and anti-inflammatory LMs, including 
LTs, upon challenge with intact bacteria (140). Here we describe bacterial exotoxins as crucial 
determinants to induce LM formation upon bacterial infections and unveil staphylococcal PSMs 
as potent 5-LOX activators in human neutrophils. Besides, the rise of multiresistent 
microorganism and their increasing impact on inflammatory diseases underline the demand 
for novel antimicrobial and anti-inflammatory compounds (3,141). Thus, this thesis presents 
the FPR2 receptor as well as the 5-LOX helper protein FLAP as potential pharmacological 
targets to modulate LM biosynthesis upon exotoxin exposure. Moreover, mutational studies of 
FLAP revealed the cytosolic loop C2 as crucial structural domain for the formation of a LT-
synthetic protein complex with 5-LOX, which will be important for ongoing drug development. 
 
5.1 Bacterial exotoxins stimulate LM formation and 5-LOX activity in cellulo 
Distinct mechanism might be responsible for in cellulo LM formation upon bacterial stimulation. 
On the one hand, phagocytosis of microorganism is a key feature of neutrophils and 
macrophages during infection (187). LTs were shown to stimulate phagocytosis and it has 
been discussed whether the internalization process simultaneously induces LM biosynthesis 
(188-190). On the other hand, microbial pattern recognition by surface receptors such as FPRs 
and toll-like receptors (TLRs) are crucial functions of the innate immune system (130,191). In 
order to evaluate whether bacteria elicit LT formation apart from immunospecific mechanisms 
resulting from a direct bacteria-host interaction, a non-immunocompetent HEK293 cell model 
stably co-expressing 5-LOX and FLAP was used in this study. Here, we show that HEK_5-
LOX/FLAP cells could be activated by both intact bacteria and sterile-filtered BCM, indicating 
an eminent role of secreted bacterial factors in mediating 5-LOX translocation. Intriguingly, 5-
LOX activation exclusively appeared for pathogenic bacteria strains, namely the Gram-positive 
S. aureus (LS1) and the Gram-negative E. coli (O6:K2:H1), while non-pathogenic S. carnosus 
(TM300) and E. coli (BL21) could not induce 5-LOX distribution upon stimulation. Since 
phagocytosis and expression of TLRs or FPRs were found to be absent in HEK293 cells (192-
194), our data indicate a more general mechanism for bacterial activation independent of direct 
bacteria-host cell interactions, but dependent on secreted soluble factors within the bacteria 
culture medium. 
Although a comparable mechanism might be conceivable for the stimulatory effect of different 
bacteria strains, we focused on the Gram-positive S. aureus for further investigations. S. 
aureus is considered as common human commensal but can cause health care- and 
community-associated infections of diverse severity (4,105). Staphylococcal exotoxins 
including α-hemolysin and α-type PSMs have been related to the virulence of community-
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associated S. aureus infections before (116-118,195). Moreover, among the genus of 
staphylococci, S. aureus and S. epidermidis are debated as main pathogens in humans, 
apparently due to the pronounced presence of virulence factors within these strains (110). The 
expression of staphylococcal toxins is regulated by the agr quorum-sensing system and sarA 
(109,113) and genetic knockout of these regulatory genes could be related to extenuated 
virulence (110). Accordingly, in our study, BCM of LS1∆agr/sarA lacking the overall set of 
exotoxins (147) failed to induce 5-LOX translocation in HEK_5-LOX/FLAP cells. Recombinant 
α-hemolysin, the archetype of staphylococcal toxins (119), induced 5-LOX redistribution in a 
dose- and time-dependent manner, while BCM from LS1∆hla insufficient in α-hemolysin 
expression (148) was still operative.  
Although HEK293 cells are an appropriate model to study 5-LOX/FLAP co-localization, 
HEK293 cells lack LT formation from endogenously released AA (98). By contrast, human 
neutrophils were shown to produce sufficient amounts of LMs, and 5-H(p)ETE, LTB4 (including 
all trans-isomers) as well as the ω-oxidized degradation product 20-OH-LTB4 are considered 
as predominant LMs released upon neutrophil stimulation (196,197). Host neutrophils act as 
first opponent as soon as bacteria overcome epithelial barriers and recognize, ingest, and kill 
invading microorganism (198). Moreover, leukocytes are supposed to be the primary defense 
against S. aureus (105,107). Apart from a direct physical host-bacteria-interaction, our data 
indicate that neutrophils can likewise be stimulated by S. aureus exotoxins. Accordingly, 
neutrophils showed remarkable LT release upon treatment with S. aureus wildtype BCMs (LS1 
and USA300, respectively). Incubations with LS1∆hla, LS1∆psmαβ, LS1∆agr/sarA or 
USA300∆pvl, revealed PSMs as key regulators for LM biosynthesis. In line with these findings, 
only recombinant PSMs (i.e. PSMα1 and PSMα3), but not α-hemolysin-induced 5-LOX 
translocation and LM formation. A summarizing principle component analysis additionally 
uncovered the striking correlation between 5-LOX activation and PSM presence in neutrophil 
stimulations, whereas α-hemolysin showed a similar pattern as vehicle incubations. 
Noteworthy, this is in sharp contrast to HEK_5-LOX/FLAP cells, were α-hemolysin efficiently 
activated 5-LOX translocation. Knockout of α- and β-type PSMs resulted in a clear but 
incomplete reduction of LM biosynthesis in neutrophils. The lack of PSMs apparently blocked 
the formation of 5-LOX products, but barely affected LMs derived from other enzymatic 
branches. On the other hand, knockout of α-hemolysin could not affect 5-LOX product 
biosynthesis but remarkably decreased 12-LOX products (e.g. 14-HDHA, 12-HEPE, 12-HETE) 
and PGs. These LMs might result from impurities with other immune cells (predominantly 
platelets) within the incubation as consequence of insufficient blood cell separation. Also, our 
results are in accordance with studies showing that human neutrophils are resistant towards 
α-hemolysin even at higher concentrations (199), apparently due to the lower expression of 
ADAM-10, the co-receptor that enhances pore-formation (200). By contrast, it was reported 
earlier that rabbit neutrophils release LTs (201) and that alveolar epithelial A549 produce PGs 
upon stimulation with α-hemolysin (202). Besides, cytolytic PVLs were insufficient in activating 
LM biosynthesis of neutrophils here, since knockout within USA300∆pvl could not affect overall 
product formation. These findings are in accordance with recent opinions that describe a 
limited role of PVLs in staphylococcal infections (203). However, although PSMs obviously 
operated as main 5-LOX activators in neutrophils, additional exotoxins and bacteria secreted 
factors might be involved in LM formation. Noteworthy, we here did not focus on other agr-
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mediated staphylococcal toxins including β-hemolysin or δ-hemolysin (equivalent to PSMγ) 
(114), which might contribute to 5-LOX activation and could explain remaining but minor LM 
biosynthesis even after stimulation by LS1∆psmαβ BCM. Further studies should likewise focus 
on other leukocytes in order to provide more knowledge about exotoxin-induced LM formation. 
It might be conceivable that monocytes, macrophages, or dendritic cells, all expressing 
additional FA-metabolizing enzymes, could differentially react on exotoxin exposure and 
release a distinct spectrum of LMs. In fact, recent investigations of our group found increased 
SPM formation of human macrophages upon stimulation with isolated α-hemolysin, underlining 
the previously discussed cell-specificity of staphylococcal exotoxins (unpublished data). In 
addition, distinct neutrophil subpopulations have been associated to varied susceptibilities to 
S. aureus infections and subsequent macrophage activation in mice (204). It might be of 
interest whether these neutrophils can be activated by staphylococcal exotoxins to the same 
extent and if LMs are involved in this process. However, it has to be mentioned that bacterial 
exotoxins have already been discussed as inducers of LTs in human granulocytes, although 
thiol-activated instead of native toxins have been applied (205). These studies have been 
published by the end of the last century, when genetic knockout approaches were not 
commonly applied and the complete set of staphylococcal toxins was still elusive (115). E.g., 
it was shown that leukocidins (PVLs) induce LTB4 formation in neutrophils (206). However, 
lower amounts of LTs were detected compared to our study and purification of leukocidins from 
bacteria cultures might have been related to impurities with other exotoxins (PSMs have not 
been discovered yet at that time) (206,207).  
According to the PSM effect in neutrophils, knockout of PSMα and PSMβ markedly altered LT 
formation in an in vivo model when mice paws were infected with the methicillin-resistant S. 
aureus USA300 strain. By contrast, the absence of PSMs barely affected PG and TX formation, 
indicating an alternative mechanism of their formation upon S. aureus infection. Noteworthy, 
we did not identify infiltrating leukocytes in this in vivo model, although neutrophils have been 
discussed to be critical for staphylococcal infections (107,154). However, it is assumable that 
additional immune cells other than neutrophils participate in the defense of S. aureus, which 
should be considered in view of cell-specific effects of exotoxins. Moreover, it has to be noted 
that the overall state of infection after S. aureus inoculation was evaluated within a different 
study and was not in the focus of this work (unpublished data). 
Collectively, our data support recent findings that PSM expression is related to the 
pathogenicity of distinct staphylococci. In detail, PSMs were found to be generally present in 
pathogenic strains (e.g. PSMs constitute about 62% of secreted proteins within USA300 
culture filtrates (115)) but could not be detected in most of commensal bacteria (128). 
Additionally, the evolutionary connection of the agr quorum-sensing system and the RNAIII-
independent psm-gene control with the regulation of further exotoxins underlines PSMs as 
important part of S. aureus virulence (111). Together, our findings add exotoxin-induced LM 
formation to the list of features contributing to S. aureus pathogenicity. 
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5.2 Staphylococcal PSMs mediate LM biosynthesis in neutrophils by targeting 
the FPR2 receptor and Ca2+ influx 
Bacterial toxins were found before to induce LT formation (205). However, although published 
almost 30 years ago, a potential mechanism elucidating the related 5-LOX activation remained 
elusive. Here we show that PSMs released from S. aureus are crucial for LM biosynthesis, and 
we identified the FPR2 receptor to be involved in this activation in neutrophils (see Fig. 5.1). 
It was published recently that PSMs mediate neutrophil chemotaxis and Ca2+ influx by targeting 
the FPR2 receptor (129,208). Accordingly, in our experiments the FPR2 selective receptor 
antagonist WRW4 significantly inhibited LT formation upon stimulation with recombinant 
PSMα3 or LS1 BCM. Interestingly, in line with our findings for BCM of LS1∆psmαβ, WRW4 
inhibition appeared to be restricted to 5-LOX products and barely affected other LMs compared 
to wildtype BCM treatment. By contrast, LM formation was globally decreased by WRW4 upon 
PSM-stimulation. Thus, we assume that additional exotoxins in the BCM might be operative to 
activate LM biosynthesis, while 5-LOX product formation strongly depends on PSM presence 
and subsequent FPR2 binding. Interestingly, FPR2 activation has been related to LM 
biosynthesis before. On the one hand, the antimicrobial peptide LL-37 released by neutrophils 
induced moderate LTB4 formation by mediating p38 MAPK activation and phosphorylation of 
cPLA2α (209). On the other hand, the synthetic peptide receptor agonist WKYMVm was shown 
to mediate AA release and LTB4 formation in neutrophils, which is in line with our results (210). 
Intriguingly, in the same study the pro-inflammatory protein SAA preferentially activated COX-
related products by acting on FPR2 without affecting LT formation (210). Together, not only 
receptor activation but predominantly the molecular properties of FPR2 ligands might influence 
corresponding LM biosynthesis. This might likewise explain that exotoxins apart from PSMs 
could target enzymatic branches other than 5-LOX/FLAP. 
 
Fig. 5.1 Proposed mechanism for an 
activation of 5-LOX by PSMs released from 
S. aureus. 
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FPR2 as Gi-protein-coupled receptor activates distinct cellular kinases (170). Here, PSM-
mediated LM formation strongly correlated with ERK1/2 activation and could be inhibited by 
the ERK1/2-inhibitor UO126 (174). Both, WRW4 and UO126 hampered the LM biosynthesis 
in a comparable manner, and WRW4 was found to alter BCM and PSM-mediated ERK1/2-
phosphorylation at Thr202/Tyr204 in neutrophils. Although Ser663 of 5-LOX was found to be a 
direct target of ERK1/2 (6), exotoxin-induced 5-LOX translocation still occurred for the 5-
LOX(S663A) mutant stably expressed in HEK293 cells. By contrast, inhibition of additional 
kinases (i.e. p38 MAPK, PI3K or PKC) that are discussed to mediate FPR2 signaling (170) 
failed in decreasing LM biosynthesis, which might underline the superior role of FPR2-ERK-
signaling for LT formation in this study. These findings are supported by the fact that inhibition 
of p38 MAPK by skepinone-L or SB203580, considered as second crucial kinase to mediate 
5-LOX activity (69), could not affect 5-LOX translocation or product formation in HEK_5-
LOX/FLAP cell or neutrophils, respectively. 
Moreover, we found that staphylococcal exotoxins induce LM biosynthesis and 5-LOX 
translocation by increasing intracellular Ca2+ concentrations in HEK293 cells and human 
neutrophils. Ca2+ binding to the N-terminal domain of 5-LOX is a key regulator to induce nuclear 
translocation and LT formation (7,61,76). Accordingly, Ca2+ capturing by EDTA completely 
prevented LM formation in neutrophils stimulated by S. aureus BCM as well as 
translocalization of 5-LOX in HEK_5-LOX/FLAP cells. Furthermore, Ca2+ as determining factor 
for PSM-mediated 5-LOX product formation might explain the intensified activation of Ca2+-
sensitive 5-LOX compared to other lipoxygenase- and COX-enzymes (7). Also, our 
experiments with EDTA indicate that Ca2+ is derived from extracellular instead of intracellular 
stores, which is in line with previous studies that discuss a sustained Ca2+ increase over the 
plasma membrane as important inducers of 5-LOX products (211). A sufficient Ca2+ influx 
potentially results from either pore-formation, cytolysis, or receptor activation, as discussed for 
δ-hemolysin (114,212). While FPR2 activation was related to intracellular Ca2+ increase before 
(129,213), cell lysis as unique factors for PSM-mediated LM formation could be repeatedly 
excluded in our study. On the one hand, LT formation remained absent in presence of lytic 
concentrations of Triton X-100 and after inhibition by MK866, a FLAP inhibitor that requires 
cellular integrity for activity (98). In addition, stimulation by LS1 BCM only caused marginal 
cytotoxicity visualized by LDH release and trypan blue staining. These results are in line with 
previous reports that indicated diminished cytolytic activities of amphipathic peptides on freshly 
isolated neutrophils (208,214), and that PSMα3 barely compromised the structural integrity of 
neutrophil membranes upon short-time incubations (195). Moreover, the phospholipid 
composition of targeted cells was shown to influence the magnitude of membrane insertion by 
PSMs and might therefore explain their cell-specific effects (215). However, the fact that 
HEK293 cells do not express FPR2, while 5-LOX translocation was likewise induced by PSMs, 
might indicate at least a supportive role of pore-formation by PSMs. Along these lines, Forsman 
et al. described both receptor-dependent and independent activities of PSMs before (208). It 
might be of interest whether 5-LOX subcellular localization upon PSM treatment is affected 
from WRW4 presence and whether AA release (discussed below), but not 5-LOX 
translocation, possibly acts as critical determinant for LM formation, giving an explanation for 
the unaltered 5-LOX translocation in HEK_5-LOX(S663A) cells. Note that HEK_5-LOX/FLAP 
cells are insufficient in LT formation from endogenous AA and cannot be utilized for 
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corresponding investigations. Moreover, since we assume that ERK activation is mediated by 
FPR2 and HEK293 cells apparently do not express this receptor, the significance of these 
results is limited. Taken together, while intracellular Ca2+ might be increased by both FPR2 
activation and minor pore-formation, sufficient LT biosynthesis seems to require receptor 
activation upon PSM treatment. 
In general, LM biosynthesis requires the initial release of FA substrates from phospholipids of 
cellular membranes by lipases (PLs) (27). Besides iPLA2 and sPLA2, cPLA2α was shown to 
play a crucial role for LT formation by liberating AA from nuclear membranes in close proximity 
to the 5-LOX/FLAP complex (27,32). cPLA2α activity is mediated by intracellular Ca2+ 
mobilization resulting in translocation to the nuclear envelope and subsequent FA release 
(1,32,34). Moreover, activation of ERK and cPLA2α-phosphorylation at Ser505 are important 
factors for catalytic activity (177). Here we show that PSM-induced LT formation can be 
inhibited by RSC-3388, a selective cPLA2α inhibitor (178,179), underlining the eminent role of 
cPLA2α under our pathophysiological conditions. In line with this, BCM of S. aureus strains that 
lack PSM expression showed diminished release of 3H-AA in neutrophils. Interestingly, RSC-
3388 failed to prevent AA release upon stimulation with BCM or PSM, indicating at least an 
alternative phospholipase that participates in substrate liberation. However, since LM 
formation was found to be reduced by RSC-3388, we assume that 3H-AA is released without 
being converted into LMs detected by the applied MS/MS lipidomic approach. Although LM 
formation was found to be partially decreased in presence of WRW4 and UO126, we still 
observed 3H-AA release in neutrophils, independent of the applied stimulus, suggesting that 
FPR2- and ERK-activation might be superior for 5-LOX activity but less important for overall 
substrate liberation. By contrast, the PSM-mediated intracellular Ca2+ increase might dictate 
the localization of FA liberation, since it was reported previously that the kinetics and amplitude 
of Ca2+ influx affect the translocation of cPLA2α to either the Golgi or nuclear envelope, 
consequently resulting in distinct metabolization by downstream enzymes such as COXs or 5-
LOX/FLAP (216). 
Besides cytolytic and pore-forming exotoxins, S. aureus releases a subset of molecules to 
evade from human immune responses (198). Among those, two proteins might be of 
outstanding importance for PSM-induced LM formation. First, CHIPS was shown to 
significantly antagonize the activation of FPR1 receptors (134). Intriguingly, in our study, PSM-
mediated LM formation remained unaltered in presence of CHIPS, while fMLP-induced LM 
biosynthesis was inhibited by approximately 50%, supporting the hypothesis of a preferential 
activation of FPR2 over FPR1 upon stimulation with isolated PSMs. However, when LS1 BCM 
was applied, minor inhibition by CHIPS could be observed (data not shown), which might 
underline a marginal but additional activation of FPR1 and subsequent LM biosynthesis by 
formylated proteins within staphylococcal BCMs. On the other hand, S. aureus was found to 
release FLIPr that shares 28% of overall structural homology with CHIPS, but specifically 
inhibits FPR2 and prevents PSM-induced Ca2+ influx (129,138). Unfortunately, in contrast to 
CHIPS, FLIPr is not commercially available and could therefore not be tested in our study. 
Nevertheless, LM formation of neutrophils should be investigated in presence of FLIPr in order 
to substantiate the role of FPR2 in S. aureus-induced LM biosynthesis. Moreover, both CHIPS 
and FLIPr might be putative targets for the treatment of staphylococcal infections to modulate 
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LM formation and in line the overall inflammatory response under these conditions. The 
activation of either FPR1 or FPR2 depending on the staphylococcal pathogenicity is 
summarized in Fig. 5.2. 
 
Fig. 5.2 Neutrophil activation by S. aureus exotoxins adopted and modified from Kretschmer et 
al. 2010 (129). Distinct activation patterns of FPR1 or FPR2 are thought to mediate the infllamatory 
response of S. aureus, depending on the pathogenicity of the corresponding bacteria strain. Moreover, 
inhibitory proteins such as CHIPS and FLIPr are released by S. aureus to mediate the host reaction to 
invading bacteria. 
 
Additionally, FPR2 was shown to be modulated by a plethora of exogenous and endogenous 
human proteins and molecules (132) including the anti-inflammatory LXA4 (131,184). In our 
experiments, PSM-induced LT formation remained unaffected from LXA4 presence. This data 
thereby supplements the controversial discussion about the modulatory effect of LXA4 on 
FPR2 activation by peptide ligands (170,217), but also implies a distinct activation of FPR2 by 
peptides and small molecules that has already been demonstrated for other GPCRs (218). 
Another key feature of FPRs is to mediate chemotaxis, and PSMs have been shown to induce 
neutrophil migration in a dose-dependent manner (129,131,168). Although the subsequent 
induction of chemotactic LTB4 appears to be a conceivable mechanism to explain these 
observations, our data indicate a subordinated role of LMs in this respect, at least in our 
experimental setting. In line, PSM-induced neutrophil chemotaxis could be significantly 
inhibited by FPR2-antagonism but remained unaffected from inhibition of the LTB4 receptor by 
LY293111. Accordingly, a hierarchy of chemotactic signals was discussed previously and 
postulated a preferential activity of bacteria-derived molecules over intermediate mediators 
such as LTB4, which might explain the findings here (17,219). However, PSM-mediated LT 
formation of tissue-resident or infiltrated neutrophils might intensify a sufficient immune 
response upon staphylococcal infections by recruiting additional leukocytes to the damaged 
tissue (17,220). 
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Taken together, here we highlight secreted exotoxins as pivotal determinants for immune 
responses upon staphylococcal infections. In detail, we substantiate PSMs and the 
subsequent activation of the FPR2 receptor as crucial factors for LT formation in neutrophils, 
which should be considered for further studies directing the role of LMs during bacteria 
challenge. However, it remains elusive whether increases in intracellular Ca2+, phosphorylation 
of 5-LOX and cPLA2α or all in conjunction are the key mechanism for LT formation upon 
stimulation with PSMs. 
  
DISCUSSION 
73 
5.3 FLAP mutagenesis affects the assembly of the LT-synthetic protein complex 
In humans, approximately 30% of all genes encode for integral membrane proteins. 
Nevertheless, only a limited number of high-resolution crystal structures have been described 
to date (93). A three-dimensional structure of FLAP was first published by Ferguson and co-
workers in 2007 and revealed four membrane embedded helices (α1-α4), two cytosolic (C1, 
C2) and one lumenal loop (L1) as well as the N- and C-terminal parts that face the inner side 
of lipid-bilayers (91). Interestingly, although FLAP is considered as promising pharmacological 
target, a clinically applied inhibitor could not reach the pharmaceutical market so far (10). Thus, 
intensive focus was set on mutational studies addressing distinct binding sites of the FLAP 
inhibitor MK-591, without considering LT formation or interaction-properties of mutated FLAP 
isoforms with 5-LOX (221). Here we asked whether mutation of distinct residues would alter 
FLAP-mediated LT biosynthesis in a HEK293 cell model. 
 
In order to overcome the lack of enzymatic activity of FLAP (222), we stably co-expressed 
FLAP isoforms with 5-LOX as published recently (98), and determined overall 5-LOX product 
formation and inhibition by MK886, interaction of 5-LOX and FLAP as well as subcellular 
Table 5.1 Effect of FLAP mutagenesis on 5-LOX activity and subcellular organization of the LT-
synthetic protein complex. Unless stated different, arrows are indicating the alteration of each mutated 
residue compared to wildtype FLAP. 
FLAP wt I119A Y112A T66A A27L S41A S41D S108A S108D S108∆
Location of 
mutated 
residue 
- α4 C2 α2 α1 C1 C1 C2 C2 C2 
Overall 
product 
formation 
88.9 
ng/106 
cells
         
Ratio 
5-HpETE vs. 
LTB4 
+ vehicle 
1.2          
Ratio 
5-HpETE vs 
LTB4 
+ MK886 
(compared to 
vehicle) 
          
Remaining 
activity upon 
MK886 
61 82 94 74 62 54 74 79 103 108 
5-LOX-
translocation           
In situ 5-
LOX/FLAP 
interaction 
 () ()      x x 
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localization of 5-LOX upon A23187 stimulation in order to assess the effects of FLAP 
mutagenesis. The results are summarized in Table 5.1. 
Variations within the second cytosolic loop and the intersection to α4 remarkably altered LT 
formation, while mutation of additional residues barely influenced 5-LOX activity. Noticeably, 
the overall 5-LOX product formation was generally unaffected from FLAP mutations, which 
might result from exogenous AA addition and related, partially FLAP-independent 5-LOX 
activity. We therefore calculated the ratio of 5-H(p)ETE versus LTB4-isomers, since it was 
discussed previously that FLAP enhances the second catalytic step of the 5-LOX reaction to 
support LTA4 formation from 5-HpETE in HEK293 cells (98). Increased ratios, indicating a 
subordinated role of FLAP for LT biosynthesis compared to wildtype cells, were found for 
mutations located on the cytosolic surface of FLAP (i.e. for S41D and S108D or S108∆) that 
in turn remained unaffected from FLAP inhibition by MK886. Moreover, interactions with 5-
LOX appeared to be absent after mutagenesis of distinct cytosolic residues (S108D and 
S108∆) of FLAP, even though replacement of all selected amino acids within FLAP could not 
diminish 5-LOX subcellular translocation upon stimulation. Our data thereby differs from early 
findings that discussed a supportive role of FLAP for 5-LOX membrane binding (85,96), but 
reflect a more recent opinion that 5-LOX redistribution is not altered by FLAP inhibition in 
human leukocytes (12). Interestingly, contrary effects have been shown for 5-LOX, since 
mutation of the residues corking the active site delayed 5-LOX membrane association, which 
in turn could be rescued by co-expression with FLAP (60). Here, we show that 5-LOX/FLAP 
co-localization is not influenced by FLAP mutagenesis, while protein complex assembly 
strongly depended on a correct FLAP structure, mainly in view of the conformation of the 
cytosolic loops. In line with this, we hypothesize that sufficient 5-LOX/FLAP interaction is 
necessary to complete the second step of LT biosynthesis from 5-HpETE to LTA4, and that in 
situ interaction of 5-LOX and FLAP might be crucial for the activity of FLAP inhibitors, at least 
in our cell model and upon exogenous FA supply. 
Considering the molecular properties of FLAP, several explanations appear to be conceivable 
for an altered 5-LOX/FLAP interaction and varied 5-LOX product formation in our study: 
(I) Mutagenesis of amino acids located on the protein surface might cause steric 
hindrance that in turn prevents a direct physical interaction of 5-LOX and FLAP 
detectable by PLA. Accordingly, it was hypothesized that one 5-LOX molecule 
binds to each trimer of FLAP and that both the C-terminal domain of 5-LOX and the 
cytosolic loops of FLAP might be important in this respect (91). However, although 
intensive efforts focused on the activities of both proteins, exact residues mediating 
their direct interaction are still elusive. Interestingly, both lumenal and cytosolic 
loops of FLAP were found to be dynamic and flexible (221), which could be 
important for in situ protein complex assembly. The mobility of the loops could 
likewise support the recent hypothesis of a time-dependent formation of the 5-
LOX/FLAP complex, which was found delayed compared to the co-localization of 
both proteins in neutrophils and monocytes (12). In parallel, a previous discovery 
of our group highlighted Cys159, located on the surface of 5-LOX, as essential 
residue for the interaction with FLAP, supporting the present findings here (223). 
Moreover, our data are in agreement with earlier studies demonstrating a FLAP 
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mutant that lacks cytosolic residues 106 to 108 to result in increased ratios of 5-
HpETE versus LTA4 (224). In line with our hypothesis, diminished 5-LOX/FLAP 
complex assembly and insufficient AA transfer were discussed but not verified as 
possible explanation for these observations (221,224). 
A structure alignment of monomeric FLAP and LTC4S (Fig. 5.3A) revealed marked 
differences in their three-dimensional configurations, and variations were primarily 
found in the length of helix α4 and cytosolic loop C2 (221). Accordingly, a direct 
physical interaction of 5-LOX and LTC4S remains controversial, although only co-
localization of both proteins appears to be related to LTC4 formation (75,225,226). 
Together, these findings confirm the crucial role of cytosolic loop C2 within FLAP 
to interact with 5-LOX during LTA4 formation.  
(II) Next, variations of residues located within the lipid-exposed domains of FLAP might 
affect binding of AA or the intermediate 5-HpETE, respectively. Along these 
lines, it was shown that 5-LOX/FLAP complex assembly is prevented by inhibition 
of endogenous FA release but can be rescued in presence of exogenous AA or 5-
HpETE, whereas 5-LOX translocation to the nuclear envelope remained unaffected 
at the same time (12,227). Although a concrete mechanism of how FLAP binds and 
transfers AA still remains unknown, it has been postulated that AA diffuses through 
the membrane and enters FLAP within its lipid-exposed grooves. Finally, the in situ 
5-LOX/FLAP interaction is mediating a reorientation of AA from FLAP to the active 
site of 5-LOX (221). Consequently, FLAP mutations affecting the binding of FA or 
oxidized lipids would alter these processes. However, a concrete crystal structure 
of FA-bound FLAP is elusive. Since binding of AA is prevented by FLAP inhibitors, 
at least an overlap of lipid and inhibitor binding sites within FLAP was assumed 
(221). Among mammalian species, two highly conserved regions in FLAP spanning 
from residues 39 to 68 and residues 74 to 128 have been revealed and short 
deletions within the former domain have been related to diminished inhibitor binding 
(228,229). Nonetheless, FAs appeared to occupy additional FLAP regions apart 
from those responsible for inhibitor binding, including cytosolic domains (224). 
However, one major drawback of the HEK293 cell model is that AA has to be added 
exogenously to achieve sufficient LT formation, as reported for artificial cell models 
before (224,230). Accordingly, is has to be noted that 5-LOX product formation 
might just partially depend on FLAP and the related FA transfer in our setting, 
resulting in subordinated effects for lipid-exposed residue mutations. Nevertheless, 
we assume that lipid-exposed domains are less important for the formation of the 
LT-synthetic protein complex. 
(III) Besides direct effects of the mutagenesis, insufficient inhibitor binding might 
likewise affect the results presented here. In detail, comparison of vehicle and 
inhibitor incubations has been utilized to evaluate the consequences of mutations 
on LT formation due to the lack of a proper enzymatic activity of FLAP (222). 
Accordingly, an attenuated inhibition by MK886 might dissemble FLAP to be less 
operative. The first crystal structure of FLAP was originally performed in presence 
of MK-591 and revealed distinct amino acids to be involved in inhibitor binding 
(including Ala27, Thr66, Tyr112, and Ile119 (91)), which appeared to be analogue for 
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MK886 that has been used in our study (221). Moreover, although apparently not 
directly involved in inhibitor binding (224,228), variations within the cytosolic loops 
have been discussed to affect inhibitor access to the lipid-exposed binding pocket 
(221). However, a PyMOL animation of FLAP(S108D) revealed the highest 
probability score for an aspartate conformer that faces the external flank of FLAP 
without corking the entrance to the inhibitor binding site from the cytosol (Fig. 5.3B). 
Thus, we conclude that our findings for modifications of C2 do not result from 
insufficient inhibitor activity. 
 
 
Fig. 5.3 A Crystal structure alignment of FLAP and LTC4S. Monomeric FLAP (red, PDB accession number: 
2q7m) and LTC4S (blue, 2pno) are presented as cartoon rendering. The grey arrow highlights the main structural 
variations at cytosolic loop C2. Phosphorylation sites of LTC4S (Ser36 and Thr40) according to Ahmad et al. (13) 
are given as blue spheres. B Mutagenesis of Ser108. FLAP (PDB accession number: 2q7m) is presented as 
cartoon rendering, while Ser108 (left hand site) and the corresponding aspartate mutant S108D (right) are given 
as blue sticks. Simulation of mutagenesis was performed with PyMOL Software and indicates a conceivable 
extension of the amino acid side-chain after mutation. Note, that the configuration with the highest probability 
has been chosen for presentation of FLAP(S108D) here, but that other conformers might be possible as well. 
 
Phosphorylation is a common cellular mechanism to regulate the activity of enzymes and 
proteins, and serine, threonine, and tyrosine were found to be frequently phosphorylated 
residues (186). In fact, various enzymes participating in the biosynthesis of LTs are regulated 
by protein kinases, including 5-LOX, cPLA2 and LTC4S (6,13,33,69,70,171). Considering the 
structural homology with LTC4S, we here asked whether FLAP serves as target for 
phosphoregulatory mechanisms in a comparable manner. In silico phospho-prediction tools 
revealed two FLAP residues, namely Ser41 and Ser108, with high phosphorylation probability 
scores, and their localization on the cytosol-facing loops C1 and C2 might allow an interaction 
with soluble kinases. Both LT formation and 5-LOX-interaction of phosphomimetic 
FLAP(S41D) and non-phosphorylatable FLAP(S41A) as well as FLAP(S108A) widely 
corresponded with wildtype FLAP, whereas FLAP(S108D) was found to lack in situ complex 
assembly with 5-LOX. Indeed, product formation of HEK_5-LOX_FLAP(S108D) showed 
increased amounts of 5-H(p)ETE compared to LTB4-isomers, underlining a subordinated effect 
of this FLAP mutant on 5-LOX product formation. These findings are in contrast to the study 
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of Ahmad et al. who demonstrated preferential phosphorylation of LTC4S on cytosolic loop C1 
instead of loop C2 (Fig. 5.3A). Phosphorylation of LTC4S at Ser36 was thereby discussed to 
disturb the protein’s active site by intermonomer-interactions (13). When FLAP(S108D) 
mutagenesis is simulated with PyMOL software, interactions with other subunits cannot be 
observed since the aspartate moiety is facing the cytosolic site of FLAP (Fig. 5.3B). However, 
despite intensive efforts, in vitro phosphorylation of FLAP could not be detected by phospho-
proteomic approaches in our study. Interestingly, several challenges have been related to the 
detection of integral phospho-proteomes before, including insolubility, low abundance or the 
complexity of fragmentation and ionization of membrane proteins (231). Hence, we do not 
finally exclude the possibility of phosphorylatable residues within FLAP. 
Taken together, we here identified the second cytosolic loop C2, and in particular Ser108 of 
FLAP as crucial determinant for sufficient 5-LOX/FLAP complex assembly and concurrent LT 
formation. Further studies should focus on this structural element to evaluate the 
consequences of its mutagenesis for the overall crystal structure of FLAP as well as for inhibitor 
and FA substrate binding, which has not been considered here. Moreover, it might be of 
interest whether loop C2 in general could serve as alternative pharmacological target to 
modulate LT biosynthesis, since the recently discovered FLAP inhibitors bind to lipid-exposed 
parts of the protein, and all exhibit high lipophilicity and thus inappropriate pharmacokinetic 
properties (10,221).
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6 CONCLUSIONS 
LMs derived from AA and related FAs exert diverse biological activities during the progression 
and resolution of inflammation (27). However, although discovered several decades ago, the 
knowledge about the activation and regulation of the enzymes involved in LM biosynthesis 
remains far from completion. This thesis first aimed at investigating the molecular mechanism 
of bacteria-induced LT formation and unveiled exotoxins secreted from pathogenic bacteria as 
determining factors for in cellulo 5-LOX activation. In case of S. aureus, a human commensal 
associated to both community- and health care-associated infections of diverse severity (4), 
we identified PSMs and their receptor FPR2 as critical factors capable to induce LM 
biosynthesis in neutrophils. Activation of FPR2, phosphorylation of ERK1/2 as well as an 
increase of intracellular Ca2+ are clearly involved in PSM-mediated 5-LOX activation. Together, 
we here present the release of LMs and the stimulation of 5-LOX as novel biological properties 
of PSMs. Moreover, our findings might encourage ongoing efforts to develop alternative anti-
microbial strategies focusing on exotoxin secretion, since the rise of antibiotic resistant bacteria 
is becoming a progressive, relevant threat to humans (3,141). Our data likewise support 
manifold publications about FPR2 activation and the resulting potential to be modulated by 
anti-inflammatory therapies (135). 
In addition, we here addressed structural elements of the integral membrane protein FLAP that 
acts as unique helper for cellular 5-LOX product formation (85,222). Our results uncover the 
second cytosolic loop (C2) of FLAP as crucial domain for sufficient assembly of the LT-
synthetic protein complex at the nuclear membrane. Prospective studies and the development 
of FLAP inhibitors should therefore consider loop C2 as novel binding site, since previous 
compounds solely target lipid-exposed domains of FLAP, resulting in highly lipophilic drugs 
and thus inappropriate pharmacokinetic properties (8,10). Accordingly, our results shed light 
on the unresolved question of amino acids that are involved in the in situ 5-LOX/FLAP 
interaction. Moreover, although indications were found for a putative phosphorylation of Ser108 
within FLAP, further investigations are needed to evaluate whether the discussed residue is 
indeed phosphorylated in cellulo. 
Taken together, our results significantly contribute to the expansive field of LM research and 
provide novel insights into the signaling and molecular determinants of LT biosynthesis upon 
bacterial stimulation as well as its dependency on FLAP. 
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